annual report human race feel better live longerfinancial summary results sterling cer growth growth turnover research development operating profit profit taxation profit taxation year profit attributable shareholders pence pence earnings per share p p diluted earnings per share p p dividends per share p p p p p p p cash flow net cash inflow operating activities capital expenditure free cash flow dividends shareholders purchase gsk shares net debt share price share price st december cer growth ifrs basis uk gaap business performance basis earlier order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates sterling represents growth actual exchange rates website glaxosmithklines website wwwgskcom gives additional information group information made available website constitute part annual report notice regarding limitations director liability english law uk companies act new safe harbour limits liability directors respect statements omissions report directors contained pages english law directors would liable company third party report directors contains errors result recklessness knowing misstatement dishonest concealment material fact would otherwise liable report directors pages inclusive consist report directors drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law cautionary statement regarding forwardlooking statements group 's reports filed furnished us securities exchange commission sec including document written information released oral state ments made public future behalf group may contain forwardlooking statements forwardlooking statements give group 's current expec tations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future oper ating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obli gation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual reportreview chairmans ceos summary every day involved race unites people gsk finding new medicines vaccines meet unmet medical needs ensuring patients access new medicines regardless financial circumstances meeting expectations many stakeholders including shareholder race many stages wont win take part never forget real focus efforts human race year positive achievement gsk continued consumer healthcare portfolio also strengthened make progress fronts sales growth coming ever launch ten products including alli first fdaapproved widening portfolio fastgrowing products combined otc treatment weight loss usa good cost control enabled us deliver strong financial best place work performance also healthy momentum pipeline work hard create working environment best ten new products added latestage development efforts people best work results biennial employee last months reasons look future opinion survey demonstrated enjoying real success confidence overall satisfaction gsk scored higher peers financial performance outlook benchmark group major companies per cent managers company delivered strong financial performance proud work gsk turnover billion increase per cent constant playing part exchange rates cer earnings per share eps pence global community investment contributions valued growth per cent million equivalent per cent group profit tax performance driven sales key pharmaceutical products significant sum commitment less including seretideadvair asthma chronic obstructive expected company industry capability pulmonary disease copd avandia group products desire reach patients find solutions diabetes coregfor heart disease lamictalfor epilepsy bipolar healthcare challenges worldwide helping people feel better disorder valtrexfor herpes vaccines live longer although performed well tough environment us human race political climate together investor concern pipeline delays investment technology people make gsk resulted share price ending year per cent lower different could succeed without commitment stjanuary expertise passion thank outstanding efforts looking ahead expect new clinical data help deliver growth seretideadvair avandia group products also thank shareholders continued support continued good performance vaccines business plan year together suppliers business partners launch new products pharmaceutical consumer work hard behalf healthcare businesses addition expect continue achieve management team performed well past savings improved operational efficiency combination months welcomed board dr moncef slaoui new new products enhanced efficiency help offset impact chairman rd thmay drdaniel podolsky stjuly generic competition zofranand wellbutrin xlduring coming dr stephanie burns thfebruary addition months expect deliver eps growth per moncef corporate executive team saw two changes jennie cent cer terms younger left june succeeded duncan learmouth delivering pipeline patients senior vice president corporate communications community pipeline significant projects clinical development partnerships ford calhoun retired january end february succeeded bill louv chief information officer best wishes go jennie ford thank valuable although setbacks year including skills great contribution good humour brought cancellation redonafor diabetes great ability reload roles years pipeline beginning flow strongly delivering much needed new treatments patients opportunities us major product opportunities phase iii development registration plan launch five major new pharmaceutical products tykerbfor breast cancer cervarixto prevent cervical cancer allermistavamys allergic rhinitis coreg cr heart sir christopher gent jp garnier conditions treximafor migraine chairman chief executive officer gsk annual report performance overview key performance indicators gsks performance development turnover earnings per share growth driven number important strategies total shareholder return strategies turnover optimising performance key products bn thepharmaceutical andconsumerhealthcare businesses focus ways improve return groups intellectual property maximising sales key products gsks activities include achieving worldwide sales force excellence cer achieving pharmaceutical consumer healthcare growth marketing excellence cer maintaining highest ethical standards growth improving costeffectiveness operations earnings per share pence cer growth delivering product pipeline patients cer growth gsk aims create best product pipeline industry benefit society includes developing focused strategy support pipeline manage full life cycle compounds launch prescription medicines potentially total shareholder return becoming overthecounter products gsk measures rd productivity number level innovation products creates theability address unmet patient needs beingthe best place best people best work gsk committed creating best place best people best workby gsk total return index gsk pharma peers return index ftse total return index recruiting developing best people industry share price supporting culture high reward high performance ensuring good communication employee involvement us maintaining diverse healthy workforce improvingaccess medicines gsk finding innovative ways bring medicines vaccines health education patients countries including suffering epidemics neglected diseases uk share price us adr price us rd february share price per adr gsk annual report keydevelopmentsin total turnover grew billion pharmaceuticals billion consumer healthcare billion top tenpharmaceutical products seretideadvair million zofran million vaccines products million valtrex million avandia group products million coreg million lamictal million imigranimitrex million wellbutrin million flixotideflovent million high potentialproductsavodart requip andbonivadelivered combined sales million top five consumer healthcare products lucozade million panadol million aquafresh million ribena million sensodyne million operating margin increased percentage points turnover continuing financial strength enabled dividend increased pence pence new share buyback programme billion three years announced details page infebruary gsk hadpharmaceutical vaccine projects inclinical development compared withinfebruary major product opportunities phase iii development registration nces new vaccines ples including cervarixcervical cancer coreg crcardiovascular conditions tykerbbreast cancer treximamigraine allermist allergic rhinitis hn pandemic flu vaccine late stage projects terminated included redonafor type diabetes andbrecanavir hivaids details page groups biennialglobal leadership survey managers showed managers believedpeople department show commitment performance integrity managers proud part glaxosmithkline managers would gladly refer friend family member work glaxosmithkline global management population female details page global community investment valued million profit tax lymphatic filariasis elimination programme continued anothermillion albendazole treatments donated makingalmost million treatments total gsk shipped million combivirtablets andnearly million epivirtablets developing countries notforprofit prices approximately million tablets supplied generic manufacturers licensed gsk international humanitarian product donations totalled million details page gsk annual report history development company annual report annual review glaxosmithkline plc public limited company incorporated th report annual report glaxosmithkline plc year december english law shares listed london ended st december prepared accordance united stock exchange new york stock exchange th kingdom requirements approved board directors december company acquired glaxo wellcome plc th february published onnd march smithkline beecham plc english public limited companies summary report year annual review way scheme arrangement merger two prepared accordance united kingdom requirements companies glaxo wellcome smithkline beecham intended investor needing full detail annual major global healthcare businesses report produced separate document includes joint gsk plc subsidiary associated undertakings constitute statement chairman chief executive officer major global healthcare group engaged creation discovery summary review operations summary financial statements development manufacture marketing pharmaceutical summary remuneration report annual review issued consumer healthrelated products shareholders annual report issued shareholders elected receive documents available gsk corporate head office london also operational glaxosmithklines corporate website wwwgskcom headquarters philadelphia research triangle park usa operations somecountries products sold report glaxosmithkline group gsk means countries principal research development rd facilities glaxosmithkline plc subsidiary undertakings company uk usa japan italy spain belgium products means glaxosmithkline plc glaxosmithkline share means currently manufactured countries ordinary share glaxosmithkline plc pamerican depositary share ads represents two glaxosmithkline shares major markets groups products usa france japan uk italy germany spain brand names appearing italics throughout report trademarks either owned andor licensed glaxosmithkline business segments associated companies exception baycol levitra gsk operates principally two industry segments trademarks bayer bonivabonviva trademark roche citrucel pharmaceuticals prescription pharmaceuticals vaccines trademark merrell pharmaceuticals entereg trademark adolor corporation usa hepsera trademark gilead consumer healthcare overthecounter medicines oral care sciences countries including usa humaxcd nutritional healthcare trademark genmab integrilin trademark millennium pharmaceuticalslymphostat b trademark human genome sciencesnicoderm trademark sanofiaventis pfizer canada elan novartis merrell glaxosmithklineand vesicare trademark astellas pharmaceuticals many countries yamanouchi pharmaceuticals certain countries used certain countries licence group gsk annual report gsk annual report srotcerid eht fo troper stnemetats laicnanif noitamrofni rotsevni contents mission report directors performance overview global quest improve quality human life financialtrends ratios enabling people feel better live longer businessreview spirit corporate governance remuneration report undertake quest enthusiasm entrepreneurs excited constant search innovation value performance achieved integrity attain success world class global leader every one people contributing passion unmatched sense urgency financial statements directors statements responsibility independent auditors report consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements financial statements glaxosmithkline plc investor information financial record shareholder information taxation information shareholders glossary terms index srotcerid eht fo troper stnemetats laicnanif noitamrofni rotsevnifinancial trends ratios growth growth cer cer turnoverpharmaceuticals consumer healthcare total cost sales selling general administration research development operating income operating profit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders earnings per share pence p p p diluted earnings per share pence p p p research development pharmaceuticals consumer healthcare total net finance cost cover net finance costs cover times times times net finance cost cover profit tax plus net finance costs divided net finance costs tax rate borrowings net debt gearing gearing ratio calculated net debt percentage total equity exchange rates group multinational business operates many countriesand earns revenues incurs costs many currencies results reported insterling affected bymovements exchange rates betweensterling othercurrencies average exchange rates prevailing period used translate results cash flows overseas subsidiary associated undertakings joint ventures intosterling period end rates used translate net assets undertakings currencies influence translations usdollar euro japanese yen gsk annual report srotcerid eht fo troperbusiness review business review discusses gsks financial nonfinancial activities resourcesdevelopments performance outlines trends factors likely affect future development following headings optimising theperformance key products deliveringtheproductpipeline patients beingthe best place best people best work improvingaccess medicines corporate responsibility community investment global manufacturing supply regulatory environment world market products competition financial review financial position resources outlook risk factors financial review performance overview pages form part business review discussion groups management structures corporate governance procedures set corporate governance pages remuneration report gives details groups policies directors remuneration amounts earned directors senior management pagesto reconciliation us accounting principles set noteto financial statements accounting presentation report prepared international financial reporting standards ifrs adoptedbythe european uniongsk taken advantage exemption permits financial instruments accounted presented ukgaap basis accordance ias ias st january data market share market growth rates gsk estimates based recent data independent external sources appropriate valued insterling relevant exchange rates figures quoted product market share reflect sales gsk licensees group operates many countries earns revenues incurs costs many currencies results group reported sterling affected movements exchange rates sterling currencies average exchange rates prevailing period used translate results cash flows overseas subsidiary associated undertakings joint ventures intosterling period end rates used translate net assets undertakings currencies influence translations us dollar euro japanese yen order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies insterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report srotcerid eht fo tropergsk annual report srotcerid eht fo troper business review optimising performance key products gsk undertakes range activities maximise commercial marketing codes potential intellectual propertyby introducing innovative products gsk committed ethical responsible patientcentred accelerating process bringing many markets marketing groups pharmaceutical marketing promotional possible increasing brand recognition improving access new activity policy governs marketing activities applies medicines pharmaceutical consumer healthcare employees suppliers contractors agents policy requires businesses focus ways optimise performance key products marketing promotional activities based valid number initiatives scientific evidence comply applicable laws regulations worldwide pharmaceutical sales force excellence policy supported regional marketing practices codes gsks sales force always ranked high surveys healthcare europe gsks international region japan usa codes professionals worldwide sales force excellence wsfe aims apply ethical standards reflect differences market improve customer satisfaction even structures national healthcare systems regulations incorporate principles industry codes practice time available physicians learn new medicines european federation pharmaceutical industries associations clinical studies precious wsfe initiative sales international federation pharmaceutical manufacturers associations representatives strengthen product knowledge learn deliver japan pharmaceutical manufacturers association pharmaceutical patientspecific treatment options efficiently research manufacturers america marketing codes effectively research shows sales visit highly effective representative engages physician dialogue around patient types next generation supports message visual aids illustrate clinical results uspharmaceutical businesses created implemented next generation operating model advertising agencies single global sales call model introduced focuses design model aims improve creativity productivity treating patient dialogue gsk achieve significant cost savings involved number key areas medicine appropriate effective administer result professional brand accounts consolidated safely field staff gsks key marketshavebeen trained single agency increased access best talent streamlined new approach entire sales organisation involved wsfe account management reduced rates team also instituted bring cultural change raises ethical standards helps key changes agency reviews created financial parameters build longterm trusting relationships healthcare community resource guides improve decision making processes addition dashboard key performance indicators product knowledge certification process effective leadership training consumer healthcare marketing excellence programmehavebeen established recent restructuring placed greater emphasison brands opportunitiesis major factor improved performance superior product knowledge essential serving needs business restructuring ateam called future healthcare professionals physicians rely gsk keep abreast group created drive pipelines marketing programmes changes prescribing information new clinical studies involving forglobal brandswith significantsales multiple markets forother gskmedicines key goal wsfe gsk expanded annual largebrands one dominant market may available certification program countries representatives several territories dedicatedteam driveseach theselead market passed certification tests pathology prescribing information brandsfor dominant marketthe remaining assets termed key messages leading products scores consistently enterprise brands locally managed inmarket commercial around many representatives achieving perfect score teams retain entrepreneurial spirit relevance pharmaceutical marketing excellence large numbers patients suffering effects disease continue unable benefit innovative medicines treatmentsfor example within europe around patients suffering chronic obstructive pulmonary disease copd diagnosed receive regular maintenance drug therapy gsks marketing initiative implements programmes overcome barriers proper diagnosis treatment providing accurate balanced information products allow many people possible benefit gsks medical advances programmes beginning show effects needs done societal costs disease decreasegsk annual report srotcerid eht fo troper business review delivering product pipeline patients research development pharmaceuticals cedd responsible identifying targets relevance therapeutic area building lead compounds produce since merger gsk rd developed one robust potential medicine fundamental steps turning lead pipelines potential new medicines industry compound medicine optimising potency efficacy pharmaceutical rd actively managingover projects safety defining biology animals humans human clinical trials across globe delivering pipeline medicine tested effects right patient groups patients safely efficiently isournumber onegoal inventive steps underpinnedthrough scientific researchand focus patient application informed judgement develop creative solutions one objective unites people work gskrd problems challenges inevitably arise discovery early staying focused patient itdrives discover development potential treatments diseaseand develop innovative medicines candidate compound selectedthe cedds responsible thatoffer truebenefitto patients reaching speaking undertaking clinical studies necessary demonstrate effect patients families understand impact disease sufficient declare proof concept first indication lives work communityarean essential part patients new medicine worksbased profile safety gsk knows patients waiting thefocus patient isour efficacy decision made whether progress driver deliver best every day medicine latestage drug development largescale clinical pharmaceutical rd gsk organised around discovery trials conducted confirm efficacy safety gain development medicines patients discovery conducted regulatory approval commercialise product molecular discovery research gsks centres excellence duringthe yearnewprojects entered phase ii clinical trials drug discovery cedds development gsks medicine first time development centres mdcs along way many othergroups provide critical scientific input conduct important experiments gsk committed developing clinical science ensure aidin managing rd process thesegroups described understanding disease processes humans learning much detail possible medicines development application experimental medicine major opportunity industry discovering potential medicines optimise drug discovery process advances clinical imaging two components needed thediscoveryofnew medicines revolutionising experimental medicine opening opportunities identification important molecular targets visualise effects medicines humans gsk opened potential impact human diseaseand discovery compounds clinical imaging centre cic biomedical research campus modulate targets alleviate disease effective imperial college london new million facility staffed safe way clinical investigation research groups working stateoftheart molecular discovery research mdr produces lead compounds magnetic resonanceimaging positron emission tomography mayinteract withtargets form basis drug discovery imaging systems facilities include radiochemistry biology image efforts gskscedds mdr progressed preclinical analysis neurophysiology laboratories formidable capabilities drug discovery programmesand performedhundreds cic augmented multiple global collaborations assays per week provided cedds withover highquality academic imaging centres established gsk last new lead compounds decade whengsk rd designed cedds theyintegrated groups addition nine cedds gsk also created centre excellence scientists clinicians organised work aroundspecific external drug discovery ceedd small team disease areas peopleeachceddis nimble responsible delivering compoundsto theproof concept stage entrepreneurial gsksnine therapeutically aligned cedds based establishing managing longterm strategic collaborations europe usaare biotechnology companies small mediumsized pharmaceutical companies academic institutions ceedd established biopharmaceuticals stevenage uk four newcollaborationsand currently oversees portfolio ofdrug cardiovascular upper merion usa discovery projects ranging target selection human infectious disease upper merion research triangle parkusa clinicaltrials metabolic research triangle park usa oncology upper providence usa developing medicines patients macrolide drug discovery zagreb croatia acquired pliva research preclinical development pcd includes wide range activities institute may throughout entiremedicinesdevelopment processin addition neurology gastrointestinal diseases harlow uk thisfunction involved enhancement existing products psychiatry verona italy devising convenient formulations early development respiratory inflammation stevenage uk process metabolism safety compounds evaluated laboratory animals testing humans testing required animals highly regulated see animals research page pcd researchers investigate appropriate dosage forms example tablets inhalers develop formulations enhance drugs effectiveness ease use patientgsk annual report srotcerid eht fo troper business review delivering product pipeline patients continued processes supporting analytical methods drug synthesis safety data routinely collected throughout development product formulation delivery scaled meet increasing programmes reported national regional regulatory supply requirements leads technical transfer agencies line applicable regulations processes methods manufacturing new product supply gsk considers chief medical officer working global process partnership rd global manufacturing safety board ultimately accountable oversight major supply ensures robust product developed largescale decisions regarding patient safety gskglobalsafetyboard commercial manufacturing launch responsible internally approving pivotal studies investigating gsk redesigned management latestage development issues related patient safety arising development dividing single large latestage development organisation programmeinformation gsk clinical trials widely easily three distinct empowered entities first component medicines available theclinicaltrialregisteron website developmentis collection six therapeutically aligned medicine gskformed dedicated pharmacogenetics group gsk development centres mdcs mdc hasultimate accountability believes pharmacogenetic researchcorrelatinggenetic data developing experimental drugs regulatoryapproved response medicine help scientists understand different medicines patients mdcs responsible creating value people respond effects medicine execution full product development plansand ensuring therapeutically intended causing adverse events rd strong partnerships rest gsk particular cedds collecting dna samples appropriate patient consentin clinical latestage development groups studies identify pharmacogenetic informationwhichmay help mdcs based major usa uk sites aligned predict patients response information intended define following therapeutic areas patient groups likely gain benefit treatment suffer side effect pharmacogenetics promises provide physicians cardiovascularmetabolic information help select medicine dose likely infectious diseases including diseases developing world benefit thepatient andin long runmay help reduce pipeline ddw attrition improve productivity musculoskeletalinflammationgastrointestinalurology neuroscience psychiatryneurology inlicensing oncology gsk continues identify compounds companiesthat respiratory would enhance portfolio create innovative collaborations ensure group regarded partner choice large mdcsdischargetheirresponsibilities throughproject teams small companies medicine development project teams responsible maximising worldwide development opportunities subjects acquisitions inlicensing comarketingcopromotion product within remitand seethat information needed future options arrangements support registration safety programmes pricing formulary genmabs humaxcdofatumumab anti cd mabin oncology negotiations available commercial input global product phase iii andrheumatoid arthritisphase ii strategy commercial operations ensures regional marketing hgslymphostat bfor lupus erythematosus phase iii needs integrated intodevelopment plans early stage gileadmyogens ambrisentan commercialisation excluding usa second component developmentoperations drives operational selective endothelin receptor antagonist pulmonary arterial excellence medicine delivery study projectand portfolio level hypertension phase iii plus marketing distribution agreement doneby establishing integrated planning ensure consistent gsk 's flolanin usa myogen predictable drug project plans supplying valued clinical akrosjapan tobaccos jtp mekinhibitor preclinical development capabilitiesin development operations managed chemocentryx options preclinical assets andtraficetphase ii clinical trials overactive patients handling everything epix options discovery targets ht agonistphase patient recruitment data management project planning galapagos options discovery programmes osteoarthritis development operations also responsible helping identify preclinical patients outside traditional markets itidentifiedmore kisseis sglt inhibitors type diabetespreclinical new patients outside western pharmacopeiaoptions discovery programmespreclinical europe north america sirnas rnaibased therapeutics respiratory diseases preclinical acquisition plivaresearch institute office chief medical officer third component late stage developmentand charged safety patients involved extending use existing products clinical trials well proper filing findings product launched important establish additional regulatory authorities clinical trials sponsored gsk irrespective ways patients may helped thiscanbe done take place conducted according international investigating whetherother illnesses may treated product standards good clinical practice applicable laws development additional convenient dosage forms regulations protocols reviewed external regulatory developments reflect feedback patients medical agencies relevant countries required protocols professionals others result continuing research considered ethics review committee whoseresponsibilitiescover disease causes siteswhere studieswill take placegsk annual report srotcerid eht fo troper business review delivering product pipeline patients continued gsk received approval usa fora controlledrelease results obtained clinical trials data regarding version coreg coreg cr allows oncedaily dosing development quality largescale production process hypertension mild severe heart failure product facilities combined regulatory file submitted launched usa q gsk also began novel investigation authorities countries vaccine determine whether diabetes treatment rosiglitazone xr made available effective alzheimers diseasethe scientific basis programme launch post marketing studies considerable size set developed thanks pharmacogenetics work undertaken assess vaccination programmesand monitor vaccine safety withrosiglitazoneover past sevenyears phase iv managing portfolio vaccine manufacturing particularly complex requires use key projects reaching significant milestones reviewed month innovative technologies living microorganisms sophisticated product management board pmb responsible quality assurance quality control procedures place ensure determining amedicinehas met criteria passing next quality safety vaccines commonly includes phase development animal useaccording health authorities requirements due progress portfolio communicated investors media biological nature individual health authorities may subject vaccines regular intervals year details gsks product second control guarantee highest quality standards development pipeline given pagesto gsk increasing capacity supply vaccines across risk rd globe developing unique global manufacturing network based pharmaceutical rd natureis inherently risky venture three major regional hubs europe north america asia time potential medicine discovered becomes establishment north american hub approved medicine take years one ten three major acquisitions gsk strengthened vaccine molecules starts human clinical trials ever reaches regulatory capabilities asia europe approval nine ten fail discontinued variety investing million set vaccine reasons frominsufficientsafety thresholds lack efficacy manufacturing site dedicated primary production manufacturing hurdlesthese discontinuations occur despite extensive paediatric vaccines singapore predictive testing latestage projects terminated includedbrecanavirforhivandredonafor diabetes opening gdll hungary million primary production facility manufacturing diphtheria tetanus pertussis research development vaccines antigens used several paediatric combinations vaccines majority gsks vaccine activities conducted itsbiologicals headquarters rixensartand wavre belgium include research investing million inits vaccine manufacturing clinical development regulatory strategy commercial strategy scaling plant st amandleseaux france increase production capacity vaccine production packaging support functions formulation filing freezedrying packaging discovery development new vaccine complex process diseases developing world requiring longterm investmentin rd scientists continued investment research diseases disproportionately devoted developing new vaccines costeffective affect developing world essential longterm convenient combination vaccines prevent infections cause improvement health people live regions part serious medical problems worldwide gsk also targeting therapeutic gsks response challenge operates drug discovery unit vaccines may prevent relapse cancer patients thanks based tres cantos spain primarily dedicated finding new use innovative technologies global business model gsk medicines malaria tuberculosis additional research sites fastgrowing vaccinemaker delivering value contributing usa uk focused discovering new medicines health wellbeing people every generation around treat hivaids drug resistant bacteria vaccine research world conducted rixensart belgium vaccine discovery involves many collaborations academia medicines vaccines enter clinical trials taken biotech industry identify new vaccine antigens development regulatory processesby dedicated groups based expressed yeast bacteria mammalian cells purified uk usa belgium rd efforts gsk high level addressing prevention treatment three world followed formulation clinical lots vaccine health organizations top priority diseases may involve mixing antigens selected gsk novel proprietary gsk currently clinical programmes relevance adjuvant systems designed enhance immune developing worldof aimed producing vaccines response first step evaluate safety efficacy medicines diseases disproportionately affect developing candidate vaccine preclinical setting usually involving animal countries model candidate vaccine tested clinical trials healthy individuals evaluate safety effectiveness inducing immune response protect body infection encountered later natural setting phase iii largescale field trials healthy individuals follow establish safety efficacy cross section population phase iiigsk annual report srotcerid eht fo troper business review delivering product pipeline patients continued publicprivate partnerships ppps remain essential fund research major nces vaccines phase iii development commercially viable market potential product ambrisentan hypertension gsk leader workinginppps continues collaborate closely lymphostatb lupus many governments academic centres united nations agencies casopitant postoperative chemotherapyinduced global funding bodies area maximise expertise vomiting nausea knowledge dual benefit encouraging research pazopanib prevention tumour growth development accelerating access medicines mepolizumab hypereosinophilic syndrome developing world promacta patients low platelet count new generation flu vaccine animals research globorix new combination paediatric vaccine hepatitis b ethical regulatory scientific reasons research using animals diphtheria meningitis c remains small vital part research development new new meningitis vaccine meningitis c hib medicines vaccines gsk uses animals synflorix vaccine prevent pneumococcal disease alternative numbers required test group entered latestage last months strives exceed regulatory standards care use animals uses undergoes internal external review assure major nces vaccines filed standards allermistavamys hay fever usapprovalexpected first half vast majority experimental methods use animals altabaxaltargo skin infectionsapprovalexpected gsk actively engaged research develop validate tests entereg forpostoperative ileusapprovalexpected either avoid use animals research reduce numbers tykerb breast cancer usapprovalexpected first half needed animals used research unnecessary pain cervarix vaccine prevent cervical cancer european suffering scrupulously avoided international launches expected second half gsk understands use animals research purposes hn pandemic vaccine commands high level public interest glaxosmithkline public latestage assets inlicensedduring last months policy position care ethical use animals research humaxcd treatment leukaemia information reports available website nonhodgkins lymphoma wwwgskcomor secretariat gepirone er major depressive disorder xp restless legs syndrome treatment research development consumer healthcare neuropathic pain focus rd identify develop novel products benefit ingsk expects launch major new pharmaceutical products consumers overthecounter otc oral care nutritional details developments information healthcare markets achieve significant increase innovation important launchesfilings expected see gsk outlook internal external sources rd hasremodelledto deliver page valuable pipeline products thischange specific tasks performed lower cost outside company maturity late stage pipeline expected lead transferred toexternal development partners transfer along increase registrations coming years content drug headcount reductions savings releases substantial funds development portfolio change time new compounds investment additional innovation projects remodellingbuilds progress discovery development development recently adopted consumer healthcare operating model market owing nature drug development process many whereby global brands rd mirrors commercial structure compounds especially early stages investigation branddedicated rd teams paired commercial brand may terminated progress development phase teams located together innovation centres nces multiple indications counted nces later weybridge uk parsippanyusa phases counted indication competitive reasons new projects preclinical development disclosed gsks pipeline project types may identified end february gsk nearlypharmaceutical gsks policy seek obtain patent protection protectable vaccine projects development clinic inventions discovered developed rd activities patent comprisingncesples andvaccines compared protection new active ingredients available significant markets protection also obtainedfor exampleon new last months nces new vaccines andinlicenced assets pharmaceutical formulations manufacturing processes medical uses entered latestage development special devices administering products see page gsk major product opportunities phase iii development registration comprising new chemical entities nces new vaccines product line extensions plesgsk annual report srotcerid eht fo troper business review delivering product pipeline patients continued key inlicense alliance relationship third party nda new drug application usa date first submission phase evaluation clinical pharmacology usually conducted volunteers date first regulatory approval maa first eu phase ii determination dose initial evaluation efficacy conducted approval letter small number patients al approvable letter indicates ultimately approval given subject resolution ofoutstanding queries phase iii large comparative study compound versus placebo andor established treatment patients establish clinical benefit safety maa marketing authorisation application europe estimated submission dates onlydisclosed within months date chart date represents likely year submission considered reasonably high probability successfully meeting date assuming clinical data meets expected endpoints clinical trials estimated submission dates compoundproduct type indication phase maa nda cardiovascular metabolic high affinity nicotinic acid receptor dyslipidaemia hma agonist lipoproteinassociated phospholipase atherosclerosis lppla inhibitor factor xa inhibitor prevention stroke atrial fibrillation p kinase inhibitor atherosclerosis also rheumatoid arthritis chronic obstructive pulmonary disease copd rilapladib lppla inhibitor atherosclerosis peroxisome proliferatoractivator receptor dyslipidaemia ii ppar delta agonist p kinase inhibitor atherosclerosis alsocopd neuropathic pain ii rheumatoid arthritis darapladib lppla inhibitor atherosclerosis lliii ambrisentan endothelin antagonist pulmonary arterial hypertension iii na coreg cr ace inhibitor beta blocker angiotensin converting hypertension fixed dose combination iii na enzyme inhibitor arixtra synthetic factor xa inhibitor treatment acute coronary syndrome approvable sjul alfeb coreg cr beta blocker hypertension congestive heart failure oncedaily approved na aoct metabolic projects sodium dependent glucose transport sglt obesity inhibitor ppar gamma partial agonist type diabetes ppar pan agonist type diabetes metabolic syndrome sgltinhibitor type diabetes ii ppar pan agonist type diabetesmetabolic syndromedyslipidaemia ii sglt inhibitor obesity ii albiglutide glucagonlike peptide agonist type diabetes ii avandia ppar gamma agonist atherosclerosis type diabetes ii avandamet xr ppar gamma agonist metformin type diabetes extended release iii na avandia ppar gamma agonist prevention diabetes iii na avandia ppar gamma agonist prevention disease progression iii na avandia simvastatin ppar gamma agonist statin type diabetes iii na avandarylavaglim ppar gamma agonist sulphonylurea type diabetes fixed dose combination approved ajun adec infectious diseases oral pleuromutilin treatment bacterial infections oral pleuromutilin treatment bacterial infections farglitazar ppar gamma agonist hepatic fibrosis ii sitamaquine aminoquinoline treatment visceral leishmaniasis ii na tafenoquine aminoquinoline plasmodium vivaxmalaria ii chlorproguanil dapsone antifolate artemisinin treatment uncomplicated malaria iil na artesunate cda altabaxaltargo topical pleuromutilin bacterial skin infections approvable sjun aldec antivirals polymerase inhibitor hepatitis c dna antiviral vaccine hiv infection integrase inhibitor hiv infection ii relenza neuraminidase inhibitor influenza prophylaxis approved aaug amargsk annual report srotcerid eht fo troper business review delivering product pipeline patients continued estimated submissiondates compoundproduct type indication phase maa nda musculoskeletal inflammation gastrointestinal urology oxytocin antagonist threatened preterm labour gselective oestrogen receptor modulator treatment menopausal symptoms vitronectin integrin antagonist agerelated macular degeneration monoclonal antibody rheumatoid arthritis potassium channel opener overactive bladder calcium antagonist osteoporosis parathyroid hormone agonist osteoporosis relacatib cathepsin k inhibitor osteoporosis osteoarthritis also bone metastases selective inos inhibitor rheumatoid arthritis also migraine ii p kinase inhibitororal rheumatoid arthritis also atherosclerosis copd ii neuropathic pain p kinase inhibitor oral rheumatoid arthritis also atherosclerosis copd ii corticotrophin releasing factor crf antagonistirritable bowel syndrome also depression anxiety ii casopitant nk antagonist overactive bladder also depression anxiety ii chemotherapy induced postoperative nausea vomiting dutasteride testosterone alpha reductase inhibitor testosterone hypogonadism fixed dose combination ii humaxcd human monoclonal antibody rheumatoid arthritischronic lymphocytic leukaemia ii ofatumumab nonhodgkins lymphoma mepolizumab antiil monoclonal antibody eosinophilic esophagitis alsosevereasthma nasal ii polyposis rosiglitazone xr ppar gamma agonist rheumatoid arthritis also alzheimers disease ii solabegron beta adrenergic agonist irritable bowel syndrome ii solabegron beta adrenergic agonist overactive bladder ii avodart alpha blocker alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fixed dose combination iii avodart alpha reductase inhibitor reduction risk prostate cancer iii belimumab antib lymphocycte stimulator monoclonal systemic lupus erythematosus iii antibody enteregentrareg peripheral muopioid antagonist opioid induced bowel dysfunction iii mepolizumab antiil monoclonal antibody hypereosinophilic syndrome also severe asthma nasal iii polyposis enteregentrareg peripheral muopioid antagonist post operative ileus approvable aljul alnov bonivabonviva bisphosphonate treatment postmenopausal osteoporosis iv injection approved amar ajan neurosciences ht antagonist depression anxiety histamine h antagonist dementia histamine h antagonist dementia crf antagonist depression anxiety ht antagonist depression anxiety dopamine antagonist drug dependency ampa receptor modulator schizophrenia nk antagonist depression anxiety selective inos inhibitor migraine also rheumatoid arthritis ii triple htnoradrenalinedopamine reuptake depression ii inhibitor glycine antagonist smoking cessation ii orexin antagonist sleep disorders ii p kinase inhibitor neuropathic pain also atherosclerosis copd ii rheumatoid arthritis dual alpha integrin antagonist vla multiple sclerosis ii ht antagonist dementia ii mixed htdopaminergic antagonist schizophrenia ii noncannabinoid cb agonist inflammatory pain ii crf antagonist depression anxiety also irritable bowel syndrome ii casopitant nk antagonist depression anxiety also overactive bladder ii chemotherapy induced postoperative nausea vomiting talnetant nk antagonist schizophrenia ii gepironeer hta agonist major depressive disorder oncedaily iii lamictal xr sodium channel inhibitor epilepsy partial generalised tonicclonic seizures oncedailyiii na rosiglitazone xr ppar gamma agonist alzheimer 's disease also rheumatoid arthritis iii lamictal xr sodium channel inhibitor epilepsy partial seizures oncedaily submitted na snov requipextended release nonergot dopamine agonist restless legs syndrome submitted na soct requipmodutabxl nonergot dopamine agonist parkinsons disease oncedaily controlled release submitted sdec sfeb hour formulation trexima ht agonist naproxen migraine fixed dose combination approvable na aljun wellbutrin xl noradrenalinedopamine reuptake inhibitor seasonal affective disorder approved na ajun wellbutrin xlxr noradrenalinedopamine reuptake inhibitor depression approved adec aauggsk annual report srotcerid eht fo troper business review delivering product pipeline patients continued estimated submission dates compoundproduct type indication phase maa nda oncology thrombopoietin agonist thrombocytopaenia human kinaseinhibitor chemoprotection pazopanib vascular endothelial growth factor nonsmall cell lung cancer colorectal cancer vegf tyrosine kinase inhibitor combination treatment regimens relacatib cathepsin k inhibitor bone metastases also osteoporosis osteoarthritis pazopanib tykerb vegf tyrosine kinase inhibitor erbb breast cancer ii epidermal growth factor receptor egfr dual kinase inhibitor pazopanib tykerb vegf tyrosine kinase inhibitor erbb cancers ii egfr dual kinase inhibitor promactaeltrombopag thrombopoietin agonist chemotherapy induced thrombocytopaenia ii promactaeltrombopag thrombopoietin agonist hepatitis c ii casopitant nk antagonist chemotherapy induced postoperativenausea iii vomiting usaonly also overactive bladder depression anxiety humaxcd human monoclonal antibody chronic lymphocytic leukaemia nonhodgkins iii ofatumumab lymphoma also rheumatoid arthritis hycamtin topoisomerase inhibitor ovarian cancer firstline therapy iii hycamtin topoisomerase inhibitor small cell lung cancer secondline therapy iii oral formulation pazopanib vegf tyrosine kinase inhibitor renal cell cancer iii promactaeltrombopag thrombopoietin agonist longtermidiopathicthrombocytopaenicpurpura iii promactaeltrombopag thrombopoietin agonist shorttermidiopathicthrombocytopaenicpurpura iii tykerb erbb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tykerb erbb egfr dual kinase inhibitor breast cancer firstline therapy iii tykerb erbb egfr dual kinase inhibitor head neck squamous cell carcinomas iii tykerb erbb egfr dual kinase inhibitor refractory breast cancer submitted soct ssep arranonatriance guanine arabinoside prodrug acute lymphoblastic leukaemia lymphomas approved smay aoct hycamtin topoisomerase inhibitor cervical cancersecondline therapy approved anov ajun respiratory pde iv inhibitor inhaled copd muscarinic acetylcholine antagonist copd monoclonal antibody severe asthma muscarinic antagonist beta agonist copd longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist muscarinic acetylcholine antagonist copd ii pde iv inhibitor inhaled asthma ii pde iv inhibitor intranasal allergic rhinitis ii longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist longacting beta agonist copd also copd asthma combination ii glucocorticoid agonist p kinase inhibitor oral copd also atherosclerosis neuropathic pain ii rheumatoid arthritis glucocorticoid agonist asthma copd combination longacting ii beta agonist also avamysallermist allergic rhinitis glucocorticoid agonist intranasal allergic rhinitis ii glucocorticoid agonist asthma copd combination longacting ii beta agonist p kinase inhibitor oral copd also atherosclerosis rheumatoid arthritis ii novel glucocorticoid agonist asthma ii mepolizumab antiil monoclonal antibody severe asthma nasal polyposis also hypereosinophilic ii syndrome eosinophilic esophagitis avamysallermist glucocorticoid agonist allergic rhinitis submitted sjul sjun seretideadvair beta agonistinhaled corticosteroid copd mortality claim submitted ssep soct ariflo pde iv inhibitor oral copd approvable aloct seretide beta agonistinhaled corticosteroid asthma initial maintenance therapy approved ajul na seretideadvair beta agonistinhaled corticosteroid asthma noncfc inhaler approved ajun ajungsk annual report srotcerid eht fo troper business review delivering product pipeline patients continued estimated submission dates compoundproduct type indication phase maa nda paediatric vaccines menacwytt conjugated neisseria meningitisgroups c w disease ii prophylaxis globorix conjugated diptheria tetanus pertussis hepatitis b haemophilus lll influenzaetype b disease neisseria meningitisgroups c disease prophylaxis hibmencytt conjugated neisseria meningitisgroups c disease iii haemophilus influenzaetype b disease prophylaxis infanrixipv subunit inactivated diptheria tetanus pertussis poliomyelitisprophylaxis iii booster thdose synflorix conjugated streptococcus pneumoniaediseaseand nontypeable lll haemophilus influenzaeprophylaxis children priorixtetra live attenuated measles mumps rubella varicella prophylaxis approved ajul rotarix live attenuated oral rotavirus induced gastroenteritis prophylaxis approved afeb vaccines hiv recombinant hiv infection prophylaxis l pneumoniae elderly recombinant conjugated streptococcuspneumoniaedisease prophylaxis l dengue fever attenuated tetravalent vaccine dengue fever prophylaxis epsteinbarr virus recombinant ebv infection prophylaxis hepatitis e virus recombinant hepatitis e prophylaxis mosquirix recombinant malaria prophylaxis tuberculosis recombinant tuberculosis prophylaxis ii varicella zoster virus recombinant varicella zoster prevention ii new generation flu vaccine inactivatedsplittrivalent seasonal influenza prophylaxisfor elderly iii simplirix recombinant genital herpes prophylaxis lll daronrix inactivated wholealuminium salt pandemic influenza prophylaxis submitted sdec monovalent flu prepandemic hn inactivated splitmonovalent pandemic influenza prophylaxis submitted sjan cervarix recombinant human papilloma virus infection prophylaxis submitted smar flulaval inactivated split influenza prophylaxis approved aoct pharmaccines p recombinant treatment prostate cancer l magea recombinant treatment nonsmall cell lung cancer melanoma llgsk annual report srotcerid eht fo troper business review best place best people best work engage wider range managers halfday workshop glaxosmithkline people ethical decisionmaking attended leaders glaxosmithkline committed creating best place extended three elearning modules implemented best people best work deliver groups business across businesses far people completed least strategy group employs people one three modules countries maintaining standards recruitment talent management leadership gsk expects employees meet high ethical standards aspects development business conducting activities honesty integrity attracting best people industry critical enhancing adhering corporate responsibility principles complying sustaining gsks performance groups talent solutions recruiters applicable laws regulations gsk audits operations ensure usa uk focused proactive identification talented relevant standards expected marketing practices external candidates key jobs reached exceeded annual performance development planning pdp process commitment gsk code conduct reinforced year ensures employees set business aligned objectives senior management certification programme behavioural goals pdps reviewed throughout year managers certified complied performance culminating end year review factored integrity principles compensation decisions pdp process includes assessment well employees annual talent management cycle identifies highest implemented gsk spiritthe principles used definegsks performing people business functionand key talent culture thismay havea significant impact bonus paymentsand developed tailored management leadership may also affect future career development way group programmes detail see groups corporate holds employees accountable delivering performance high responsibility report exposure top management standards integrity protect enhance gsks reputation programmes chief executive forum stretch assignments pool potential successors identified foreach diversity vicepresident positionand critical roles organisation diversity inclusion initiatives focuson improving performance responding diverse needs employees customers performance reward external stakeholdersinthe fifth year theannual multicultural reward systems designed support culture high marketing diversity awards teams fromaround world performance attract retain best people performance highlighted innovative activities demonstrated business impact based pay bonuses share awards share options align global management population male employee interests themeetingof business targets female details diversity measures see communication employee involvement employment practices section corporate responsibility report group conducts global leadership survey gls every two years group committed employment policies free recent survey conductedin among discrimination existing potentialstaff grounds managers gauge opinions critical issues culture age race ethnic national origin gender sexual orientation faith confidence groups future scores morale disability gsk committed offering people disabilities engagement steadily increased since comparevery access full range recruitment career opportunities every favourably global benchmarks topranked companies effort made retain support employees become disabled survey managers proud part working group glaxosmithkline would gladly refer friend family member work glaxosmithkline business function health wellbeing developsaction plans address areas improvement based healthy employees healthy ways working contribute tothe results gls surveys sustained performanceof group global policies onemployee health supported mandatory standards integrate employee group also consults employees changes affect health safety environmental requirements standards discusses developments businesses european employee applied groups facilities operations worldwide consultation forum similar bodies countries national practice uk new national consultation commitment flexible working flexitime tele forum created uk information consultation forum conferencing remote working flexible work schedules recognises made elected employee representatives seven employees work best environment helps management representatives meets regularly employee integrate work personal lives views taken account major changes affecting groups employee health management function employees implemented developed aresilience programme translated business ethics reputation languages adopted incountries performance withintegrity central operating gsk glsshowed believe people department show commitment performance integrityand agree report unethical practices without fear reprisalgsk annual report srotcerid eht fo troper business review improving access medicines access healthcare developing world access medicines developed world access healthcare developing countries remains major challenge programmes usa global community problem rooted poverty gsk working provide meaningful access medicines people demands significant mobilisation political additional resources limited financial resources without prescription drug true spirit partnership gsk continues play vital role insurance gsks uspatient assistance programmes provided commitment rd diseases particularly prevalent million worth medicines valued wholesale acquisition cost developing world programme preferential pricing qualifying low income us residents antiretrovirals arvs antimalarials vaccines gsk worked expand patient assistance programmeand created community investment programmes see page gsk access include enrolled medicare part beginning willingness seek innovative solutions voluntary gsk access help eligible partdenrolledpatients licencing arrangements spent least money current year preferential pricing programme outpatient medicines may qualify receive gsk medicines free gsk offered vaccines key organisations vaccination uninsured americans qualify medicare medicaid programmes developing countries preferential prices gsk pharmaceutical companies created together rx years group also sets single notforprofit price access programme qualified individuals offering reductions arvs antimalarials wide range customers least pharmacy cost medicinesover together developed countries un definition subsaharan africa well rxaccess cardholderssaved million country coordinating mechanismprojects fully funded global fund fight aids tb malaria us presidents gsk participates partnership prescription assistance ppa emergency plan aids relief pepfar july gsk introduced largest national programme dedicated helping people need access two new arvs kivexaand telzirto notforprofit offering prescription medicines ppa helped million us patients reduced prices gsks abacavircontaining products need find programmes providing significant help gsk us pharmaceutical companies launched programmein working gsk committed contributing health improvements healthcare physician patient advocacy organisations sustainable manner prices arvs antimalarials therefore set levels profit made direct costs patient advocacy covered allowing supply sustained long required patient advocacy initiative demonstrated significant progress gsk shipped developing countries million since inception initially launched us programme tablets notforprofitpriced combivirandnearly million tablets critical initiative throughout gsk patient advocacy teams notforprofitpriced epivir licensees supplying usa europe share best practices established processes key markets significant way optimise interaction patient groups typically relationships provide mutual opportunities learn patient needs offer notforprofit prices requires sustainable framework priorities patient groups develop understanding drug combining gsks commitment preferential pricing commitments development challenges governments developed world avoid price referencing preferentially priced medicines governments patient advocacy leaders summits held usa help prevent product diversion gsk taken steps minimise brazil japanwith attending gsk sponsored meetings threat diversion registration specific access packs access usa gsk partnered centers medicaid medicare tablets differentiated red tablet opposed traditional white services develop regional meetings educate patient groupson key arvs gsk company registered arvs new medicare drug benefit increase programme participation european unions antidiversion regulation programmes countries innovative solutions group also introduced orange cards providing discounts gsk shown industry leadership granting voluntary licences certain gsk prescription medicines eligible patients bulgaria eight generic companies manufacture supply arvs lithuania ukraine nature discounts varies public private sectors subsaharan africa gsk also countriesand way healthcare system operates leader collaborating publicprivate partnerships enable new september gsk announced agreement russian drug discovery development take place effectively government supply antiretroviral medicines treatment looking ahead hivaids discounted prices agreement first direct gsk continue build product pricing partnership federal purchase antiretroviral medicines russia commitments help improve healthcare developing world preparing flu pandemic however significant increase funding global community part commitment support governments health still needed also important maintain incentives rd authorities prepare threat aninfluenza pandemic gsk protection intellectual property announced promising data immunogenicity new muchhas beenachieved sustainable progress occur generation hn pandemic influenza vaccine innovative significant barriers stand way better access pandemic vaccine candidate also believed potential healthcare tackled shared responsibility sectors global offer protection againstdriftedvariants hn virus allowing society governments international agencies charities academic proactive prepandemic vaccination approach considered institutions pharmaceutical industry otherscommitment corporate responsibility uk gsk contributed million continuing programme charitable activities supporting organisations gsk committed connecting business decisions ethical social health medical research science education arts environmental concerns thus corporate responsibility environment integral embedded part way gsk business programmes north america focused improving public education gsk published set corporate responsibility principles access better healthcare children seniors nationally provide guidance standards group committed locally funding million sets approach areas standards ethical conduct research innovation products customers access gsk operate single charitable foundation community medicines employment practices human rights community investment programmes number country based investment caring environment leadership advocacy foundations grants made foundations engagement stakeholders groupreports annually included investment total progress upholding principles corporate responsibility global health programmes report available website wwwgskcom eliminating lymphatic filariasis partnership success groups effort eliminate disabling disease lymphatic gsk works partner underserved communities filariasis lf world continued close partnership developed developing world supports programmes governments countries disease endemic innovative sustainable bring real benefits partner organisations gsk committed donate much communities group engages numerous external antiparasitic drug albendazole required treat one stakeholders funds communityled initiatives around world billion people risk countries million albendazole donates medicines support humanitarian efforts community treatments worth million wholesale acquisition cost based healthcare donated countries since global elimination programme started cumulative total almost million albendazole community investment treatments donated gsks global community investment activities valued positive action hivaids million equivalent group profit tax positive action gsks pioneering global programme working comprised product donations million cash giving communities affected aids started supports million inkind donations million costs million communitybased organisations deliver effective hiv aids manage deliver community programmes countries education prevention healthcare services positive action worked partners support programmes product donations cash giving follows countries positive action principal sponsor product donations community section global village international aids conference held toronto glaxosmithkline african malaria partnership since partnership supported three behavioural development programmes working eight african countries programmes targeted nearly two million people focusing particularly young children pregnant women encouraging effective prevention measures prompt treatment antenatal malaria management addition gsks malaria advocacy programme mobilising malaria launched country coalitions gsks cash giving targeted primarily health malaria uk belgium france ethiopia cameroon education initiatives increase awareness malaria mobilise resources breakdown cash giving gsk annual report srotcerid eht fo troper business review corporate responsibility community investment patient assistance programs million albendazole lf million humanitarian product donations million health education arts culture environment phase gsk helped launch puppets talking scienceengaging phase programme personal hygiene sanitation education science ukprimary schools grants initiated gsk providing education thousands four years puppets supporting materials increase school children kenya uganda zambia nicaragua peru childrens engagement motivate talk science gsks bangladesh improve health hygiene fight infectious support enable teachers attend subsidised training diseases group committed three year funding next four years provide set puppets training materials million extend programme mexico tajikistan participating schools partnership save children usa secondary school science teachers england humanitarian product donations chemistry specialists chemistry nonspecialists gsk donated essential products antibiotics developed royal society chemistry train teachers teach nonprofit partners including americares map international chemistry confidence flair enthusiasm gsk supporting project hope support humanitarian relief efforts programme donation three years starting community healthcare total value groups international humanitarian product donations million excludes employee involvement albendazole donated part groups commitment gsk employees encouraged contribute local lymphatic filariasis elimination programme product donations communities employee volunteering schemes support varies valued wholesale acquisition costwhich wholesale list price around world includes employee time cash donations including discounts standard industry method charities employees volunteer matching gifts programme community initiatives usa group matched employee gsk dedicated strengthening fabric communities retiree gifts value million group also matched providing health education initiatives support local civic million employee donations gsks annual united cultural institutions improve quality life way campaign gsks give program provided grants almost gsks contribution improve healthcare includes grant almost organisations us employees million three years childrens health fund expand volunteered referral management initiative rmi sites philadelphia gsks making difference programme uk provided grants including delaware valley community health center rmi nonprofit organisations registered charities ensures continuity specialist medical care highrisk children based employee involvement often homeless annual glaxosmithkline impact awards recognise excellence work nonprofit community health organisations across uk greater philadelphia area usa charities receive unrestricted awards work dealing diverse difficult social issues domestic violence sexual health services young people community health support counselling services medical research provided four uk medical charities asthma uk british retinitis pigmentosa society deafness research ukand muscular dystrophy campaign education initiatives gsks efforts improve public science education included million endowment national board professional teaching standards increase number science teachers attaining certification initially north carolina philadelphia areas extending states gsk supported institute competitive workforce new business coalition staffed business civic leadership center us chamber commerce aimed improving education creating skilled workforce gsk also supports range local initiatives usa example science summer free librarybased science education programme philadelphia area teaching basic scientific concepts continued receive support grant almost gsk annual report srotcerid eht fo troper business review corporate responsibility community investment continuedgsk annual report srotcerid eht fo troper business review global manufacturing supply gsk manufactures large portfolio products ranging tablets operational excellence toothpaste inhalers complex capsules within gms operational excellence provides capability drive different pack sizes presentations improvements process robustness quality performance manufacture medicines starts development customer service operational excellence underpinned extensive therapeutic active ingredient bulk active selected formulation education culture continuous improvement global manufacturing supply gms develops manufacturing vision factory processes full scale volume production active compounds gsk introduced vision factory initiative work towards simpler primary manufacturing sites secondary sites convert active efficient operating model within gms vision factory enabling compounds finished medicines manufacturing operations accelerate improvement year gms produces around tonnes bulk actives performance cost control four billion packs sold countries quality also supports new product line extension launches quality organisation oversees product quality across supply every year chain suppliers third party manufacturers adopting leading edge practices developing people manufacturing supply operations deliver productsinto gms provides market quality organisation focuses improving quality compliance increasing product quality understanding secure source supply high quality products harmonising quality approach across sites gsk continues compliance regulatory requirements customer expectations work fda good manufacturing practice st best class cost century initiatives organisation external suppliers gms spends billion annually many external suppliers gms operates single global network sites countries purchasing active ingredients chemical intermediates packaging sites grouped four supply divisions based common components partfinished finished products takes business drivers areas expertise commercial activities appropriate steps protect supply chains disruption support procurement primary supply widely recognised industry analysts best practice leader primary supply sites six countries supplying high quality procurement works collaboratively develop implement sourcing competitively priced bulk actives division focused strategies ensures gsk receives best value buying improvements primary technologies processes goods services gsk leverages procurement activities across new product global supply group structure new product global supply sites seven countries vaccines supply chain sites work closely rds development team ensure gsk biologicals manufacturing network based three major right technical competencies place support rapid regional hubs europe north america asia europe vaccine successful new product introduction sites also ensure secure manufacturing located primarily rixensart wavre belgium supply key brands sold across many markets division three sites france germany hungary north focal point developing introducing new secondary america gsk established vaccine production network manufacturing technologies gms three major acquisitions us based corixa corporation regional pharma supply production site hamilton montana manufactures mpl regional pharma supply operates supply key products particular key component gsks adjuvant systems vaccine production site regions markets tailor packaging meet specific local marietta pennsylvania id biomedical flu vaccine requirements division focuses reducing costs allowing gsk manufacturing facilities laval quebec canada asia new compete effectively markets regional vaccine production facilities built india singapore pharma supply sites countries managing vaccine supply chain involves anticipating market needs using flexible approach able meet fluctuations consumer healthcare supply demand based forecasts different markets consumer healthcare supply delivers highquality competitively priced firm orders health authorities mass vaccination campaigns products supports rapid new product introduction highly innovative competitive business far shorter time frames bulk filling packaging carefully balanced stocking pharmaceuticals new technologies become fundamental vaccines helps manage shortterm increases demand platform driving innovation lowering costs providing flexibility increases result disease outbreaks increased demand operations sites countries consumer public owing disease awareness campaigns healthcare supplybusiness review regulatory environment regulation pharmaceuticals price controls manycountries prices pharmaceutical products controlled gsk operates within highly regulated environment regional law governments may also influence prices control countryspecific laws regulations define data required show national healthcare organisations may bear large part safety efficacy pharmaceutical products well govern cost supplying products consumers testing approval manufacturing labelling marketing drugs regulatory requirements major factor determining recent government healthcare reforms countries france whether marketable product may successfully developed spain germany may restrict pricing reimbursement amount time expense associated development usa recent legislation healthcare reform crossborder trade europe pharmaceutical firms regulators managing acceleration generics market increased patient transition following implementation new medicines legislation contributions increased focus pricing end significant changes implemented currently government price controls private including approval procedures post marketing requirements sector purchases federal law requires pharmaceutical manufacturing controls labelling requirements pharmacovigilance manufacturers pay prescribed rebates certain drugs order processes increased emphasis transparency eligible reimbursement medicaid federal regulatory processes healthcare programmes climate change set continue finalisation new medicare paediatric regulation end regulation aimed us medicare program federally funded healthcare stimulating industry research paediatric indications via intellectual insurance program benefiting senior citizens certain disabled property incentives implementation activities continue americans included coverage prescription medicines new provisions become operational new benefit medicare program dramatic change program since inception coverage eu commission championing better regulation initiative voluntary includes brandname generic drugs open cut red tape overregulation industry gsk actively supporting million americans medicare coverage initiativeand similar one uk example uk gsk made wide ranging better regulation proposals number competing private organisations provide new benefit government covering significant areas interest group many premiums subsidised government benefits must satisfy positively received considered minimum standard outlined federal law law provides incorporation new regulations incentives manufacturers negotiate prices private plans provide government price controls government usa safety prescription drugs remains primary focus provides additional help million people medicare fda congressional oversight committees evaluating limited incomes resources qualifying beneficiaries ability resourcing fda continue provide pay reduced premiums deductibles low copayments important role new safetyrelated legislation proposed prescriptions congress may enacted likely impact pharmaceutical industry europe evaluation benefit risk value money continues important consideration approval new payers around world concerned cost healthcare drug fda pricing medicines requirement satisfy healthcare purchasers value money becoming additional hurdle fdais second year critical path initiative facilitate product acceptance regulatory tests safety innovation drug development new tools processes efficacy quality pharmacogenomics surrogate markers efficacy manufacturing innovations pursued enhance development safe appropriate payers seek value money effective drugs pharmaceutical industry including gsk purchasing medicines often translates costcontainment collaborating fda national institutes health measures delay patient access new medicines make number areas including evaluation new biomarkers difficult even significantly improved therapies achieve price reflects added value healthcare budgets could managed us government making information benefits strategic longterm manner focus shift value risks prescription drugs readily available via internet cost pricing reflect value value defined including full prescribing information posted within one broadly matters whether medicine works responds day approval gsk providing product labelling fda medical patient needs rewarded appropriately electronic format allows easier access key details prescribing information gsk well placed manage effectively changes external regulatory environment gsk annual report srotcerid eht fo troperbusiness review regulatory environment continued payers must also allocate resources efficiently provide best patent position respect active ingredients significant health outcomes attention focused three areas products follows prevention innovationand better management chronic diseases avandiaand avandamet patent rosiglitazone due part triple solution innovative medicines vaccines expire ac usa b europe patents play key role preventing providing better treatments commercial form active ingredient rosiglitazone maleate expensive diseases cervical cancer breast cancer asthma due expire usa b europe litigation alzheimers diabetes challenging validity patents protecting products possible predict whetherand extent groups ongoing usae business affected future legislative regulatory avodart patent dutasteride due expire developments relating specific pharmaceutical products usa beurope price boniva patent ibandronate due expire ab regulation consumer healthcare usaand europe consumer healthcare industry subject national regulation combivir patent specific combination lamivudine testing approval manufacturing labelling marketing zidovudine due expire usa b europe products many countries high standards technical appraisal coreg gsk exclusive licensee us patent carvedilol involve lengthy approval process new product launched due expire ac national regulatory authorisation also required approve switch epivir patent lamivudine due expire ac products prescription otc requirements include long usa beurope term experience quality safety efficacy product imigranimitrex patent sumatriptan due expire wide patient population data confirm relevant cusa expired europe except cyprus italy condition selflimiting easily diagnosed consumer switzerland litigation challenging validity patent protecting product usa settlede intellectual property lamictal patent lamotrigine due expire ac intellectual property key business asset gsk effective legal usa litigation challenging validity patent usa protection intellectual property critical ensuring reasonable settled europe corresponding patent expired return investment rd intellectual property protected generic competition exists patents trademarks registered designs copyrights domain name registrations levitrad gsk copromotion rights uspatent vardenafilwhich due expire certain markets including usa eu canada also provide period regulatory data exclusivity qualifying drugs lexivatelzir gsk exclusive licensee patent new chemical entities new formulations uses fosamprenavir due expire usa marketed drugs manufacturers generic drugs may following beurope period data exclusivity launch attempt launch paxilseroxat patent commercial form paroxetine generic versions patented drugs prior normal patent expiry expired europe due expire cin usa arguing relevant patents invalid andor infringed litigation relating validity infringement patent directed product significant litigation concerning challenges method manufacture paroxetine hydrochloride anhydrate summarised note financial statements ongoing usae generic competition paxilinstant release legal proceedings ir oral suspension commenced usa europe patents certain markets paxil cris protected formulation patent gsks policy seek obtain patent protection protectable due expire generic manufacturer inventions discovered developed rd activities patent applied fda approval generic form paxilcr asserting non protection new active ingredients available significant infringement patente markets protection also obtainedforexample new requip patent ropinirole due expire ausa pharmaceutical formulations manufacturing processes medical uses beurope patent relating use ropinirole special devices administering products patents protecting parkinsons disease due expire usa b new active ingredients generally applied early europe litigation challenging validity parkinsons use development process since term patent countries patent ongoing usae set period filing date typicallyyears effective term depends long product development seretideadvairthe patent specific combination salmeterol launch leads variation patent term product xinafoate fluticasone propionate due expire product basis although number markets including usa usa beurope application reissue us patent europeit possible certain circumstances obtain partial allowed uspatent trademark office usptoe restoration patent term compensate length uk patent revoked ukcourts patents development process individual ingredients expired uk usa patent salmeterol xinafoate expire gsk annual report srotcerid eht fo troperbusiness review regulatory environment continued sereventthe patent salmeterol xinafoate due expire responsibility environment health safety usa europe patent expired except france environment health safety ehsis key element corporate b italy b responsibility group high priority responsibility trizivir patent method treatment using combination ehs highest level corporate group reporting lamivudine zidovudine abacavir expire usa general counsel overall responsibility providing europe governance leadership ehs issues head group makes regular reports corporate executive team cet valtrex patent valaciclovir due expire audit corporate responsibility committees board within usa beurope except greece spain litigation businessesoperations managers responsible ehs challenging validity patent usaeis ongoing supported sitebased ehs occupational health staff wellbutrin sr wellbutrin xl andzybanthe patent active ehs strategy plan ingredient expired generic competition gsk strategic planning process ehs looks forward sustained release srand instant release ir forms usa years reviewed every year plan aligned gsk generic competition mg dosage form wellbutrin xl business drivers includes management objectives commenced usa december europe regulatory performance measures targets gsks progress first data exclusivity provides protection markets five years ehs plan excellence evaluated ayear litigation ongoing usa relating formulation patents plan extending developed covering wellbutrin xlthat expirein e first five years focused establishing fundamentals ziagen patent abacavir due expire acusa preparing programmes would contribute environmental beurope sustainability business successes included greater zofran patent ondansetron expired usa integration ehs manufacturing planning process europe except france b italy b patent use introduction ehsdirectors manufacturing executive teams treating emesis expired usa generic entry establishment new performance targets establishment new ondansetron injection oral solution dosage forms commenced targets audit scores gsks november tablet orally disintegrating tablet dosage manufacturing sites contract manufacturers publication forms december generic competition also positions pharmaceuticals environment selection commenced number countries europe hazardous chemicals manufacturing energy conservation next phase plan strengthens focus operational including granted pending patent term restoration hatchwaxman act b including granted pending extension term national european efficiency renews commitment stakeholder engagement supplementary protection certificates three aspirations embedding ehs c including granted pending extension term paediatric exclusivity registered trademark bayer ag business environmental sustainability open transparent e see note financial statements legal proceedings stakeholder relations trademarks strategic focus gsks pharmaceutical products protected registered plan provides area special focus year trademarks major markets may local variations focus embedding ehsin business making ehs integral example usa trademark paxilis used instead seroxatand part gsks business processes continuous improvement culture advairis used instead seretide participation employees goal develop culture every employee mindful importance safe working trademark protection may generally extended long protecting environment focus trademark used renewing necessary gsks trademarks take one year accomplish pharmaceutical products important maintaining brand identity product upon expiration patent consumer healthcare trademarks particularly important business brand orientated many products patent protection gsk annual report srotcerid eht fo troperbusiness review regulatory environment continued part embedding ehs gsk meant business developed gsk selected measures performance improvement based plan moving ehs forward based risks potential adverse impact people environment opportunities accomplishments objectives business continuity business reputation measures contributed overall focus selected similar reported companies recommended global reporting initiative longterm multi reduce need respiratory protective equipment stakeholder international undertakingto develop disseminate occupational hygiene monitoring data utilised focus globally applicable sustainability reporting guidelines targets attention processes need improvement set eliminate cfcs uses year improve efficiency manufacturing processesit agreed reduce energy use nonhazardous waste disposed reduce new products launched evaluated water use volatile organic compound voc releases using green chemistry tools target double reduce chemical oxygen demand wastewater targets manufacturing efficiencywhich result waste per tonne normalised sales product new processes reduced half comparison ehsperformance existing processes performance improve ehs management systemsa target set improve cfc emissions patient use inhalers per sales audit scores pharmaceutical manufacturing sites required certified iso ohsas volatile organic compound emissions per sales minimise ehs risks arising new product introduction chemical oxygen demand wastewater per sales process changes ehs requirements sustainability principles nonhazardous waste disposed per sales incorporated product development process energy use per sales improve ehs performance rd processes novel technologies explored water use per sales ehs audits sustainability part governance responsibility gsk conducts ehs audits work towards sustainability gsk addressing economic sites assessing performance ehsstandards environmental social issues research manufacturing sales assigning quantitative performance scores sites distribution medicines sustainability starts healthcare audited achieved audit scores better site solutions found rd continues sustainable solutions scored less part continuous improvement manufacturing sales rd considering improving operational process progress monitored actions arising issues raised efficiency new products future ehs plan excellence audits proposes investigating use renewable resources group seeks dialogue external stakeholders considers views part commitment corporate responsibility pro developing approaches sustainable development active management gsk manufacturing supply base information ehs programmes performance may found suppliers also assessed representing priority gskwebsite suppliers process evaluated management key ehs risks impacts well human rights issues based groups requirements priority suppliers recommendations made improvements needed ehstargets part ehs plan targets set every five years baseline year next group fiveyear targets ehs reportachievements targets reported progress towards meeting targets tracked every year final data published website wwwgskcom gsk annual report srotcerid eht fo tropergsk annual report srotcerid eht fo troper business review world market world economy world market pharmaceuticals global economy remained relatively robust positive global pharmaceutical sales increased billion growth many markets usa chinaworld gross world market value growth domestic product growth estimated geographic region bn total analysts expect fall back towards end usa oecd trimmed global growth forecast europe lowest rate since france equity marketsroseduring concerns regarding inflation germany started torecedeas year progressedonly return regions uk later year global oil prices hit abarrel highs midjuly italy followingthe crisis israel lebanon closed oil japan fell towards mark levelaroundwhich many analystsfeelit asia pacific trade barring unforeseen events latin america middle east africa usagdp growth slipped two year high canada first quarter fourth quarter performance total impacted asignificant extent weakeninghousing market drop new housing starts expected continue growth us market hasincreasedtobut still represents throughout us interest ratesrosefrom global prescription pharmaceutical market compared seventeenth rise two half years december decade ago us dollar fell lowest level almost two yearsagainst euro year low againststerlingin us economy th september gsk heldsecondposition world expected experience softlanding rather major slowdown pharmaceutical market market share behind pfizer growth predicted rangeto market share gsk six worlds top pharmaceutical products avandia lamictal rapid expansion chinese economy seretideadvairvaltrexwellbutrinand zofran grew byover whileindia reportedgrowth indias sensex index gained value japans nikkei world market value growth index moved ahead year japan currently experiencing top five therapeutic classes bn total cer longest period uninterrupted growth since second world cardiovascular war reporting gdp growth yearend central nervous system eurozone interest rates began year rising five alimentary tract metabolic separate steps year end economic growth antiinfectives bacterial across continent germany expanded viral fungal excluding france byand spain uk interest rates rose vaccines november ftse gaining almost respiratory economic growth treasury bank note data based months thseptember england expecting growth exchange currencies influence groups results us dollar euro japanese yen us dollarfellby poundto yearend yearend rates euro weakened japanese yen againststerlingbusiness review products competition pharmaceutical products antivirals combivir combination retrovirand epivir consolidated glaxosmithklines principal pharmaceutical products currently position two reverse transcriptase inhibitors directed toeightmain therapeutic areas analysis salesby cornerstone many multiple antihiv product regimens physician therapeutic areas description principal products acceptance clearly demonstrated value placed minimising setout pill burden faced patients ziagenis reverse transcriptase inhibitor products potency ease turnover therapeutic area use resistance profile allow play significant role respiratory variety highly active well tolerated simplified hiv central nervous system treatment regimens antivirals metabolic triziviris combination combivirand ziagen combining three anti vaccines hiv therapies one tablet twice daily administration cardiovascular urogenital epzicomkivexa approved use usa europe antibacterialsantimalarials combination epivirand ziagenthat taken one tablet oncology emesis oncedaily dosing hivaids combination least one antihiv drug lexivatelziris protease inhibitor treatment hiv well products formulations may approved tolerated convenient agenerasewhich supersedes indications markets available lexiva may taken twice daily daily boosted ritonavir respiratory seretideadvair combination sereventand flixotide offers along zeffixhas approved marketing usa europe china acting bronchodilator antiinflammatory single inhaler markets treatment chronic hepatitis b approved treatment asthma copd valtrexis treatment episodic genital herpes well long flixotidefloventand becotidebecloventare inhaled steroids term suppression reduction transmission genital herpes treatment inflammation associated asthma copd zoster shingles cold sores chicken pox valtrex supersedes zovirax also used treat herpes infections sereventis longacting bronchodilator used treat asthma copd ventolinis selective shortacting bronchodilator used metabolic treat bronchospasm avandia potent insulin sensitising agent acts underlying pathophysiology type diabetes flixonaseflonaseand beconaseare steroid intranasal preparations treatment perennial seasonal rhinitis avandametis combination avandiaand metformin hciit first medicine targets insulin resistance decreases glucose central nervous system cns production one convenient pill seroxatpaxilis selective serotonin reuptake inhibitor ssri treatment major depressive disorder panic obsessive compulsive avandarylis acombination avandiaand amaryl sanofiaventis disorder post traumatic stress disorder social anxiety disorderand productavandaryltargets insulin resistance stimulates pancreatic generalised anxiety disorder controlled release formulation paxil cr insulin production also available usa bonvivabonivais longactingbisphosphonate available wellbutrin antidepressant available usa monthly oral quarterly injection forms treatment international markets normal sustainedrelease sr oncedaily osteoporosis xlformulations vaccines imigranimitrexis ht receptor agonist used treatment gsk markets vaccines worldwide half ofsevere frequent migraine cluster headache become combination vaccines protect children adolescents andor reference product sector naramigamergeis also ht adults againstup tosix diseasesat time receptor agonist indicated treatment ofmigraine infanrixis gsks range paediatric vaccine combinations infanrix lamictal well established treatment epilepsy also indicated provides protection diphtheria tetanus pertussis bipolar disorder whopping cough infanrix pentaeuropepediarixusa canada provides additional protection hepatitis b polio requipis specific dopamine dd receptor agonist indicated infanrix hexafurther adds protection haemophilus influenzae treatment ofparkinsons disease restless legssyndrome rls type b cause meningitis usa boostrixis available add protection pertussis whopping cough routine tetanusdiptheria booster administered teenagers gsks hepatitis vaccines range havrixprotects hepatitis engerixbagainst hepatitis b gsk annual report srotcerid eht fo tropergsk annual report srotcerid eht fo troper business review products competition continued twinrixis available combined hepatitis b vaccine integrilinis gp iibiiia inhibitor approved eu prevention protecting diseases one vaccine available early myocardial infarction patients unstable angina non adult paediatric strengths europe fendrix vaccine qwave mi prevent hepatitis b patients renal insufficiency including high antibacterials antimalarials risk groups prehaemodialysis haemodialysis patients augmentinis broadspectrum antibiotic suitable treatment available years age onwards wide range common bacterial infections particularly gsk added fluviralto portfolio products acquired effective respiratory tract infections augmentin esis canadian vaccine manufacturer idbiomedical corporation extra strength suspension specifically designed treat children december fluviralis marketed canada recurrent persistent middle ear infections augmentin xris extra flu vaccine approved usfood drug administration strength tablet form adults combat difficult treat infections fda active immunisation adults years older ceftinzinnat oral antibiotic used primarily community influenza disease thebrandflulaval fluviraland flulavaladd acquired infections lower respiratory tract fluarix gsks seasonal flu vaccine distributed countries including theusa malarone oral antimalarial used treatment prophylaxis malaria caused plasmodium falciparum gsk also markets priorix measles mumps rubella vaccine typherix vaccine protection typhoid fever varilrix lapdapis effective well tolerated therapy treatment vaccine varicella chicken pox priorixtetra gsks new malaria developed publicprivate combination vaccine prevent measles mumps rubella varicella collaboration mmrv firstlaunched germany august addition oncology emesis group markets range vaccines prevent meningitis zofran used prevent nausea vomiting associated umbrella name mencevax gsks new hibmenc vaccine chemotherapy radiotherapy cancer available menitorix available uk gsks meningitis vaccine bothoral injectable forms also approved use portfolio complimented new meningitis conjugate vaccines prevention treatment postoperative nausea vomiting near future hycamtinis second line treatmentfor ovarian cervical andsmall part paediatric franchise gsk continued roll launch cell lung cancer vaccine rotavirus induced gastroenteritis rotarixwhich launched incountries worldwide rotavirus vaccination bexxaris treatment patients cd follicular nonhodgkins included national vaccination calendar five latin lymphoma without transformation whose disease american countries rotarixwill available free public health refractory rituximab relapsed following clinics part ofgovernmentalpaediatric immunisation programmes chemotherapy cardiovascular urogenital arranon nelarabine treatment patients tcell acute coregis alphabeta blocker proven effective lymphoblastic leukaemia tcell lymphoblastic lymphoma received intreating patients mild moderate severe heart failure heart us approval submitted european approval attack hypertension gsk sole marketing rights usa canada generic versions product available canada levitrais pde inhibitor indicated male erectile dysfunction category includes betnovate thehigher potency dermovateand gsk copromotion rights usa newer cutivate antiinflammatory steroid products markets used treat skin diseases suchas eczema psoriasis relafen nonsteroidal antiinflammatory drug treatment arthritis avodartis ari inhibitor currently indicated benign prostatic zantac treatment peptic ulcer disease range hyperplasia large clinical outcome study underway examining ofgastric acid related disorders efficacy prevention prostate cancer arixtra selective factor xa inhibitor indicated prophylaxis deep vein thrombosis may lead pulmonary embolism hip fracture surgery knee replacement hip replacement surgery abdominal surgery also indicated treatment deep vein thrombosis pulmonary embolism fraxiparineis lowmolecular weight heparin indicated prophylaxis thromboembolic disorders particularly deep vein thrombosis pulmonary embolism general surgery orthopedic surgery treatment deep vein thrombosis prevention clotting hemodialysisgsk annual report srotcerid eht fo troper business review products competition continued pharmaceuticals competition antivirals gsk pioneer hiv market launching azt retrovir pharmaceutical industry highly competitive gsks principal epivirin today available combivirin single competitors range small largepharmaceutical companies tablet cornerstone hiv combination therapy launches often substantial resources companies ziagen agenerase trizivir lexiva epzicom broadened major products mentioned thegroups portfolio hiv products major competitors hiv pharmaceuticals may subject competition products market include gilead bristol myers squibb abbott roche period patent protection patent boehringer ingelheim generic versions manufacturers generic products typically valtrexhas strengthened groups position antiherpes area donot bear significant research development education gsks valtrex zovirax compete novartis famvir marketing development costs consequently areable offer valtrex market leader whilst zovirax faces competition products considerably lower prices thebranded competitors generic acyclovir hepatitis b market gsks zeffixwas first research development based pharmaceutical company antiviral market gileads hepsera second group normally seek achieve sufficiently high profit margin sales secured marketing rights hepserain key markets volume period patent protection repay original investment generally substantial fund research forthe metabolic future competition generic products generally occurs patents major competitor avandiais takeda chemicals actos major markets expire increasingly patent challenges made prior copromoted eli lilly usa takeda also market patent expiry claiming innovator patent valid andor actoplusmet combination metformin hci actos usa infringed generic product following loss monthly bonivabonvivacompetes mercks weekly fosamax patent protection generic products rapidly capture large share proctor gamblesanofiaventiss weekly actonel generic fosamax market particularly usa alendronate available several eumarketsincluding uk gsk believes remaining competitive dependent upon germany also canada discovery development new products together effective vaccines marketing existing products within pharmaceutical industry vaccine market dominated five key players gsks major introduction new products processes competitors may competitors include sanofipasteur sp merck novartis wyeth affect pricing levels result changing patterns product use within paediatric vaccine field infanrixsmain competitor sps assurance products become outmoded range dtpabased combination vaccines although infanrix notwithstanding patent trademark protection addition hexa combination available hexavalent paediatric increased government pressures physicians patients combination europe use generic pharmaceuticals rather brandname medicines may increase competition products longer protected cardiovascular urogenital patent gsk markets coregin usa major competitors toprol xl generic betablockers avodartcompetes directly mercks respiratory proscar within bph market group copromotion rights gsks respiratory franchise driven growth seretideadvair usa levitra faces competition pfizers viagra major respiratory competitors singulair merck especially lillyscialis usa symbicort astrazeneca spiriva pfizer boehringer ingelheim antibacterials antimalarials generic versions augmentinand ceftinzinnatare available cns disorders usa augmentinalso faces generic competition various major competitors usa paxilare generic forms well european countries augmentin xr augmentin es compete generic fluoxetine generic form eli lillys prozac generic broad range branded generic antibiotics sertraline generic form pfizers zoloftcymbalta eli lilly malaronessafety profile convenient dosing regimen helped forest laboratories celexa lexapro effexor xr wyeth put product strong position versus mefloquine principal competitors usa wellbutrinare generic forms malaria prophylaxis bupropion generic forms ssris lexapro effexor xr cymbalta paxil cr oncedaily wellbutrin xlhelp retain oncology emesis strong presence antidepressant market given availability zofranprovidedgsk leadership position antiemetic generic paroxetine bupropion usa generic market competitor companies include roche sanofiaventis competition seroxatpaxil also occurred number recently mgi merck generic competitors became markets available late zofrannow full generic competition usa major competitors diverse cytotoxic market include bristol major competitors lamictal epilepsy jjs dilantin myers squibb sanofiaventis novartis rochegenentech gsks generic phenytoin novartiss tegretoltegretol xr generic cytotoxic portfolio led hycamtin currently holds relatively small carbamazepine ucbs keppra abbots depakotedepakote er market position inbipolar major competitors generic lithium anti epileptics including abbotts depakotedepakote erand atypical antipsychotics including astrazenecas seroquel major competitors imitreximigranare astrazenecas zomig mercks maxalt pfizers relpaxgsk annual report srotcerid eht fo troper business review products competition continued consumer healthcare products oral care leading oral care products toothpastes mouthwashes glaxosmithklines principal consumer healthcare products three aquafresh odol sensodyneandmacleansbrand names major areas analysis sales areas isset range toothbrushes sold aquafreshand dr best names addition denture care products available principally polident poligripand coregabrand names otc medicines nutritional healthcare oral care leading products category lucozadeenergy sports nutritional healthcare drinks ribena blackcurrant juicebased drink horlicks range milkbased malted food chocolate drinks major products necessarily sold markets consumer healthcare competition category product gsk holds leading global positions key consumer product overthecounter medicines areas worldwide third largest oral care otc analgesics panadol medicines nutritional healthcare holds leading position dermatologicals zovirax uk india ireland abreva environment consumer healthcare business external nasal dilators breathe right operates become ever challenging gastrointestinal tums citrucel consumers demanding better quality better value respiratory tract contac improved performance beechams retailers consolidated globalised strengthened smoking control commit negotiation power nicorette nicoderm cq manufacturers consolidating leading aggressive niquitin cq competition across elements marketing mix nicabate cq cycle times innovation reduced natural wellness support abtei main competitors include major international companies oral care aquafresh colgatepalmolive johnson johnsonprocter gamble unilever dr best wyeth addition many companies macleans compete gsk certain markets odol odol med major competitor products otc medicines polident usa metamucil laxative pepcid indigestion private poligrip label smoking control products sensodyne nutritional healthcare lucozade uk lemsip cold remedy nurofen anadin analgesics ribena nicorette nicotinell smoking control treatments horlicks oral care major competitors colgatepalmolives colgate procter gambles crest overthecounter medicines leading products panadol widely available paracetamol nutritional healthcare major competitors horlicksare ovaltine acetaminophen analgesic nicorettegum usa nicoderm milo malted food chocolate drinks competitors niquitin cq nicabaterange smoking control products tums ribena primarily local fruit juice products lucozade calciumbased antacid citrucellaxative contacfor treatment competes energy drinks colds abtei natural medicines vitamin range zovirax abrevafor treatment cold sores december company acquired breathe rightnasal strips gently lift open nasal passages provide better breathing fiberchoicedaily fibre supplements acquisition cns inc gsks portfolio strengthened us launch alli new treatment weightlossgsk annual report srotcerid eht fo troper business review financial review pharmaceutical turnover central nervous system cns cns sales increased billion sales increased usa growth rates included review turnover constant international declined europe due generic competition exchange rates cer unless otherwise stated sterling growth total seroxatpaxilsales grew million due strong rates may found tables pharmaceutical turnover growth paxil crin usa paxil irin japan partly offset therapeutic area pageand geographic region page generic competition paxil irin europe total pharmaceutical turnover million compared million increase cerwithin total wellbutrinsalesgrew millionsalesof wellbutrin groups portfolio turnover new products first launched major xlaoncedaily productgrew millionin december market within last five years accounted generic competition wellbutrin xl mg tablet total turnover grew million approximately wellbutrinsales entered us market million turnover established franchise products sales lamictal treatment epilepsy bipolar disorder amounted million million representing grew billion benefiting new indication total turnover increased compared last year treat one serious forms epilepsy primary generalised turnover older products less actively promoted tonicclonic seizures lamictalis also medicine longterm million millionrepresenting total turnover clinical data demonstrates delay onset depressive declined sterling terms total pharmaceutical turnover episodes bipolar disorder november gsk submitted lamictal xr increased less cer due principally strength new daily treatmenttothe fda treatment epilepsy sterling major international currencies company intends present data lamictal xr american academy neurology meeting april pharmaceutical turnover therapeutic area sales requip parkinsons diseaseand restless legs syndrome gsks abilityin deliver continued pharmaceutical turnover rls grew million december fda accepted growthwas primarily due exceptionally broad product portfolio gsks file approval ofthe new formulationrequipcr ofhighvalue growth productscoupled withsalesandmarketing excellence growth products include seretideadvair antivirals avandiaproduct group vaccines lamictal valtrex coreg requip total sales hiv products billion competition avodartand boniva older products combivirdown million epivir million wasmostlyoffset strong sales growth respiratory new products epzicomkivexawhich doubled gsk continues global leader respiratory pharmaceuticals million lexivaageneraseup million sales three key products seretideadvair flixotideflovent serevent amounting billion total sales sales valtrexrose million us sales seretideadvair asthma copd rose billion million driven patients switching suppression therapy usa sales grew billion europe sales grew metabolic billion international markets sales grew gsk launched avandiafor treatment type diabetes million market share value antiasthma copd combination product avandamet blood sugar control therapy class europe usa increase product group expanded february ofpercentage points europe aflatmarket share growth launch usa fixeddose combination treatment usa reflectinglower prescription volumes due toa label change avandaryl combines avandiawith sulfonylurea early restricted gsks ability promote product offset favourable pricingchanges sales avandiaproduct group grew billion usa europe sales grew million driven market share value increasing use avandamet sales international markets rose million avandiaproduct group achieved market share value oral antidiabetics usa europe percentage points respectively usa avandametprescription volumegrowth adversely impacted product supply issues yearwhich havenowbeen resolved december gsk presented data landmark adopt study demonstrated avandiais effective metformin sulphonylurea longterm blood sugar control type diabetes europe usa europe usa data addition recently presented dream september september study showed avandiacan reduce risk progression type diabetes data studies expected positive results towards revolution copd health filed regulatory agencies first half torch study largest kind filed regulators early gsk recorded turnover million share copromotion income february published new england journal bonivabonviva new oncemonthly oral bisphosphonate medicine results three year study sponsored gsk treatment postmenopausal osteoporosis developed showed important benefits seretidein treatment patients roche launched copdgsk annual report srotcerid eht fo troper business review financial review continued pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrinir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis infanrix pediarix boostrix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine antibacterials augmentin zinnatceftin oncology emesis zofran hycamtin zantac cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given financial record pagestogsk annual report srotcerid eht fo troper business review financial review continued vaccines individual governments determine pricing medicines overall vaccine sales increased billion good countries within europe result wide price variations performances regions us sales rose million product parallel trade occurs third parties exploit european sales grew million sales international price differential purchasing products markets low prices million key contributors infanrixpediarix enforced selling governments purchasers gsks combination vaccines children sales markets higher prices agreed parallel million sales hepatitis vaccines grew trade permitted single market rules european million benefiting strong us performance havrix following union gsk derive benefit profit resale approval last year broader paediatric use higher price sales new vaccines also helped drive overall sales growth total result management believes within european region sales rotarix rotavirus boostrix prevention diphtheria turnover market invoiced basis presented tetanus whooping cough influenza vaccines fluarixflulaval properly represent consumption products within reached million first full year sales market gsk employees based market instrumental flulavalfollowing acquisition id biomedical late promotion groups products within market thereby creating product sale final consumption market oncology emesis sales zofrangrew million driven us market following table gives adjustments made order restate million europe international sales declined turnover markets within europe turnover created basis respectively due generic competition generic pharmaceutical turnover europe region competitor zofranentered usmarket innovember turnover created basis cardiovascular urogenital sales coregfor heart diseasegrew million avodart region invoiced adjustment created invoiced adjustment created benign prostatic hyperplasia enlarged prostatehad strong major markets year sales increasing million europe france antibacterials uk antibacterial sales declined reflecting generic competition italy weaker flu season germany therapeutic areas spain sales zantacfell million declines europe europe international partially offset growth usa adjustments gsks estimates based recent data regional analysis independent external sources valued insterling relevant exchange rates management believes turnover created basis pharmaceutical turnover geographic region reporting turnover market provides better reflection invoiced basis performance businesses market within europe turnover reported table represents sales invoiced gsks local entity customers local market plus co total turnover europe region unaffected promotion income within market restatement region growth parallel trade occurs occasionally elsewhere world major markets total cer sufficiently material affect significantly turnover data market usa presented invoiced basis europe france uk italy germany spain europe international asia pacific japan middle east africa latin america canada cer represents growth constant exchange rates represents growth actual exchange ratesgsk annual report srotcerid eht fo troper business review financial review continued pharmaceutical turnover geographic region vaccines grew reflecting good performance pediarixand turnover created basis boostrix fluarixand launch flulavalin turnover market within europe adjusted effects coregsales increased million continued benefit parallel trade show turnover basis country wide range indications heart disease zofran sales product finally consumed product sold gsk increased million generic competitor zofranentered market innovember region growth major markets total cer antibacterial sales declined result generic competition usa europe europe discussion individual market performance europe region france turnover created basis uk italy sales europe contributed pharmaceutical turnover germany grew billion strong sales seretide spain avandiaavandametand vaccines offsetting impact generic europe competition number products continued price cuts resulting fromgovernment healthcare reforms international asia pacific markets recorded good growth included germany uk japan central southeast europe whilst growth france middle east africa netherlands poland italy spainwas adversely impacted pricing latin america generics canada major growth drivers seretide gsks largest selling product europe growth avandiaavandametwhich grew vaccines franchise sales ofantiviralsgrew cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given financial record primarily due government orders ofrelenzaas measure pagesto event ofa potential flu pandemic usa generic competitionnegatively impacted sales seroxatdown strong sales performance usa billionwas lamictaldown zofrandown imigran main contributor tototal pharmaceutical turnover growth sales antibacterials decreased due combination weaker flu season generic competition advairsales grew millionfloventsalesincreased international flonase indicated treatment perennial rhinitis international region reported year year turnover growth declined following launch generic competitor strong growth japan despite biennial price q reductions chinahong kong latin america partly offset bymodest sales growth canada sales wellbutrinproducts grew million reflecting australia canadian sales performance reflected generic performance wellbutrin xl new oncedaily product grew competition imigranand zofranwhilst australian business million negatively impacted government pricing reforms generic total sales paxilwere millionlargely due tothe competition lamictaland paxil rectification supply issues experienced cidra plant performance japan driven sales paxil puerto rico serevent antivirals full year impact sales antivirals therapeutic area grew hiv products zyrtec allergy product inlicenced fromucbin herpes products competition older partially offset declines older products zantacand zovirax productscombivirdown epivirdown partly flonasealso declined due low pollen season offset growth new products epzicomkivexaup across markets international key products driving growth lexivaup valtrex herpes grew driven seretide grew record sales million patients switching suppression therapy avandiarange products grew million hiv sales avandiaproduct group increased reflectingthe products grew vaccines franchise recorded resupply product following supply disruption cidra plant growth achieved sales million puerto rico price increasesgsk annual report srotcerid eht fo troper business review financial review continued consumer healthcare sales selling general administration analysis consumer healthcare sales set selling general administration sga costs percentage following table turnover reduced percentage points constant exchange rates decrease percentage points reflecting flat expenditure growth cer compared prior year turnover growth sga costs otc medicines flat due higher advertising promotion selling expenditure analgesics offset lower general administration expenditure advertising dermatological promotion selling increased accounted increase gastrointestinal total sga general administration expenditure declined respiratory tract accounted decline total sga one smoking control percentagepointwas due lower charges related legal matters natural wellness support one percentage point due lower costs related programmes deliver future cost savings oral care research development nutritional healthcare rd expenditure increased partly result higher charges related restructuring programmes excluding restructuring costs rd grew broadly inline turnover pharmaceuticals rd consumer healthcare sales grew billion sales expenditure excluding restructuring costs represented international europe performing well total sales pharmaceutical turnover usa flat improved performance fourth quarter sales operating income otcmedicines operating income includes royalty income equity investment disposals impairments product disposals fair value overthecounter medicine sales grew billion panadol adjustments quest collar theravance options smoking control performing well operating income million compared oral care million decrease primarily due lower product oral care sales grew million sensodynegrew strongly asset disposal profits partially offset favourable fair value year million sales aquafreshwere movement quest collar theravance options million operating profit nutritional healthcare overallthe operating profit margin increased percentage points nutritional healthcare products sales grew million operating profitincreased sterling termsto million lucozade grew million horlicks grew operating profit increased constantexchange rates million ribenasales million margin increased percentage points reflectingsga growth rate turnover growthpartially offsetbyhigher costs operating profit related programmes deliver future cost savings lower operating income analysis operating profit subsequent discussion compares results results gains asset disposalswere million million growth costs legal matters million million cer fair value movements quest collar theravance options turnover resulted income million million charges relating costsaving programmes million cost sales million total operating profit impact items selling general million charge compared million charge administration research profit taxation development operating discussion compares results results income share profitslosses joint ventures associated operating profit undertakings share profits associates arises principally groups cost sales holding quest diagnostics inc cost sales declined percentage turnover percentage points constant exchange rates decline percentage disposal interest associates points reflecting favourable price regional miximpact disposals interests associates groups shareholding quest st december gsk annual report srotcerid eht fo troper business review financial review continued net finance costs gsk open issues japan canada subject court proceedings japan tax authorities claiming financeincome approximately yen billion million respect transactions interestincome gsk paid tax claimed required law applied fair value adjustmentsand hedges refund court decision expected late march court decision groups dispute canadian revenue authority pricing zantacin years finance costs expected first half interest costs unwinding discount liabilities gsk uses best advice determining transfer pricing fair value adjustmentsand hedges methodology seeking manage transfer pricing issues satisfactory conclusion basis external professional advice continues believe made adequate provision finance income increased compared predominantly due liabilities likely arise open assessments ultimate liability increased income extended credit receivables increased matters may vary amounts provided interest income due higher usdollar interest rates finance costs dependent upon outcome litigation proceedings reduced due refinancing two expensive bonds december negotiations relevant tax authorities january well lower swap costsresulting reduced interest rate differentials profit year growth cer taxation profit taxation year profit attributable uk corporation tax shareholders overseas taxation earnings per share pence p p current taxation earnings per ads us deferred taxation weighted average number shares millions total diluted earnings per share pence p p charge taxation profit amounting million diluted earnings per ads us represents effective tax rate group weighted average number balance sheet st december included tax payable liability shares millions million tax recoverable asset million reported last year gsks largest unresolved tax issues profit year million increase us internal revenue service irs uk hm revenue sterling terms profit attributable minority interests customs hmrc respect transfer prices related glaxo million profit attributable shareholders million heritage products increase sterling terms earnings per share increased reflecting higher profits also reduction weighted th september gsk irs agreed resolution average number shares resulting groups share buyback dispute agreement gsk made gross payments programme interest cost programme also adversely irs approximately billion final net cash cost impacts groups earnings actual rates exchange earnings group approximately billion covers federal state per share increased unfavourable currency impact eps local taxes interest benefit tax relief payments three percentage points reflects strengthening ofsterling made settlement resolved transfer pricing issues dispute major currenciesand compares atwo percentage point period due go trial february unfavourable currency impact turnover also covers subsequent years gsk previously made provision dispute settlement dividend significant impact thegroups reported earnings tax board declared fourth interim dividend pence per share rate year resulting dividend year pence four pence increase dividend pence per share equivalent gsk continues dispute hmrc primarily respect interim dividend receivable adr holders cents per ads transfer pricing controlled foreign companies legislation matters based exchange rate dividendhadan ex years date parties preparing dividend date th february record date th february litigation hmrc formally quantified claims respect paid th april liability interim matters continues wide difference dividend recognised paid usually group hmrc positions matters accounting period relates financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends total million milliongsk annual report srotcerid eht fo troper business review financial review continued critical accounting policies us medicaid programme stateadministered programme providing assistance certain poor vulnerable patients consolidatedfifnancial statements prepared accordance medicaid drug rebate program established reduce state international financial reporting standards adopted use federal expenditure prescription drugs gsk participates european union following accounting policies approved providing rebates states accruals medicaid rebates board described noteto financial statements calculated based specific terms individual state agreements accounting policies management required make estimates using combination historical experience product assumptions affect amounts assets liabilities revenue population growth anticipated price increases impact expenses reported financial statements actual amounts contracting strategies results could differ estimates following considered critical accounting policies adopted cash discounts offered customers encourage prompt payment accrued time invoicing adjusted turnover subsequently reflect actual experience revenue recognised title risk loss passed customer reliable estimates made relevant deductions historical experience customer returns gsk gross turnover reduced rebates discounts allowances records accrual estimated sales returns applying historical product returns given expected given vary product experience customer returns amounts invoiced together arrangements buying groups arrangements market related information stock levels wholesalers purchasing organisations dependent upon submission anticipated price increases competitor activity claims time initial recognition sale accruals reconciliation gross turnover net turnover us made time sale estimated rebates discounts pharmaceuticals businessis follows allowances payable returns made based available market information historical experience amounts estimated may fully reflect final outcome amounts subject change dependent upon amongst gross turnover things types buying group product sales mix level managed care gpo accrual reviewed adjustedregularly light contractual rebates medicare legal obligations historical trends past experience projected part market conditions market conditions evaluated using wholesaler chargebacks thirdparty analyses market research data internally usgovernment generated informationfuture events could cause assumptions state programmes accruals based change could affect future cash discounts results group customer returns groups largest business us pharmaceuticals us market prior year adjustments complex arrangements rebates discounts items allowances following briefly describes nature total deductions arrangements existence groups us pharmaceuticals net turnover business rebates given us government medicaid programme customer rebates offered key managed care group fallen replaced rebates granted purchasing organisations gpo direct indirect medicare part programmethe overall level rebates fallen customers arrangements require customer achieve slightly partly result products traditionally higher rebate certain performance targets relating value product purchased percentages becoming subject generic competition formulary status predetermined market shares relative replaced sales newer products lower rebate percentages competitors rebates given medicare part included category medicare part programme introduced total accruals rebates discounts allowances returns replaces government medicaid subsidies us pharmaceuticals businesswere follows individuals subsidised coverage provided private st st prescription plans accrual rebates estimated based december december specific terms agreement historical experience product growth rates managed caregpo rebates gsk arrangements certain key parties whereby party medicare part able buy products wholesalers lower prices chargebacks chargeback represents difference invoice price usgovernment state programmes wholesaler indirect customers contractual discounted cash discounts price accruals estimating chargebacks calculated based customer returns terms agreement historical experience product growth rates total gsk annual report srotcerid eht fo troper business review financial review continued monthly process operated monitor inventory levels intangible assets wholesalers abnormal movements process uses gross intangible assets acquired glaxosmithkline third sales volumes prescription volumes based third party data sources parties costs acquisition capitalised licences compounds information received key wholesalers aim development amortised point maintain inventories consistent level year year based available use estimated useful lives years pattern consumption basis us pharmaceutical estimated useful lives reviewed annually impairmenttestsare inventory levels wholesalers distribution channels undertaken events occur call question carrying values st december estimated amount toapproximately assets brands acquired businesses capitalised onemonth turnoverthis calculation uses third party information independently separable expected life accuracy totally verified butis believed one year brands amortised estimated useful sufficiently reliable purpose lives exceeding years except end useful economic life foreseen brands amortised taxation subject annual impairmenttests impairmenttestsare current tax provided amounts expected paid based riskadjusted future cash flows discounted using appropriate deferred tax temporary differences tax bases assets interest rates future cash flows based business forecasts liabilities carrying amounts rates therefore inherently judgemental future events could cause enacted substantially enacted balance sheet date values intangible assets impaired would group open tax issues number revenue authorities adverse effect future results group principally relation transfer pricing disputes gsk uses best pensions postemployment benefits advice determining transfer pricing methodology seeking costs providing pensions postretirement benefits manage transfer pricing issues satisfactory conclusion charged income statement accordance ias basis external professional advice continues believe period benefit derived employees services made adequate provision liabilities likely arise open costs assessed accordance advice received assessments however continues wide difference independent actuaries basis assumptions selected views open issues exist ultimate liability matters management use ifrs usgaap may vary amounts provided dependent upon assumptions include future earnings pension increases discount outcome litigation proceedings negotiations relevant rates expected long term rates return assets tax authorities disclosed note financial statements pensions legal disputes postemployment benefits expected long term rates return gsk provides anticipated settlement costs reasonable bonds determined based portfolio mix indexlinked estimate may made likely outcome dispute legal government corporate bonds equity risk premium added expenses arising claims group equities discount rates based appropriate longterm companys directors taken legal advice established indices including iboxx year aaindex uk provisions taking account relevant facts moodys aa index usa sensitivity analysis provided note circumstances matter accordance accounting reduction discount rate would lead requirements provisions product liability claims certain products increase net pension deficit approximatelymillion made incurred reported basis increase annual pension cost approximatelymillion sufficient history claims made settlements available selection different assumptions could affect future results provisions made unasserted claims claims group reasonable estimate likely outcome yet product rights goodwill made ultimate liability pending unasserted claims may addition critical accounting policies outlined vary amounts provided dependent upon accounting policy product rights goodwill deemed outcome litigation proceedings investigations possible important respect balance sheet prepared accordance settlement negotiations us generally accepted accounting principles us gaap impairment fixed assets merger glaxo wellcome smithkline beecham carrying values fixed assets subject depreciation accounted acquisition gave rise product rights amortisation reviewed impairment indication billion goodwill billion recognised goodwill values assets might impaired impairment product rights determined indefinite lives determined reference higher net realisable value amortised rather reviewed annually impairment value use measured reference riskadjusted future cash flows impairment reviews assess business projections prepared part discounted using appropriate interest rates future cash flows groups annual budgeting planning process determine based business forecasts therefore inherently whether impairment value occurred business judgemental future events could cause assumptions used projections include assumptions future events changes impairment reviews change consequent adverse effect future events could cause assumptions business projections future results group change consequent adverse effect future results group reported us gaapgsk annual report srotcerid eht fo troper business review financial position resources financial position property plant equipment total cost groups property plant equipment st december billion net book value assets billion land buildings represented billion plant noncurrent assets equipment billion assets construction billion property plant equipment gsk invested million new renewal property plant goodwill equipment mainly related large number projects intangible assets renewal improvement expansion facilities various worldwide investments associates sites property mainly held freehold new investment financed joint ventures group liquid resources st december gsk capital investments contractual commitments future expenditure million deferred tax assets operating lease commitments million noncurrent assets gsks business sciencebased technologyintensive highly total noncurrent assets regulated governmental authorities group allocates significant financial resources renewal maintenance property current assets plant equipment minimise risks interruption production inventories achieve compliance regulatory standards number current tax recoverable processes use chemicals hazardous materials trade receivables liquid investments group observes stringent procedures uses specialist skills cash cash equivalents manage environmental risks activities environmental assets held sale issues sometimes dating operations modified discontinued reported responsibility environment total current assets health safety note financial total assets statements legal proceedings gsk believes facilities adequate current needs liabilities current liabilities intangible assets shortterm borrowings intangible assets include cost intangibles acquired trade payables third parties computer software thenet book valueof current tax payable intangible assets st december million shortterm provisions millionthedecrease reflects currency movements amortisation existing intangiblespartly offset byadditions total current liabilities million largestelement additionsrelates noncurrent liabilities acquisition cns inc added gsk portfolio breathe longterm borrowings right nasal strips fiberchoicedietary products deferred tax provision investments pensions post gsk held investments including associates joint ventures employment benefits carrying value st december million provisions million market value st december million noncurrent liabilities million investments mainly equity shares total noncurrent liabilities holding derives directly groups business total liabilities largest investments associate quest diagnostics inc book value st december million net assets million investments include stakes companies equity group research collaborations provide access share capital biotechnology developments potential interest interests share premium account companies arise business divestments retained earnings trade receivables reserves trade receivables include million million shareholders equity derivative financial instruments held fair value remaining increase reflects increased sales higher vat minority interests recoverables partly offset impact weakening overseas total equity currencies translation foreign currency receivables trade payables trade payables include million million derivative financial instruments held fair value remaining decrease reflects impact weakening overseas currencieson translation foreign currency payablesgsk annual report srotcerid eht fo troper business review financial position resources continued provisions share purchases group carried deferred tax provisions shortterm esop trusts make market purchases shares noncurrent provisions million st december gsk plc nil shares held trusts satisfy future million respect estimated future liabilities exercises options awards group share option million related legal disputes award schemes proportion shares held trusts respect awards rules scheme require company provision made forlegal disputes indemnified satisfy exercises market purchases rather issue disposal liabilities costs manufacturing restructuring new shares shares held trusts matched options merger integration extent balance sheet date actual awards granted diminish dilutive effect new share issues constructive obligation existed could reasonably estimated shareholders equity earnings pensions postemployment benefits st december esop trusts held million gsk group accounts pension postemployment shares future exercise share options share awards arrangements accordance ias net deficit carrying value million deducted allowing deferred taxation million reserves market value shares million millionthe pension postemployment liabilities decreased following improvements asset values special funding gsk repurchased million shares held contributions uk us pension funds million treasury shares company completed second billion share million strengthening longterm interest rates repurchase programme september october commenced including increase rate used discount uk pension liabilities new share buyback programme totalling billion programme expected completed three year period including billion exact amount timing future purchases net debt extent repurchased shares held treasury shares rather cancelled determined company dependent market conditions factorsat st december cash cash equivalents gsk also held million shares treasury shares cost liquid investments million deducted retained earnings borrowings repayable within one year borrowings repayable one year commitments contingent liabilities net debt financial commitments summarised innoteto thefinancial statements commitments contingent liabilities net debt increased million primarily due gross obligations respect short longterm debt set innote payment billion billion transfer pricing dispute thefinancial statements contingent liabilities andnoteto settlement us internal revenue service see taxation thefinancial statements net debt page higher share repurchases partly offset increased amounts provided pensions postretirement benefitsare set operating profits note financial statements pensions post total equity employment benefitsamounts restructuring integration summary movements equity set plans legal environmental disputes set innote thefinancial statements provisions contractual obligations commitments total equity beginning year following table sets groups contractual obligations implementation accounting commitments st december fall due payment financial instruments ias total yr yrs yrs yrs total equity beginning year adjusted total recognised income expense loans year interest loans dividends shareholders finance lease obligations ordinary shares issued operating lease ordinary shares purchased held commitments treasury shares intangibleassets ordinary shares issued esoptrusts property plant equipment sharebased payments investments changes minority interest shareholdings business combinations minority interests purchase commitments total equity atend year pensions theravance put option st december total equity increased million agreement st december million increase arises principally commitments retained earnings actuarial gains defined benefit pension total plans yearpartially offset purchases treasury sharesgsk annual report srotcerid eht fo troper business review financial position resources continued commitments respect future interest payable loans cash flow disclosed taking account effect interest rate swaps asummary consolidated cash flow statement set group entered number research collaborations develop new compounds pharmaceutical companies terms arrangements include upfront fees equity net cash inflow operating activities investments loans commitments fund specified levels net cash outflow investing activities research addition group often agree make net cash outflow financing activities payments future milestones achieved decreaseincrease cash bank overdrafts agreements relate compounds early stages development milestone payments continue number years exchange adjustments compounds move successfully development process cash bank overdrafts beginning year generally closer product marketing approval greater cash bank overdrafts end year possibility success payments shown within intangible assets represent maximum would paid cash bank overdrafts end year milestones achieved number commitments made comprise licensing agreements including cash cash equivalents chemocentryx inc epix pharmaceuticals inc genmab overdrafts gsk formalised agreementwith trustees uk pension schemes make additional contributions ofup million per yearin addition normal contributionsovera four net cash inflow operating activities taxation paid yearperiod endingst december order eliminate million adecreaseof million arisingmainly thenpension deficits ias basis point tableon gross taxation payment billion billionunder pageshows commitmentbut excludes normal ongoing transfer pricing dispute settlement see partially offset annual funding requirement approximately milliongsk byhigher operating profits also committed eliminate future deficits may arise net cash outflow investing activities million rolling fiveyear period commitments made past decreaseof million reflected increased capital expenditure st december purchase ofbusinesses including cnsin formillion contingent liabilities purchases businesses wereover billion reflecting following table sets contingent liabilities comprising purchase corixa id biomedical discounted bills performance guarantees letters creditand free cash flow millionadecreaseof items arising normal course business principally reflecting us tax settlement higher levels capital expected expire expenditure free cash flow amount cash generated total yr yrs yrs yrs business meeting obligations interest tax dividends paid minority interests capital expenditure noncurrent guarantees tangible intangible assets contingent liabilities free cash flow used gsks management planning total reporting purposes discussions presentations investment analystsand rating agencies gsks free cash flow measure normal course business gsk provided various defined inifrs measure may directly comparable indemnification guarantees respect business disposals similarly described measures used companies legal disputes subsequently arisen provision made reconciliation net cash inflow operating activities reasonable estimate made likely outcome closest equivalent ifrs measure free cash flow shown dispute included noteto thefinancial statements provisions reconciliation free cash flow groups policy provide settlement costs asserted claims environmental disputes reasonable estimate may net cash inflow operating activities made prior point liability recorded legal purchase noncurrenttangible assets environmental costs discussed risk factors pagesto purchase noncurrent intangible assets gsk uses best advice determining transfer pricing disposal noncurrent tangible fixed assets methodology basis external professional advice interest paid continues believe made adequate provision interest received liabilities likely arise open taxation assessments ultimate dividends received joint ventures liability matters may vary significantly amounts provided associated undertaking dependent upon outcome litigation proceedings dividends paid minority interests negotiations relevant tax authorities discussed free cash flow noteto thefinancial statements taxationgsk annual report srotcerid eht fo troper business review financial position resources continued reconciliation net cash flow movement net debt payment performance st december average number days purchases represented trade fixed asset creditors parent company net debt beginning year nil nil respect company uk decreaseincreasein cashand subsidiaries aggregate wasdays days bank overdrafts cashoutflowinflowfromliquidinvestments treasury policies net increase longterm loans glaxosmithkline plc reports insterling pays dividends net repayment shortterm loans sterling profits role corporate treasury gsk manage exchange movements monitor groups external internal funding requirements net debt end year financial risks support group corporate objectives treasury activities governed policies procedures approved investment appraisal board monitored treasury management group gsk formal process assessing potential investment proposals order ensure decisions aligned groups overall gsk maintains treasury control systems procedures monitor strategy process includes analysis impactof project foreign exchange interest rate liquidity credit earnings return invested capital anassessment financial risks return based discounted cash flows discount rate used liquidity perform financial analysis decided internally allow determination gsk operates globally primarily subsidiary companies extent investments cover groups cost capital established markets group trades due specific investments discount rate may adjusted take nature gsks business patent protection many account country risk weightings products portfolio groups products compete largely capital expenditure financial investment product efficacy rather price selling margins sufficient cash payments tangible intangible fixed assets amounted exceednormal operating costs groups operating subsidiaries million million disposals realised million substantially cash generative million cash payments acquire equity investments operating cash flow used fund investment research million million made year sales development new products well routine outflows capital equity investments realised million million expenditure tax dividends repayment maturing debt future cash flow group may time time additional demands finance group expects future operating cash flow sufficient share purchases acquisitions fund operating debt service costs satisfy normal levels gsk operates high level interest cover low levels capital expenditure meet obligations existing licensing net debt relative market capitalisation addition strong agreements meet routine outflows including tax positive cash flow normal trading activities additional liquidity dividends subject risk factors discussed pagesto readily available via commercial paper programme short gsk may time time additional demands finance term investments group also european medium term note acquisitions access sources liquidity programme billion billion issue st banks financial institutions addition cash flow december group established us shelf operations forsuch needs registration billion st december billion billion issue payment policies treasury operations group companies responsible monitoring managing objective treasury activity manage posttax net working capital terms sales collections supplier payments costincome financial operations benefit group earnings reflect local commercial practice corporate treasury operate profit centre gsk uses uk company uk subsidiaries policies variety financial instruments including derivatives finance ensure suppliers paid time particular uk operations manage market risks operations companies seek derivatives principally comprising forward foreign currency contracts settle terms payment suppliers agreeing terms interest rate currency swaps used swap borrowings transaction liquid assets currencies required group purposes ensure suppliers made aware agreed terms manage exposure funding risks changes foreign exchange ofpayment rates interest rates abide terms payment policy includes arrangements accelerated payment small suppliersgsk annual report srotcerid eht fo troper business review financial position resources continued gsk balances use borrowings liquid assets regard based composition net debt st december tothe cash flow operating activitiesthecurrencies appreciation insterling major currencies would result earnedthe tax cost intragroup distributionsthe currencies reduction groups net debt approximately million business assets denominatedand posttax cost weakening insterling major currencies would result borrowings comparedwiththeposttax return liquid assets increase groups net debt approximately million liquid assets surplus immediate operating requirements interest rate risk management group companies generally invested managed centrally gsks policy interest rate risk management requires corporate treasury requirements group companies operating amount net borrowings fixed rates increases ratio finance met whenever possible central resources forecast net interest payable trading profit external borrowings mainly managed centrally corporate treasury group uses limited number interest rate swaps comprise portfolio long mediumterm instruments short redenominate external borrowings interest rate coupon term finance required group purposes duration swaps matches duration theprincipal debtinstruments interest rate derivative gsk hold issue derivative financial instruments trading instruments accounted fair value cash flow hedges purposes groups treasury policies specifically prohibit relevant assets liabilities activity transactions financial instruments undertaken manage risks arising underlying business activities group manages centrally shortterm cash surpluses speculation borrowing requirements subsidiary companies uses forward contracts hedge future repayments back funding maturity counterparty risk originating currency group invests centrally managed liquid assets government bonds shortterm corporate debt instruments minimum sensitivity analysis considers sensitivity groups net debt shortterm credit rating ap money market funds credit hypothetical changes market rates assumes rating aaaaaa structured investments credit ratings variables remain constant based composition net debt shown standard poors moodys investors financing arrangements st december taking services respectively consideration fixed rate borrowings place one percentage point basis pointsdecrease average interest rates would result group manages net borrowing requirements increase groups annual net interest charge portfolio longterm borrowings including bonds together approximately million shortterm finance us billion commercial paper programme equity risk management equity investments classified current assets availableforsale groups longterm borrowings mature dates group manages disposals meet overall business include private financing although maturing requirements arise group regularly monitors value may redeemed gsk time particular equity investments enters hedges selectively event accelerating event would increase cost approval board funding group gsks longterm debt rating aa standard poors aa moodys investors services financial assets liabilities agencies shortterm ratings paper issued groups analysis net debt given note financial statements commercial paper programme p respectively net debt analysis financial assets liabilities carrying value fair value reconciliation net debt given note foreign exchange risk management financial statements financial instruments related gsk foreign currency transaction exposure arising normal trade disclosures together discussion derivative financial flows respect external intragroup trade instruments quantitative disclosures market risk hedged policy minimise exposure overseas operating accordance requirements ias ias subsidiaries transaction risk matching local currency income local currency costs purpose intragroup trading transactions group continues benefit strong positive cash flow group matched centrally intragroup payment terms managed net debt would decreased significantly year st reduce risk exceptional foreign currency cash flows hedged december groups purchase shares selectively management corporate treasury market billion gross us tax settlement usbillion billionand acquisitions approximately billion group seeks denominate borrowings currencies principalassets cash flows primarily denominated financial assets liabilities st december usdollars euros sterlingcertain borrowings representative treasury policies strategies gsk applied swapped currencies required group purposes consistently year significant changes policies throughout year borrowings denominated swapped foreign currencies match investments overseas group assets treated hedge relevant net assetsgsk annual report srotcerid eht fo troper business review outlook risk factors outlook risk factors sales growth existing products launch new products risks uncertainties relevant groups business key drivers gsks business performance thesalesgrowth seen factors listed among group thinks could key products seretideadvair avandiagroupof cause groups actual results differ materially expected products vaccines lamictal valtrex coregand thehigh potential historical results productsrequip avodartand boniva expected continue risk rd deliver commercially successful typically sales existing products decline dramatically generic new products competition introduced either patent expiry earlier continued development commercially viable new products critical successful challenge groups patent q generic groups ability replace sales older products decline competitors wellbutrin xlmg tablet approximately upon expiration exclusive rights increase overall sales wellbutrinsales zofranentered usmarket gskis engaged developing new products costly lengthy uncertain process legal proceedings regarding validity infringement new product candidate fail stage process groups patents relating many products discussed one latestage product candidates could fail receive risk factors noteto financial statements regulatory approval legal proceedings new product candidates may appear promising development five major new pharmaceutical product launches expected significant investment fail reach market include tykerbfor breast cancer cervarix cervical limited commercial success example could result cancerin europeallermist allergic rhinitis coreg cr heart efficacy safety concerns inability obtain necessary regulatory failure trexima migraine approvals difficulty excessive costs manufacture erosion gsk also expects launch several important products patent term result lengthy development period infringement year including arixtra treat acute coronary syndromes acs patents intellectual property rights others inability altabaxaltargo skin infections entereg management differentiate product adequately postoperative ileus competes gsks consumer brand portfolio strengthened risk unplanned loss patents launch products including alli new treatment patent infringement litigation weightloss usatwo brandsbreathe rightnasal strips groups patents common patents challenged fiberchoice dietary fibre supplements added time efforts generic manufacturers may involve challenges portfoliofollowing acquisition cns inc completed validity patent assertions generic product december infringe groups patents group successful defending attack patentsand maintaining exclusive rights several new products expected filed approval market one major products particularly usa regulatory authorities includingvaccine opportunities us group highest turnover margins groups filing ofcervarixfor cervical cancerandrotarixfor rotavirus turnover margins would adversely affected see note european filing synflorix vaccine pneumococcal disease financial statements legal proceedings discussion gskcontinues progress development vaccines use patentrelated proceedings group involved event flu pandemicin january gsk submitted hn vaccine european regulators approval generic drug manufacturers seeking market generic versions prepandemic use many groups important products prior expiration groups patents exhibited readiness gsk major product opportunities phase iii development products future us launch generic registration comprising nces new vaccines product productscompetingwith paxil irand wellbutrinhad significant line extensions impact groups overall turnover earnings gsks published earnings guidance earnings per share weakness intellectual property protection certain growth expected incerterms countries group net debt billion low relative countries group operates patent market capitalisation positions take advantage protection may significantly weaker usa opportunities might arise build business european union addition effort control public health crises developing countries south africa brazil risks uncertainties inherent business may considered plans substantial reductions scope patent affect future performance including rd projects anticipated sales protection pharmaceutical products particular countries growth expected earnings growth discussed risk could facilitate competition within markets generic factors manufacturers would otherwise unable introduce competing products number yearsany loss patent protection including abrogation patent rights antitrust litigation compulsory licensing likely affect adversely groups usa become increasingly common following operating results national markets expected publicity around government investigations adverse outcome material group overall absence adequate patent protection prosecution patent infringement actions defendants could limit opportunity look markets future direct indirect purchasers payers initiate antitrust sales growth actions well claims direct indirect purchasers payers typically filed class actions relief sought may risk substantial adverse outcome litigation include treble damages restitution claims damages adverse government investigations antitrust verdicts subject automatic trebling usa see noteto financial statements legal proceedings similarly antitrust claims may brought following settlement discussion proceedings governmental investigations patent litigation alleging settlements anticompetitive group currently involved unfavourable resolution violation antitrust laws similar future proceedings investigations may material adverse effect groups financial results group made sales marketing regulation material provisions related legal group operates globally complex legal regulatory proceedings investigations reduced earnings group environments often vary among jurisdictions failure may also make additional significant provisions related legal comply applicable laws rules regulations proceedings investigations future would reduce jurisdictions may result civil criminal legal proceedings earnings many cases practice plaintiff bar claim rules regulations change governmental interpretation damages compensatory punitive statutory amounts rules regulations evolve prior conduct may called bear relationship underlying harm accordingly question usa example group responding potentially misleading quantify potential exposure claims federal state governmental investigations pricing marketing proceedings investigations type described note reimbursement prescription drug products investigations could result related restitution civil false claims act recent insurance loss experience including pharmaceutical product litigation behalf federal state governments well liability exposures increased cost narrowed related proceedings initiated group behalf coverage afforded insurance pharmaceutical companies consumers private payers proceedings may result generally including group trebling damages awarded fines respect violation order contain insurance costs recent years group law criminal proceedings may also initiated group continued adjust coverage profile accepting greater degree companies individuals uninsured exposure addition claims made risks competition price controls limitations sales insurance policies insurers may reserve right deny coverage third party competition various grounds denial coverage ultimately upheld group operates highly competitive businesses claims could result material additional charges pharmaceuticals business faces competition proprietary groups earnings products large international manufacturers producers product liability litigation generic pharmaceuticals significant product innovations technical preclinical clinical trials conducted development advances intensification price competition competitors potential products determine safety efficacy products could adversely affect groups operating results continued use humans following approval regulatory bodies consolidation pharmaceutical industry could adversely affect notwithstanding efforts drugs vaccines groups competitive position continued consolidation introduced marketplace unanticipated side effects may among groups customers may increase pricing pressures become evident group currently defendant number group hadproducts million annual global sales product liability lawsuits including class actions involve substantial claims damages related groups pharmaceutical among products augmentin ir respect products litigation particularly usa inherently group generic competition avandiavaltrex wellbutrin unpredictable excessive verdicts justified xl respect groups intellectual property rights evidence occur class actions sweep together persons usa currently subject litigation two others zofran prescribed groups products inflate potential mg tablet version wellbutrin xl respect liability force numbers claims pain suffering group generic competition since fourth quarter punitive damages frequently asserted product liability actions allowed represent potentially openended exposure gsk annual report srotcerid eht fo troper business review outlook risk factors continuedgsk annual report srotcerid eht fo troper business review outlook risk factors continued groups major products become regulatory controls subject problem unplanned loss patent protection group must comply broad range regulatory controls unexpected side effects regulatory proceedings publicity affecting testing approval manufacturing marketing many doctor patient confidence pressure competitive products pharmaceutical consumer healthcare products particularly new effective treatment introduced usa countries european union affect adverse impact groups revenues operating results could cost product development also time required reach significant particular group faces intense competition market uncertainty successfully stricter manufacturers generic pharmaceutical products major regulatory controls also heighten risk withdrawal regulators markets generic products often enter market upon expiration basis postapproval concerns product safety patents data exclusivity periods groups products would reduce revenues result product recalls introduction generic products typically leads dramatic loss product liability lawsuits sales reduces groups revenues margins proprietary addition cases group may voluntarily cease marketing products expiration dates patents groups major product example withdrawal lotronexin shortly products set pageand legal proceedings involving initial launch usa face declining sales based patent challenges set noteto financial statements concerns efficacy safety whether scientifically justified legal proceedings even absence regulatory action development governmental payer controls postapprovaladverse event profile product product class pharmaceutical products subject price controls pressures may major impact marketing sale product restrictions many markets including japan germany france risk interruption product supply italy governments intervene directly setting prices manufacture pharmaceutical products constituent addition markets major purchasers pharmaceutical materials requires compliance good manufacturing practice products whether governmental agencies private health care regulations groups manufacturing sites subject review providers economic power exert substantial pressure approval fda regulatory agencies compliance prices terms access formularies failure suppliers key materials groups manufacturing group predict whether existing controls increase facilities could lead product recalls seizures interruption new controls introduced reduce groups margins production delays approvals new products pending affect adversely ability introduce new products profitably resolution manufacturing issues noncompliance also result fines disgorgement profits interruption supply fines example usa group highest margins disgorgement remedy could materially adversely affect sales country pricing pressures could significantly groups financial results groups cidra puerto rico facility increase following implementation pharmaceutical benefit worked resolution fda observations deficiencies medicare event state programmes control manufacturing practices subject consent decree entered cost prescription drugs adopted experience develops fda referred noteto medicare programme outpatient pharmaceutical coverage financial statements legal proceedings consequence beneficiaries began us government discussions supplies certain products manufactured cidra private insurers coverage offered curtailed constricted adverse impact sales enormous purchasing power programme could demand discounts may implicitly create price controls prescription drugs changes enabling legislation could afford us althoughthe group undertakes business continuity planning single government direct role negotiating prices medicare sourcing certain components bulk active materials finished programme additionally number states proposed products creates risk failure supply event regulatory implemented various schemes control prices senior noncompliance physical disruption manufacturing sites citizens programmes including importation countries risk concentration sales wholesalers bulk purchases drugs growth number patients usa line pharmaceutical companies group covered large managed care institutions usa sells products small number wholesalers addition likely increase implementation medicare benefit also hospitals pharmacies physicians groups sales increases pricing pressures groups products trends may three largestwholesalesamounted approximately adversely affect groups revenues margins sales groups us pharmaceutical sales st december group usa trade receivables due three wholesalers totalling million st december million group exposed concentration credit risk respect wholesalers one affected financial difficulty could materially adversely affect groups financial resultsgsk annual report srotcerid eht fo troper business review outlook risk factors continued reliance information technology accounting standards group increasingly dependent information technology new revised accounting standards rules interpretations systems including internetbased systems internal communication promulgated time time byinternational us accounting well communication customers suppliers standard setting boards could result changes recognition significant disruption systems whether due computer income expense may adverselyimpactthe groups reported viruses outside incursions could materially adversely financial resultsinternational us accountingstandardschanges affect groups operations market valuation certain financial instruments equity collar linked groups investment quest diagnostics taxation put call options linked groups strategic alliance effective tax rate groups earnings benefits fact theravance impairments equity investments reflected portion earnings taxed favourable rates groups reported results gains losses actually jurisdictions outside uk changes tax laws application realised could significant impact theincomestatement respect matterssuch transfer pricing risk double given period also international accounting standards taxationthat relate portion groups earnings taxed accounting deferred taxation intercompany inventory may favourable ratesor restriction tax relief allowed give rise volatility depending upon ownership inventory interest intragroup debt could increase groups effective tax balance sheet date rate adversely affect financial results group resolved claims us internal revenue service related glaxo regulators regularly review financial statements listed heritage products group open issues revenue companies like gsk compliance accounting regulatory authorities uk japan canada matters discussed requirements note financial statements taxation group believes complies appropriate regulatory disruption pandemic influenza requirements concerning financial statements disclosures event pandemic influenza group could subject however companies experienced investigations disruption range factors national governments may potential noncompliance accounting disclosure willing abrogate intellectual property rights medicines requirements resulted restatements previously reported might otherwise short supply country afflicted results sometimes significant penalties pandemic flu would risk employees families human resources affected consequence sales distribution group approximately employees around world manufacturing activities could shut supply continuity subject laws regulations concerning employees active ingredients finished goods affected ranging discrimination harassment personal privacy environmental liabilities labour relations vary significantly jurisdiction jurisdiction environmental laws various jurisdictions impose actual failure continue recruit retain right people maintain potential obligations group remediate contaminated sites culture compliance could significant adverseeffect group also identified potentially responsible party group us comprehensive environmental response compensation liability act number sites remediation costs relating groups use ownership sites failure manage properly environmental risks could result additional remedial costs could materially adversely affect groups operations see note financial statements legal proceedings discussion environmentalrelated proceedings group involved global political economic conditions group conducts substantial portion operations outside uk groups management foreign exchange rates discussed inbusiness review foreign exchange risk managementsee fluctuations exchange rates sterling currencies especially us dollar euro japaneseyen could materially affect groups financial results group control changes inflation interest rates foreign currency exchange rates controls economic factors affecting businesses possibility political unrest legal regulatory changes nationalisation jurisdictions group operates factors could materially affect groups future results operationsgsk annual report srotcerid eht fo troper business review financial review accordance ussec disclosure requirements following pharmaceutical turnover discussion compares results year st december total pharmaceutical turnover million compared results year st december information million increase cer sterling terms prepared ifrs turnover increased principally due strength euro growth rates constant exchange rates cer unless otherwise international currencies stated sterling growth rates may found tables pharmaceutical turnover therapeutic area pharmaceutical turnover therapeutic area exchange gsks ability continue deliver pharmaceutical turnover growth primarily due exceptionally broad product portfolio currencies influence groups results us fastgrowing highvalue products sales gsks largest product dollar euro japanese yen seretideadvair billion continued gain us dollar strengthened pound market share across regions market share value rising yearend following two years weakness antiasthma copd therapy class europe euro japanese yen yearend rates weakened usa increase percentage points cases compared pound sales diabetes treatments also strong avandiaavandametup billion gsk launched avandia world market pharmaceuticals treatment type diabetes combination product avandamet blood sugar control product global pharmaceutical sales increased billion group expanded february launch world market value growth usa fixeddose combination treatment avandaryl geographic region bn total combines avandiawith sulfonylureain avandiaavandamet usa achieved market share value oral antidiabetics europe europe usa percentage germany points respectively france uk fast growing products lamictal epilepsybipolar italy disorder billion valtrexfor herpes japan billion coregfor heart disease billion vaccines asia pacific billion latin america addition therewasa rapid uptake number high middle east africa potential products requip restless legs syndrome sales canada million avodartfor benign prostatic hyperplasia sales total doubled million bonivabonvivafor treatment osteoporosis launched captured share growth us market slowed still represents new prescriptions oral bisphosphonates us market global prescription pharmaceutical market compared decade ago respiratory gsk continues global leader respiratory pharmaceuticals th september gsk held second position world sales three key products seretideadvair flixotideflovent pharmaceutical market market share behind pfizer sereventamounting billion seretideadvair market share gsk eight worlds top sales rose billion usa sales also strong pharmaceutical products avandia flixonase european international markets imigranimitrex lamictal seretideadvair seroxatpaxil wellbutrin billion billion respectively zofran central nervous system cns world market value growth cns sales declined billion sales declined usa top five therapeutic classes bn total cer europe small gain international total paxilsales fell million due generic competition interruption cardiovascular supply paxil crduring year see product supply page central nervous system partially mitigating decline strong performance paxil alimentary tract metabolic japan million antiinfectives bacterial viral fungal excluding vaccines respiratory note data based months thseptember gsk annual report srotcerid eht fo troper business review financial review continued total wellbutrinturnover fell million wellbutrin irand cardiovascular urogenital srsales fell million due generic competition sales ofcoregfor heart disease grew million largely offset strong performance wellbutrin xlup avodartfor benign prostatic hyperplasia enlarged prostate million strong year sales doubling million january strong growth gsks epilepsy bipolar disorder treatment product accounted new prescriptions us lamictalcontinued sales million driven alpha reductase inhibitor market indication maintenance treatment bipolar disorder therapeutic areas requipsales rose million q weekly new sales zantacfell million declines regions prescriptions product quadrupled usa since product supply launched restless legs syndrome rls q following fda inspections october november antivirals identified possible deficiencies manufacturing practices global hiv product sales grew billion sales groups facility cidra puerto rico fda halted distribution new products epzicomkivexa lexiva together supplies paxil cr avandamet march site doubling million offsetting performance trizivirdown engaged tableting packaging range gsk products million epivir million sales primarily us market including paxil paxil cr coregavandia herpes treatment valtrex grew million performance avandamet april group reached agreement driven usa million fda consent decree provides independent product clear market leader treatments genital herpes expert review manufacturing processes site compliance fda good manufacturing practice requirements decree antibacterials also allows potential future penalties maximum antibacterial sales declined worldwide usa decline million year gsk fails meet terms reflecting increased generic competition june group began resupplying us markets metabolic paxil crand avandamet sales products diabetes treatments avandiaavandametcontinued perform significantly impacted interruption supply strongly overall sales billion usa impact avandametwas mitigated switching patients sales grew million avandiaavandamet also avandia group also established provision establishing strong positions europe sales rising external costs required rectify manufacturing issues plant million helped launch avandamet sales international details see risk factors pagestoand note markets rose million financial statements legal proceedings bonivabonviva new oncemonthly oral bisphosphonate consumer healthcare sales treatment osteoporosis developed roche growth strong launch usa february share cer new prescriptions oral bisphosphonates boniva injection first otc medicines ever quarterly treatment osteoporosis approved usa analgesics january received positive opinion chmp dermatological europe th january gastrointestinal vaccines respiratory tract vaccines business performed well total sales rising smoking control billion led infanrix vaccine sales particularly strong natural wellness support usa turnover rose million helped oral care launch two new products fluarix boostrix nutritional healthcare july gsk acquired corixa corporation million december completed acquisition id biomedical corporation billion growth consumer healthcare sales billion comprised otc medicines sales increase nutritional oncology emesis healthcare sales increase oral care sales increase sales zofrangrew million driven us market milliongsk annual report srotcerid eht fo troper business review financial review continued pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxilir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es xr zinnatceftin metabolic avandia avandamet bonvivaboniva vaccines hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac cer represents growth constant exchange rates represents growth actual exchange ratesgsk annual report srotcerid eht fo troper business review financial review continued otcmedicines due lower charges related legal matters equal overthecounter medicine sales million growth reduction total sga lower sharebased payment charges analgesics respiratory tract helped offset equal decrease total sga partly offset higher costs loss sales dermatological products divested related programmes deliver future cost savings equal panadol growth international markets key driver increase total sga growth analgesics research development oral care rd expenditure percentage turnover line oral care sales grew million sales sensodyneand increased compared previous year partly denture care brands polident poligripand corega grew result writeoffs intangible assets excluding write respectively helping offset lower sales offs rd expenditure grew slightly turnover growth toothpaste products pharmaceuticals rd expenditure represented pharmaceutical turnover nutritional healthcare nutritional healthcare product sales grew million operating income lucozade continued grow strongly europe operating income includes royalty income equity investment disposals impairments product disposals fair value operating profit adjustments quest collar theravance options analysis operating profit subsequent discussion operating income million compared compares results results million increased income predominantly due increased product asset disposal gains compared growth cer favourable fair value movement million quest collar theravance options turnover cost sales operating profit selling general overall operating profit margin increased percentage points administration operating profit million increased sterling terms research constant exchange rates operating profit increased development margin increased percentage points reflecting lower charges operating relating legal matters sharebased payments higher product income asset disposals increases advertising promotion selling rate turnover growth partially offsetting operating profit items higher costs related programmes deliver future cost savings increased rd expenditure cost sales cost sales percentage turnover increased percentage profit taxation points constant exchange rates increase also percentage points reflecting higher costs related ongoing discussion compares results results rectification manufacturing issues cidra site puerto rico gains asset disposals including associates million partly offset operating efficiencies compared million costs legal matters million previous year million charges relating costsaving programmes million million sharebased payments selling general administration million million selling general administration sga percentage turnover decreased percentage points constant exchange share profitslosses joint ventures associated rates decrease percentage points reflecting flat undertakings expenditure compared prior year turnover increase share profits associates arises principally groups sga costs line overall higher holding quest diagnostics inc advertising promotion selling expense offset lower disposal interest associates general administration expenditure advertising promotion disposals interests associates selling expenses increased accounted increase group disposed million shares investment total sga general administration costs declined quest diagnostics inc cash proceeds million profit accounted reduction total sga million recognised groups shareholding quest st december gsk annual report srotcerid eht fo troper business review financial review continued net finance costs profit year growth finance income cer interest income profit taxation year unwinding discount assets profit attributable fair value adjustments shareholders earnings per share pence p p earnings per ads us finance costs weighted average number shares millions interest costs unwinding discount liabilities diluted earnings per share pence p p fair value adjustments diluted earnings per ads us weighted average number shares millions finance income increased compared predominantly due higher interest rates higher cash balances finance costs increased profit year million increase due higher interest rates well higher interest costs resulting sterling terms profit attributable minority interests issue two million bonds million profit attributable shareholders million increase sterling terms taxation earnings per share increased reflecting higher profits also reduction weighted average number shares resulting groups share buyback programme interest cost uk corporation tax programme also impacts groups earnings overseas taxation actual rates exchange earnings per share increased current taxation favourable currency impact eps three percentage points reflects deferred taxation strengthening us dollar euro average exchange rates total relative compares favourable currency impact turnover difference principally arises different mix charge taxation profit amounting million currencies profits compared turnover represents effective tax rate tax rate benefited higher tax relief actual potential exercise share options employees arising increase share price year integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable taxdisagreements revenue authorities intragroup transactions particular price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits taxed individual territories resolution issues continuing fact life gsk group hadsignificant open issues revenue authorities usa uk japan canada details set noteto financial statements taxationgsk annual report srotcerid eht fo troper corporate governance section discusses glaxosmithklines management structures governance procedures contains companys reporting disclosures corporate governance required combined code corporate governance financial reporting council combined code including required statement compliance company reports compliance uslaws regulations apply board corporate executive team governance policy dialogue shareholders annual general meeting internal control framework committee reports combined code us law regulation gsk annual report srotcerid eht fo troper corporate governance continued board dr daniel podolsky aged appointed st july nonexecutive director dr podolsky sir christopher gent aged mallinkrodt professor medicine chief gastroenterology appointed st june chairman sir christopher chief massachusetts general hospital harvard medical school well executive officer vodafone group plc retirement july chief academic officer partners healthcare system ispast nonexecutive director lehman brothers holdings inc editorinchief journal gastroenterologypast president nonexecutive director ferrari spa member kpmgs american gastroenterological association chairman board chairmans advisory groupa member financial reporting andscientific cofounder gicompany councila senior adviser bain co member advisory board reform sir ian prosser aged appointed rd may senior independent director sir ian dr jeanpierre garnier aged formerly nonexecutive director smithkline beecham plc appointed rd may chief executive officer dr garnier chairman chief executive bass plc ultimately appointed executive director smithkline beecham plc chairman demerged intercontinental hotels group plc became chief executive officer april non chairman world travel andtourism council executive director united technologies corporation member london stock exchange listed advisory council nonexecutive board trustees eisenhower exchange fellowships deputy chairman bp plc nonexecutive director sara lee holds phd pharmacology university louis pasteur corporationand member cbi presidents committee france mba stanford university usa dr ronaldo schmitz aged dr stephanie burns aged appointed rd may nonexecutive director dr schmitz appointed th february nonexecutive director dr burns formerly nonexecutive director glaxo wellcome plc chairman president chief executive officer dow corning nonexecutive director legal general group plca member corporationshe also member american chemical society board directors rohm haas company cabot sits executive committee society chemical corporationand member supervisory board sickag industryamerica sectionserves onthe american chemistry council board directors society womens health research dr moncef slaoui aged board trustees conference board dr burns holds appointed th may chairman research development aphdin organic chemistry iowa state university dr slaoui joined gsk biologicals engineered development robust vaccines pipeline phd molecular lawrence culp aged biology immunology universit libre de bruxelles appointed st july nonexecutive director mr culp president chief executive officer danaher corporation prior tom de swaan aged joining danaher held positions accenture previously appointed st january nonexecutive director mr de swaan andersen consulting member managing board chief financial officer abn amrountil st january hewasa nonexecutive director sir crispin davis aged financial services authority member oftheboard appointed st july nonexecutive director sir crispin directors zurich financial services switzerland member chief executive reed elsevier plc prior chief supervisory board royal dsm buhrmann executive aegis group plc joined guinness plc netherlands ischairman board netherlands opera member main board group managing member board royal concertgebouw orchestra director united distillers spent early career procter gamble sir robert wilson aged appointed st november nonexecutive director sir robert julian heslop aged nonexecutive chairman bggroup plc andthe economist group appointedon st april chief financial officer mr heslop joined previously executive chairman rio tinto glaxo wellcome financial controller april january following merger appointed senior vice president directors operations controller prior joining glaxo wellcome held senior dr lucy shapiro formerly nonexecutive director retired finance roles grand metropolitan plc board th may dr tachi yamada formerly chairman research development retired board st may sir deryck maughan aged appointed st june nonexecutive director sir deryck details membership board committees may found managing director kohlberg kravis roberts co formerly page chairman ceo citigroup international salomon brothers inc nonexecutive director reuters group plcand blackrock inc well serving boards directors carnegie hall lincoln center nyumedical center servedas vice chairman new york stock exchange gsk annual report srotcerid eht fo troper corporate governance continued corporate executive team cet bill louv chief information officer jp garnier mr louv succeeded dr calhoun chief information officer st chief executive officer january responsible information technology global chief executive officer dr garnier responsible function enables key business processes across parts management group oversees operational aspects group joined company held number group including establishing policies objectives initiatives increasingly senior roles including us pharmaceuticals directs longterm strategy formerly chief executive gsks rd functions officer smithkline beecham joined group dan phelan rupert bondy senior vice president human resources senior vice president general counsel mr phelan responsible benefits compensation recruitment mr bondy responsible legal matters across group together organisation development leadership development succession environmental health safety issuesand security planning human resource information systems employee health lawyer private practice joining smithkline beecham management lawyer private practice joining smith john clarke kline french president consumer healthcare david pulman mr clarke responsible consumer healthcare business president global manufacturingandsupply produces oral overthecounter nutritional healthcare products dr pulman responsible global manufacturing supply joined beecham president futures organisation global procurement joined glaxo group current appointment january responsible north american supply network marc dunoyer manufacturing strategy logistics current appointment president pharmaceuticals japan mr dunoyer appointed president pharmaceuticals japan march moncef slaoui joined group senior vice president chairman research development regional director japan current appointment dr slaoui leads groups complexdrug discovery development russell greig activities joined group senior vice president president pharmaceuticals international worldwide business development current appointment dr greig leads pharmaceutical operations outside usa japan june europe covering countries joined david stout group senior vice president worldwide business president pharmaceutical operations development rd prior current appointment mr stout responsible forall pharmaceuticals vaccinesoperations march worldwide including usa europe international japan julian heslop global manufacturing supply joined smithkline beecham chief financial officer president uspharmaceuticals current mr heslop became chief financial officer st april head appointment january finance function mr heslop responsible activities chris viehbacher financial reporting control tax treasury finance systems president uspharmaceuticals internal audit insuranceand real estatehe joined glaxo wellcome mr viehbacher responsible us pharmaceuticals joined financial controller april wellcome responsible gsks european duncan learmouth pharmaceuticals business current appointment senior vice president corporate communications andrew witty community partnerships president pharmaceuticals europe mr learmouth responsible groups investor relations internal mr wittyis responsible groups pharmaceuticals operationsin external communications image partnerships global europe joined glaxo andwas senior vice president asia communities joined glaxoin vice president global pacific current appointment investor relations appointment current position july members mr ziegler retired head theconsumer healthcare business st january mrs younger left group june dr calhoun retired chief information officer st january mr ingram continues toactas specialconsultantto group attendscet meetings capacitycorporate governance continued governance policy sir ian prosser appointed senior independent director sid st january held role throughout board corporate executive team directors listed boardon page board process board authority accountable shareholders board responsible groups system corporate ensuring company appropriately managed achieves governance ultimately accountable groups activities strategic objectives sets board discharges responsibilities strategy financial performance annual programme meetings includes chief executive officer ceo responsible executive approval overall budgetary planning business strategy management group assisted cet cet meets board reviews companys internal controls risk management times per year otherwise necessary members policies approves governance structure code ethics responsibilities listed corporate executive team board appraises approves major financing investment page licensingdecisions excess defined thresholds additionthe board comprisesthreeexecutive andtennonexecutive directors board evaluates monitors performance group board considers nonexecutive directors independent whole includes character judgement dr schmitz served board engaging board meetings ceo executive nine years appointed board glaxo directors members cet appropriate financial wellcome plc st january consideration operating performance gsk external issues material annual review board effectiveness meeting december groups prospects board concluded dr schmitz remained independent notwithstanding length service opinion board evaluating progress toward achievement groups financial dr schmitz continued demonstrate characteristics business objectives annual plans independence objectively challenging management monitoring reports received directly various taking part rigorous debate time possessing committees significant risks facing group outstanding knowledge companys business affairs together experience gained chairman audit board overall responsibility succession planning committee long cycle investment business gsk ceo executive directors board given ceo considered particularly important experienced members broad authority operate business group ceo board sir christopher gent appointed board accountable reports board business performance deputy chairman determined board cet members make regular presentations board areas independent upon taking chairmanship board st responsibility board meets cet members january accordance combined code annual basis discuss collectively groups strategy excluded determination whether least half board independent nonexecutive directors sir christopher gent primary element induction process new nonexecutive hold position board committee independence directors undertaken members cet nonexecutive required combined codehe however appointed directors encouraged separate informal discussions member remuneration committee effective st january discretion cetmembers following recent change combined code board metsixtimes member attending board considers dr burns mr culp sir crispin davissir follows deryck maughan dr podolsky sir ian prosser dr schmitz mr de number meetings number swaan sir robert wilson independent accordance name held whilst board member meetings attended recommendations combined code sir christopher gent dr jpgarnier date publication throughout majority mr j heslop board members excluding chairman independent non dr slaoui executive directors dr shapiro left board th may mr l culp considered independent due remuneration sir crispin davis received group member glaxosmithkline sir deryck maughan scientific advisory board dr podolsky sir christopher gent succeeded sir christopher hogg st january sir ian prosser chaired company throughout dr garnier dr r schmitz ceo chairman leads board represents board mr de swaan ceo cet members necessary board meetings sir robert wilson ceo manages group implements strategy dr yamada policies adopted board chairman chairmen dr l shapiro board committees communicate regularly ceo addition thesixscheduled meetings board also met cet members division responsibilities role quorate basis onthreeoccasions chairman ceo set writing agreed board appears full companys website gsk annual report srotcerid eht fo tropercorporate governance continued business environment development audit committee ensure board kept uptodate important matters audit committee reviews financial internal reporting including legal governance regulatory developments process system internal controls management risks presentations made regular basis external external internal audit process committee also proposes internal advisers shareholders appointment external auditors directly responsible remuneration oversight work independent advice committee consists entirely independent nonexecutive board recognises may occasions one directors meets least four times year otherwise directors feel necessary take independent legal andor necessary audit committee report pagesto financial advice companys expense agreed procedure enable explained corporate remuneration committee governance section companys website remuneration committee determines terms service remuneration executive directors members cet indemnification directors assistance external independent advisors evaluates qualifying third party indemnity provisions defined section makes recommendations board overall executive b companies act force benefit remuneration policythe committee consists entirely independent directors former directors held office nonexecutive directors together chairmanin accordance company secretary combined codeit meets leastfourtimes year company secretary responsible board available otherwise necessary information remuneration directors individual directors respect board procedures company given remuneration report pagesto secretary simon bicknell appointed may chairman company ceo responsible barrister joined group secretary board evaluating making recommendations board committees remuneration nonexecutive directors boardcommittees nominations committee board established number ofcommittees provides nominations committee reviews structure size sufficient resources enable undertake duties composition board appointment memberstothe executive directors members audit remuneration board cet makes recommendations board nominations corporate responsibility committees although appropriate committee also monitors planning succession may invited attend meetings director member board senior management committee consists corporate administration transactions financial results entirely nonexecutive directors majority committees membership thesecommittees isshown table independent meets least year otherwise necessary nominations committee report given page corporate audit remuneration nominations responsibility corporate responsibility committee sir christopher gent c c corporate responsibility committee consists entirely non dr burns executive directors provides boardlevel forum regular mr l culp review external issues potential serious impact sir crispin davis upon groups business reputation andfor oversight sir deryck maughan reputationand views external stakeholders committee dr podolsky also responsible governance oversight groups worldwide sir ian prosser donations community support committee meets formally dr r schmitz threetimes year otherwise necessary mr de swaan c financial results committee sir robert wilson c financial results committee reviews approves behalf mr de swaan succeeded dr schmitz chairman audit committee board annual report form f annual review september convening annual general meeting together keyc chairman member preliminary quarterly statements trading results director following summary role terms reference member committee quorum meeting committee current full terms reference eachcommittee three members quorate meeting must include may obtained company secretary thegovernance chairman chairman audit committee ceo section companys website chief financial officer cfo committee meets necessary gsk annual report srotcerid eht fo tropercorporate governance continued corporate administration transactions committee groups investor relations department offices london corporate administration transactions committee reviews philadelphia acts focal point contact investors approves matters connection administration groups throughout year business certain corporate transactions committee consists chairman meets regularly institutional investors hear directors cet members company secretary views discuss issues mutual importance committee meets necessary chairman remuneration committee meetsannuallywith evaluation board board committees directors major shareholders discuss executive remuneration policy performance evaluation board committees directors undertaken sid implemented nonexecutive directors including new appointees available collaboration committee chairmen support meet major shareholders requested company secretary board considered review conclusions companys website provides access current financial meeting december agreed number minor business information group improvements procedures operating methodology share buyback programme external consultant appointed assist evaluation company repurchased billion shares audit committee cancellation held treasury shares billion spent october programme totalling billion dialogue shareholders ofshare repurchases three years commenced expected financial results announced quarterly billion worth shares brought back inthe first months programmes cover purchases company shares company reports formally shareholders twice year cancellation held treasuryshares accordance halfyear fullyear results announced fullyear results authority renewed shareholders companys agm included companys annual report annual review arepublished forshareholders companys halfyear results may company authorised purchase maximum published national newspaper shortly release ceocfo ofmillionshares million shares representing president pharmaceutical operationsgive presentations issued share capital purchasedand held treasury fullyear results institutional investors analysts media shares see noteto thefinancial statements share capital share premium account webcast teleconferences release first second third quarter results institutional investors analysts exact amount timing future purchases extent media annual report annual review quarterly results repurchased shares held treasuryshares rather available companys website cancelled determined company dependent market conditions factors annual general meeting agm takes place london formal notification sent shareholders least one month donations political organisations eu advance meeting business presentation made political expenditure shareholders directors able attend available formally agm may shareholders first authorised company theagm informally afterwards questions committee make donations eu political organisations incur eu chairmen ordinarily attend agm respond shareholders political expenditure provisions political parties questions entire board attendance atthecompanys agm elections referendums act year may resolutions agm decided poll authority since renewed annually although required companys articles association results company make intend make payments poll announced london stock exchange posted donations eu political parties within normal meaning companys website details agm set expression definition legislation eu political section annual general meetingseepage organisation wide may extend bodies company subsidiaries might wish support including concerned ensure nonexecutive directors aware policy review law reform representation business understand views major shareholders company community special interest groups concerned board place process focusing sectorspecific issues well environment donations made eu political general shareholder preferences atits meeting inseptember organisations group made donations noneu board received external review ofshareholder opinion political organisations totalling ceo cfo maintain dialogue institutional shareholders performance plans objectives programme regular meetings gsk annual report srotcerid eht fo tropercorporate governance continued donations made usa special business canadaand australia company seek authority usa largest recipient political donations reflects make donations eu political organisations incur eu us political system candidates sponsored solely political expenditure donations individuals ngos companies parties allot ordinary shares company line us law corporate donations gsk made federal level candidates political parties state give directors authority disapply preemption rights local levels donations accepted practice usa allotting newshares connection rights issues otherwise major employer heavily regulated industry important maximum current issued share capital gsk engage fully political process donations one purchase ordinary shares maximum ways gsksupports candidates seek current issued share capital environment appropriately rewards highrisk highinvestment amend companysarticles ofassociationtoenableelectronic industries believe free market principles intellectual communicationwith shareholdersin accordance new property rights companies act situation similar canada donations follow guidelines rest world donations rare internal control framework low value board recognises responsibility present balanced also gsk political action committee pac usa understandable assessment groups position prospects gives political donations pacs employee organisations structure accountability audit operated gsk follows allow employees contribute fund political donations board accountability reviewing approving adequacy employees decide upon recipients pac donations effectiveness internal controls operated group including total donated political financial operational compliance controls risk management organisations gsk pac board delegated responsibility review audit committee receives reports individuals identified annual general meeting committees report pagesto responsibility agm held pm wednesday rd may management cet implement board policies risk queen elizabeth ii conference centre broad sanctuary control cet responsible identifying approving westminster london swp ee business transacted monitoring enforcing key policies go heart meeting include group conducts business internal control framework includes central direction resource allocation risk management key receiving adopting glaxosmithkline 's annual activities research development manufacturing marketing report sales legal human resources information systems financial approving remuneration report practice part framework comprehensive planning remuneration report pages sets system annual budget approved board results remuneration policies operated glaxosmithkline disclosures operating units reported monthly compared budget directors remuneration including required forecasts prepared regularly year companies act directors remuneration report extensive financial controls procedures selfassessment exercises regulations resolution proposed approve risk activities reviewed groups internal auditors commercial remuneration report financial responsibility however clearly delegated local retirement election reelection directors business units supported regional management structure dr podolsky anddr burnshave appointeddirectors since principles designed provide environment central leadership agm offerthemselves election boardmr coupled local operating autonomy framework heslopsir deryck maughan dr schmitz sir robert wilson exercise accountability control within group retire offer reelection board group also attaches importance clear principles procedures article companys articles association designed achieve appropriate accountability control group reappointment remuneration auditors policy risk management legal compliance mandates resolutions proposed reappoint pricewaterhousecoopers business units establish processes managing monitoring risks llp auditors authorise audit committee determine significant businesses group remuneration internal control framework also relies following overseeing reporting risk compliance issues gsk annual report srotcerid eht fo tropercorporate governance continued risk oversight compliance council rocc areas potentially significant risk rocc council senior executives authorised board details risks affecting group seerisk factors pages assist audit committee oversee risk management noteto thefinancial statements legal proceedings internal control activities group membership comprises several effectiveness controls cetmembers heads departments internal internal control framework operation whole control risk management audit compliance responsibilities year review continues operate date rocc meets regular basis review assess significant approval report system internal controls designed risks mitigation plans rocc responding group manage rather eliminate risk achieving business policy referred provided business units objectives provide reasonable absolute framework risk management upward reporting significant assurance material misstatement loss risks mitigation planning identification manager overall audit committee receives reports areas significant risk responsibility management given risk requirement group related internal controls following consideration risk management compliance boards rmcbs reports audit committee reports annually board risk management compliance boards rmcbs effectiveness controls controls may mitigate established major business units membership often eliminate risks addition areas groups comprises members senior executive team respective business necessary take risks achieve satisfactory business unit augmented specialists appropriate rmcbs return shareholders investment rd acquiring oversee management risks considered important new products businesses cases groups objective respective business units including risks designated apply expertise prudent management rather significant glaxosmithkline whole thus increasing number elimination risk directors review relates company risks actively managed across group subsidiaries extend material associated undertakings joint ventures investments rmcb regularly reports status regarding significant risks rocc board audit committee reviewed assessment risks internal control framework operates compliance functions glaxosmithkline considered effectiveness system number risk areas specific standards meet exceed internal control operation group year covered requirements applicable law established specialist audit report date approval board process compliance functions examplecorporate environment followed board reviewing system internal controls health safety global quality assurance worldwide regulatory accords guidance internal control issued turnbull compliance assist dissemination implementation audit committee standards corporate ethics compliance cec committee reports rocc also supported corporate ethics compliance audit committee report department responsible supporting development audit committees role flows directly boards oversight implementation practices facilitate employees compliance function authorised board investigate activity laws group policy within terms reference committee written terms thrust groups compliance effort due diligence reference approved board committee preventing detecting misconduct noncompliance law reports regularly board performance activities regulation promoting ethical behaviour compliance laws assigned committees main responsibilities include regulations corporate responsibility levelsand effective reviewing corporate accounting financial reporting process compliance systems monitoring integrity financial statements evaluating system internal control management risks overseeing cec managed corporate compliance officer activities groups compliance audit functions reports directly ceo corporate compliance officer chairs overseeing compliance laws regulations ethical codes rocc provides summary reports roccs activities practice committees oversight role requires address regularly groups significant risks cet audit committee relationships management internal external regular basisthe corporate compliance officers direct reporting auditors understand monitor reporting relationships line audit committee provides mechanism bypassing tiers accountability executive management need ever arise gsk annual report srotcerid eht fo tropercorporate governance continued committee receives regular reports members cet committee worked structured programme senior managers covering key compliance activities activities standing items committee required group including concerning rd manufacturing sales consider meeting together matters focused marketing ehs coincide key events annual financial reporting cycle committee members bring considerable financial accounting external auditors reported committee critical experience committees work members past accounting policies practices used company alternative employment experience either finance accounting roles accounting treatments discussed comparable experience corporate activities management resultant conclusion external auditors material written communications management dr schmitz chairman committee april restrictions access information september prior appointment nonexecutive director cfo reported financial performance company company nonexecutive director glaxo wellcome technical financial accounting matters plc served audit committee dr schmitz also member executive board directors deutsche bank general counsel reported material litigation ag retired board charge company secretary reported corporate governance investment banking dr schmitz formerly member heads groups compliance audit groups executive board directors basf including reported audit scope annual coverage audit resources cfo holds mba insead results audits conducted throughout year mr de swaan joined board committee effect corporate compliance officer reported activities st january succeeded dr schmitz chairman undertaken rocc committee effect september appointing mr company secretary chairman disclosure committee de swaan committee board determined recent reported matters affected quality timely disclosure relevant financial experiencein accordance combined financial material information board code coming conclusion board paid particular attention public markets shareholders enabled committee mr de swaans role chief financial officer abn amro review clarity completeness disclosures retired st december board also considers published annual financial statements interim reports quarterly mr de swaan audit committee financial expert defined preliminary results announcements formal sarbanesoxley announcements relating financial performance prior sir deryck maughan managing director kohlberg kravis release board roberts co kkr chairman kkr asia chairman audit committee management internal auditors full ceo citigroup international vice chairman citigroup inc board work together ensure quality companys corporate prior creation citigroup chairman cochief accounting financial reporting committee serves executive officer salomon smith barney also chairman primary link board external internal auditors chief executive officer salomon brothersinc facilitates necessary independence management sir ian prosser cfo later ceo bassplcand member encourages external internal auditors communicate freely institute chartered accountants england wales regularly committee committee met sir robert wilson began professional career economist collectively separately external auditors head chairman bggroup plc held senior management positions gia without members management present rio tinto plc culminating appointment executive chairman committee primary responsibility making retired recommendation shareholders appointment reappointment dr danielpodolsky appointed committee effect removal external auditors annually assessing st january worldrenowned researcher qualifications expertise resources independence external advanced knowledge underlying mechanisms disease new auditors effectiveness audit process therapies gastrointestinal disorders background enable bring scientific expertise committees deliberations committee supported company secretary attends committees meetings available financial resources take independent professional advice considered necessary meetings committee attended chairman ceo cfo general counsel head global internal audit gia corporate compliance officer external auditors gsk annual report srotcerid eht fo tropercorporate governance continued making assessment committee considers papers customised induction process conducted new detail relevant regulatory requirements relating external auditors nonexecutive directors focusing particular experience evaluates reports external auditors compliance taking account different backgrounds process includes requirements external auditors provide nonaudit meeting members cet senior executives visiting services committee ensures auditor objectivity particular operational facilities group independence safeguarded policy requiring preapproval committee continued keep review succession audit committee services services may include planning senior executive positions including ceo audit services auditrelated services tax services services committee agreed process selecting dr preapproval detailed particular service categories garniers successor ceo gsk services subject specific budget external auditors management report regularly committee regarding extent appointingnew executive directors cetmembers services provided accordance preapproval fees committee considers theskills knowledge experience required services performed committee may also preapprove particular executive position committee consider additional services casebycase basis expenditure audit potential external internal candidates recommending nonaudit services set outin note financial statements board approve new appointmentall new directors offer operating profit election companys next agm appointments announced publicly guidelines set companys policy engaging external auditors provide nonaudit services include ascertaining committee recommended appointment dr podolsky tothe skills experience external auditors make corporate responsibility committee effect june suitable supplier nonaudit services adequate safeguards audit committeewith effect st january place objectivity independence audit committee also recommended appointment compromised fee levels relative annual audit fee sir christopher gent remuneration committee effect within limits set committee st january company also wellestablished policies including code committee met four times full session ethics available website helpline facility members present full meetings reporting investigation unlawful conductno waivers remuneration report code made remuneration report found pagesto committee met full sessionfivetimes andfivetimes corporate responsibility committee report quorate basis full session attended members year corporate responsibility committee reviewed exceptmrde swaan sir deryck maughan unable gsks activity number responsibility areas including access attendonemeeting medicines community partnerships reputation management caring nominations committee report environment ethical conduct direct consumer dtc nominations committees terms reference include responsibility advertising gsks commercial practices codes proposing appointment board committee members membership committee changed year following committee made recommendations board dr shapiros retirement board may tom de swaan appointment ofdr podolsky nonexecutivedirectorand dr daniel podolsky joined committee scientificmedical expert committee met five times meeting february committee recommended board dr attended committee members except sir ian prosser moncef slaoui would succeed dr yamada chairman research unable attend one meeting dr shapiro unable developmenton retirement company st may attend two meetings february committee boards approval gsks corporate responsibility report accessed appointed dr stephanie burns nonexecutive director wwwgskcom recruiting nonexecutive directors committee considers particular skills knowledge experience would benefit combined code board significantly appointment broad selection throughout company complied code provisions criteria used focus achieving balance combined code except follows representation european uk us markets individuals ceo experience skills developed various sectors bin designing schemes performancerelated remuneration specialities particular focus placed upon remuneration committee follow provisions recruiting nonexecutive scientific medical expertise schedule code item schedule states general professional search agencies engaged specialising basic salary pensionable companys position recruitment high calibre nonexecutive directors dossiers explained remuneration report pagesto potentialnonexecutive appointees provided committee candidates shortlisted interview considering relevant qualifications gsk annual report srotcerid eht fo tropercorporate governance continued us law regulation section corporate responsibility financial reports sarbanesoxley also introduced requirement ceo number provisions us law regulation apply gsk cfo complete formal certifications confirming companys shares quoted new york stock reviewed annual report form f exchange nyse form adss nyse rules based knowledge contains material misstatements omissions general nyse rules permit company follow uk corporate governance practices instead ofthoseapplied usa provided based knowledge financial statements company explains significant variations explanation financial information fairly present material respects ison companys websitenyse rules came effect financial condition results operations cash flows require company file annual interim written affirmations dates periods presented annual report concerning audit committee companys statement form f significant differences corporate governance responsible establishing maintaining disclosure sarbanesoxley actof controls procedures ensure material information following number corporate accounting scandals usa made known evaluated effectiveness congress passed sarbanesoxley actof sarbanesoxley controls procedures year end results sarbanesoxley wide ranging piece legislation concerned largely evaluation contained annual report form f financial reporting corporate governance responsible establishing maintaining internal control recommended securities exchange commission sec financial reporting provides reasonable assurance gsk established disclosure committee committee reports regarding reliability financial reporting preparation ceo cfo audit committee chaired financial statements external purposes accordance company secretary members consist senior managers generally accepted accounting principles finance legal compliance corporate communications disclosed annual report form f investor relations changes internal controls financial reporting external legal counsel external auditors invited attend period covered annual report form f meetings periodically responsibility considering materially affected reasonably likely affect materially materiality information timely basis determining companys internal control financial reporting disclosure information responsibility timely filing disclosed based recent evaluation reports sec formal review annual report internal control financial reporting external auditors form f committee mettimes audit committee significant deficiencies material sarbanesoxley requires annual report contains statement weaknesses design operation internal control whether member companys audit committee financial reporting reasonably likely affect adversely audit committee financial expert explanation details companys ability record process summarise report basis boards judgement matter refer page financial information fraud regardless materiality additional disclosure requirements arise section involving persons significant role companys section respect ofdisclosure controls proceduresand internal control financial reporting internal control financial reporting group carried outanevaluation supervision participationof groups management including ceo cfo effectiveness design operation groups disclosure controls procedures st december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives ceo cfo expect complete certifications report conclusions effectiveness disclosure controls procedures nd march following certificates filed sec part groups form f gsk annual report srotcerid eht fo tropercorporate governance continued section managements annual report internal control financial reporting accordance requirements section sarbanes oxley following report provided management respect companys internal control financial reporting defined rules af df ussecurities exchange act management responsible establishing maintaining adequate internal control financial reporting group internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance ifrs including reconciliations required usgaap management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated frameworkissued committee sponsoring organisations treadway commission changes groups internal control financial reporting materially affected reasonably likely affect materially groups internal control financial reporting management assessed effectiveness internal control financial reporting st december andits conclusion filedas part ofthe groups form f pricewaterhousecoopers llp audited consolidated financial statements group year ended st december also audited managements assessment effectiveness internal control financial reporting effectiveness groups internal control financial reporting auditing standard public company accounting oversight board united states audit report filed groups form f gsk annual report srotcerid eht fo tropergsk annual report srotcerid eht fo troper remuneration report remuneration report sets remuneration policies operated gsk respect directors corporate executive team cet members together disclosures directors remuneration including required directors remuneration report regulations regulations accordance regulations following sections remuneration report subject audit annual remuneration nonexecutive directors remuneration share options incentive plans performance criteria performance share plans share options pensions opinion thereon expressed page remaining sections subject auditnor pages referred within audited sections report submitted shareholders board approval annual general meeting referenced notice annual general meeting throughout remuneration report executive directors cetmembers referred executives references glaxosmithkline shares adss mean respectively ordinary shares glaxosmithkline plc p american depository shares glaxosmithkline plc ads represents two glaxosmithkline shares introduction remuneration policy executive director terms conditions remuneration nonexecutive director terms conditions fees directors senior management remuneration annual remuneration nonexecutive directors remuneration directors interests share options incentive plans pensions directors senior management directors interests contracts gsk annual report srotcerid eht fo troper remuneration report continued introduction two quorate meetings held year approve formal grant share options performance share awards remuneration committee committee responsible accordance gsk remuneration policy making recommendations board companys remuneration policy within terms agreed policy exception mr bicknell company secretary employees determining total individual remuneration packages company involved conduct committee meetings executives dr garnier ceo mr phelan senior vice president human resources invited attend part meetings gsks remuneration policy agreed extensive consultation committee required process shareholders institutional bodies course appropriateness elements policy deloitte touche llpdeloitte appointed kept review committee committee provide independent advice executive remuneration chairman remuneration committee continues regular dialogue institutional investors regarding gsks deloitte provided consulting services gsk year remuneration policy provide advice executive remuneration matters committee glaxosmithklines remuneration policy designed establish framework remuneration consistent companys towers perrin provides market data data analysis scale scope operationsmeets recruitment needs committee business closely aligned uk shareholder guidelines st december company second largest remuneration policy pharmaceutical company world revenue operationson principles five continents products sold overcountries withover remuneration policy glaxosmithkline designed sales generated usa secure outstanding executive talent provide pay remuneration committee performanceand performancewithin transparent sir robert wilson chairman committee since th robust governance structure may sir crispin davis mr culp dr schmitz members committee determined thatgsks remuneration policy would committee throughout board deemed based following key principles members committee independent nonexecutive directors accordance combined code remuneration structure must support needs business competitive market place following change combined code made financial uk shareholder guidelines followed maximum extent reporting council effect st november sir consistent needs business company would christopher gent appointed member committee maintain regular dialogue shareholders effect st january global pharmaceutical companies primary pay comparator committee met four times member group attending follows performance conditions would based measurable delivery strong financial performance delivery superior returns number meetings number meetings held whilst attended shareholders compared pharmaceutical companies name committee member committee member high proportion total remuneration opportunity sir robert wilson based performancerelated remuneration delivered mr larry culp medium long term sir crispin davis remuneration would determined using projected value dr ronaldo schmitz method see benchmarking would one remuneration structure executive directors meetings amongst items committee considered cetwith performance conditionsapplying equally terms service remuneration levels new executive longterm incentive awards appointments exgratia payments made competitiveness companys total reward package pay structures would simple consistent including level annual longterm incentive opportunity business needs effectiveness annual bonus plan particularly overall policy intended provide median total remuneration rd employees median performance opportunity earn upper quartile structure competitiveness us pension arrangements total remuneration exceptional performance poor performance policy aspects discussed chairman result total remuneration significantly pay comparator chairman committee annual meetings group median institutional investors additioneach year following agm strong alignment performance demonstrably committee considers gsks remuneration policy context interests shareholders provides executives market best practice unambiguous signals importance delivering success companys shareholdersgsk annual report srotcerid eht fo troper remuneration report continued commitment performance line expectations total remuneration committee apply policy consistent transparent targeted median pay comparator group long basis significant changes measures used assess term incentive opportunity set way provides performance discussed shareholders use positioning total remuneration median group comparators pay benchmarking committee use valuation method discretion ensure remuneration levels reasonable projected value method used benchmark total remuneration believes changes may cause concern amongst shareholders method projects future value remuneration package position discussed shareholders prior implementation different performance scenarios method taken together pay performance comparators assessment pay comparator groups incentive policies following table sets companies used pay overseveral years moderates impact market fluctuations performance comparison short term strengthens focus performance market cap following independent review committee made company country deliberate conscious decision use projected value method abbott laboratories usa pay benchmarking purposes enables comparison amgen usa packages different structural characteristics provides astrazeneca uk insight value gearing different equity instruments bristolmyers squibb usa individual elements remuneration eli lilly usa balance fixed base salary variable annual glaxosmithkline uk bonus longterm incentive elements remuneration changes johnson johnson usa performance chart shows anticipated normal merck usa range mix fixed variable pay different levels novartis switzerland performance ceo typical case executive pfizer usa directors ed years ranges may higher lower roche holdings switzerland depending performance company individual sanofiaventis france scheringplough usa ceo ed takeda pharmaceutical company japan wyeth usa included performance comparison merger aventis sanofisynthelabo reduced size comparator group companies base salary annual bonus longterm incentives glaxosmithklineduring year committee reviewed thisgroup part continuous appraisal gsks remuneration base salary arrangements result determined amgen base salaries set reference median relevant added thegroup effect st january market executives pharmaceutical pay comparator group actual salary levels reviewed annually andare influenced benchmarking executives experience responsibility market value benchmarking purposes total remuneration incorporates base changes usually take effect st april salary annual bonus longterm incentives notwithstanding setting pay committee also due regard table sets base salary increases took effect executives pension arrangements year take effect april base salary percentage base salary global pharmaceutical industry used primary pay st april increase st april comparator executives appropriate marketplace dr garnier companys senior executive talent mr heslop first instance pay benchmarked publicly available dr slaoui remuneration data companiesto provide additional context base salary increases reflect thecommittees assessment performance reference also made towers perrin annual global respective roles sinceappointment pharmaceutical pay survey pharmaceutical human resources dr slaoui appointed board effect th may succeeded dr yamada effect fromst june association phra ensure global pharmaceutical industry benchmark subject scrutiny review committee also regularly considers pay data global businesses primarily theconsumer manufacturing sectors prior determining annual longterm incentive opportunity committee considers range payout levels may achieved based different assumptions share price growth performance levels etcremuneration report continued annual bonus annual grant ltiawards using one plan consistent bonuses determined basis formal review annual practice pay comparator group leading uk performance stretching financial targets based profit companiesltis cet provided basis interest tax subject detailed assessment executive directors level annual lti opportunity individual business unit andgroup achievements objectives considered carefully yearonyear committee context bonus payable financial performance less market practice gsks policy market positioningfollowing target maximum bonus executives earn based solely review committee determined appropriate make corporate performance approximately twothirds maximum adjustments lti awards number executives line bonus opportunity individual performance objectives policy increase decrease bonus level factor range align award cycles closely gsks financial year zero bonuses subject upper limits budgeting process committee decided change executives ceo range annual grant date forlti awards eligible employees base salary ceosmaximum bonus opportunityis fourth quarter year first quarter year following review annual bonus plan committee compensation provided change award cycle determined bonus measures linked pipeline would historically performance period awards made fourth introduced rd employees including dr slaoui robust quarter started st january following date award lti governance structure established ensure bonus awards made thereafter performance periodstarts payable revised arrangements fairly reflects rd st january year award ie st january awards productivity performance well profit targets committee made february review bonus arrangements first year operation performance share awards share options delivered us aim remuneration policy deliver annual cash line resident executives form adss awards delivered median pay comparator group ontarget business form ordinary shares executives resident uk performance countries awards made plans incorporate case ceo bonus targets set board dilution limits consistent guidelines provided setting objectives ceo board takes account association british insurers national association pension strategies developed company set funds shareholder representative bodies current pageof annual report estimated dilution existing awards glaxosmithkline employee share schemes made since merger approximately reasons commercial sensitivity specific objectives set companys share capital st december strategic business drivers set kept confidential following end financial year theboard reviews performance shares ceos performance generally againsttheset objectives executives level performance shares vesting based committee determines bonus payable companys total shareholder return tsr relative executives ceo makes recommendations committee performance comparator group see threeyear regarding performance level achieved objectives measurement period tsr chosen appropriate recommendations considered committee comparative measure since focuses return shareholders determine resultant bonus wellunderstood tested mechanism measure performance allows comparison companies operating different objectives set focused particular building best countries product pipeline industry delivering commercial operational excellence tsr measured sterling performance period represents change value share together value committee took account thecompanys success achieving reinvested dividends paid order remove impact objectives well individual executivesperformance varying tax treatments dividends different jurisdictions determining bonus awards dividends reinvested gross longterm incentives table sets performance share awards made executives eligible performance share awards share february full disclosure made options remuneration policy provides annual longterm remunerationreport incentive lti awards normally made performance market price share award share option award executive director performanceshareaward date grant dr garnier adss committee considers performance shares provide stronger mr heslop shares alignment shareholderinterests therefore remuneration dr slaoui adss policy places greater emphasis use performance shareslti awards determined ontarget performance gsk ranked medianof performance comparator group half lti rewardshould bederived performance shares shares vest ranking point result shares vesting gsk one top two companies shares vest determining vesting levels committee regard companys underlying financial performance gsk annual report srotcerid eht fo troperremuneration report continued table sets thevesting schedule awards following key principles govern use eps performance based performance comparator group comprising companies measure excluding gsk adjustments considered major items percentage adjustments judgement committee tsr rank award vesting purpose adjustments ensure performance measurement fair reasonable participants shareholders discretion exercised committee disclosed shareholders annual report committee set basis decision considers appropriate make adjustment median table sets share option awards made february belowmedian full disclosure made remuneration tsr measured prorata basis glaxosmithklines performance report falls two comparators level vesting determined executive director share option award option price actual relative level tsr rather simple ranking dr garnier adss provide closer link shareholder returns payments mr heslop shares executives notional dividends reinvested paid dr slaoui adss proportion vesting award receipt dividends incorporated benchmarking award levels addition forshare option grants vesting increases straightline performance shares earned executives sold except basis eps performance hurdles set meet related tax liabilities two years following end following graph vesting period committee believes aligns interests executives longterm interests shareholders performance share plan awards granted indecember performance period starting st january ending st december vest executives office gsks relative tsr performance median result awards lapsed awards made senior executives including dr slaoui mr heslop dependent part tsr performance part eps performance half awards vested gsks eps performance reached target level full vesting vesting tables performance share awards granted given page b share options share options allow holder buy shares future date share price prevailing time grant share options granted thanmanagers glaxosmithkline including executives thevesting share options granted executives performance condition substantially consistent uk linked achievement compound annual eps growth shareholder guidelines expectations demanding performance periodeps measured constant exchange rates compared operated global pharmaceutical cer gsks practice measure performance cerbasis companies consistent policy providing pay performance performance committee considers eps key measure performance business andisfully reflected business performance measured overperiods three financial yearsthe measures extended throughout group ensuring organisational performance period startsin year awardwith base year alignment preceding financial year performance retesting performance condition met threeyear period setting eps targets committee considers prior options lapse grant companys internal projections analysts forecasts glaxosmithklines eps performance well analysts forecasts share optionsgranted invested full pharmaceutical industry extensive careful consideration committee agreed annualised growth eps achieve vesting share option awards granted infebruary would berpi gsk annual report srotcerid eht fo troper rpi pa egatnecrep gnitsev exceptional superior baseline threshold rpi rpi rpi pa pa pa eps targetremuneration report continued pensions share ownership requirements executives participate glaxosmithkline senior executive pension align interests executives shareholders plans pension arrangements structured accordance executives required maintain significant holdings shares plans operated executives country glaxosmithkline requirements important part executives likely retire details individual arrangements aligning interests executives shareholders ceo executive directors set page response new required hold shares value four times base salary pensions regime uk committee carefully considered executive directors required build shareholding value impact change legislation anddecided following three times base salary members cet required build shareholding value two times base salary top company continue fulfil obligations existing executives group required build shareholding pension arrangements value one times base salary required confirm holding compensation provided participants adversely audited kpmg annual basis affected new pension regime order shares qualify share ownership requirements gsk pension policy executives uk must held personally executive spouse except newly employedexecutivesbenefit company contribution spouse also employed gsk andis also subject base pay defined contribution plan together requirements minor children earned deferred opportunity receive matched one share programmes operated company contributions unexercised share options included calculation legacy final salary plans provide twothirds final salary st december dr garniers holding wasadss age grandfathered existing employees new dr slaouis wasadss andordinary sharesand mr heslops entrants allowed wasordinary shares dr garniersholding excess capped employees benefits excess cap currently share ownership requirements mr heslop december provided unfunded arrangements dr slaoui december build holdings legacy final salary plans actuarial reduction factors apply value three times base salary participant leaves employmentofhis accord age effectively spreading value pension earned executives required continue satisfy shareholding longer life expectancy employment terminated requirements minimum twelve months following retirement company eg redundancy reduction factors apply company dr yamada mr coombe retired st may st march respectively met usa gsk operates us cash balance plan provides requirement annual contribution interest sum accumulated cash balance plan contractual promise provide specific remuneration elements levels retirement income executives participate various legacy glaxo wellcome smithkline beecham allemployee share plans either uk light market data extensive review pension usa glaxosmithkline plans replaced arrangements us executives undertaken committee review took account cost implications sharesave plan sharereward plan uk hm revenue company well competitiveness current arrangements andcustoms approved plans open uk employees conclusion pension offered gsk usa terms mr heslop member sharesave plan fallen significantly behind market senior level contributes month provides option buy shares end threeyear savings period line view taking account concerns raised opportunity available uk employees institutions investors relation basis contributions previously determined us cash balance mr heslop also contributes per monthto buy shares plan committee approved introduction new us sharereward plan company matches number shares executive cash balance plan change took effectfrom st january bought month forsenior us executives exception ceo whose executives also receive benefits including healthcare provisions grandfathered light hisanticipatedretirement medical dental personal financial advice life assurance plan contributions determined solely cash value benefits received executive directors reference executives base salary contribution rates shown page plan range base salary capped employees usa benefits cap provided unfunded non qualified plan gsk annual report srotcerid eht fo troperremuneration report continued executive director terms conditions addition dr garnier entitled receive one years worth remuneration pension contributions termination executive director contracts following table sets details executivedirectors ' policy set provides framework contracts service contracts executive directors appointed since going forward current directors date contract effective date expiry date dr garnier aspect policy mr heslop notice period calendar months dr slaoui termination employing company former directors date contract effective date expiry date executive dr yamada termination payment x annual salary mr coombe x annual ontarget bonus dr yamada retired board company st may mitigation required termination payments made respect part benefits governed benefits policy notice period extending beyond contract expiry dates including individual pension arrangements healthcare medical dental personal financial advice individual pension arrangements executive directors refer life assurance contributions page vesting longterm rules relevant equity incentive entitlements incentives plan addition contractual provisions outlined event pension based existing arrangements thatexecutive directorsservice agreements terminated terms relevant pension plan employing company following would apply noncompete clause months termination case outstanding awards glaxosmithkline notice date annual investment plan provided agreement terminated cause deferred amount income dr garniers target bonus salarydr slaouis salary mr heslops gains automatically distributed soon administratively salary reviewing level severance payments committee considered investor dti guidance however determined line practicable termination resign retire termination competitive practice appropriate provide payment salary target cause deferred amount distributed bonus termination end minimum threeyear deferral period imposition month noncompete period executives considered line policy applicable us senior executives dr garnier vitally important company order protect groups intellectual property light noncompete clause competitor practice committee believes dr yamada entitled receive continuing medical dental would appropriate provide mitigation contracts insurance dr slaoui member plan may become approved shareholders glaxosmithkline glaxo wellcome smithkline eligible future date receive continuing medical dental beecham appropriate cover retirement dr garnier agreed changes previous contractual following merger participants legacy share option terms without compensation come broadly line new schemes elected exchange legacy options options contractual framework including reduction contractual notice glaxosmithkline shares receive additional cash benefit period calendar months however order honour equal grant price original option certain aspects old contractual terms number additional benefit triggered new option exercised individual features retained lapses qualify additional cash benefit participants include entitlement reimbursement excise tax retain options least second anniversary change control related paymentsand life insurance benefit funded effective date merger company age outside appointments executive directors relation lti awards thesearesubject performance testing outside appointments must approved chairman options performance share awards made within monthsof behalf board companys policy remuneration termination notice date lapse however termination earned appointments may kept individual company cause retirement resignation executive director good reasonie resignation due elected retained director company merged company result change control provided resignation occurs within days first anniversary change controloptions remain exercisable full option term gsk annual report srotcerid eht fo troperremuneration report continued nonexecutive director terms conditionsand fees chairman sir christopher gents letter appointment board dated nonexecutive directors glaxosmithkline service th may agreed serve company contracts instead letters appointmentunder deputy chairman st december st january agreed serve company nonexecutive director chairman conclusion annual general meeting conclusion annual general meeting following third following third anniversary appointment may anniversary appointment case extended extended term three years mutual agreementin term three years mutual agreement directors received per annum plus allocation serve term longer three years without offering glaxosmithkline shares value per annum reelection shareholders company aims provide non chairmanfollowing review theboard agreed increase fees executive directors fees competitive effect st january per annum plus companies equivalent size complexity allocation glaxosmithkline shares value per following table shows date initial letter appointment annum nonexecutive director tsrperformance graph nonexecutive date letter following graph sets performance company relative director appointment ftse index company constituent dr sburns performance comparator group st january st mrl culp december graph prepared accordance sir crispin davis regulations indication likely vesting awards sir deryck maughan granted companys incentive plans dr podolsky sir ian prosser dr r schmitz mr de swaan sir robert wilson fee structure nonexecutive directors follows per annum standard annual cash retainer fee supplemental fees senior independent director audit committee chairman scientificmedical experts chairmen remuneration corporate responsibility committees nonexecutive director undertaking intercontinental travel meetings per meeting exchange rate fees paid usdollars converted rate us exchange rate applied th july new fee arrangements approved board nonexecutive directors share allocation plan directors senior management remuneration enhance link directors shareholders glaxosmithkline requires nonexecutive directors receive following tables set directors glaxosmithkline plc significant part fees form shares least remuneration earned interests shares nonexecutive directors total fees excluding chairman paid glaxosmithkline plc interests share options incentive form shares adss allocated share account plans pension benefits members cet nonexecutive directors may also take opportunity invest part company secretary known senior management also balance fees share account participate remuneration plans executive directors aggregate remuneration interests directors shares adss notionally awarded nonexecutive senior management also provided directors allocated interest accounts included within directors interests tables page accumulated balance shares adss together notional dividends subsequently reinvested paid nonexecutive directors retirement upon retirement nonexecutive directors receive either shares adss cash amount equal value shares adss date retirement nonexecutive directors entitled compensation appointment terminated gsk annual report srotcerid eht fo troper glaxosmithkline total return index glaxosmithkline pharma peers return index ftse total return indexremuneration report continued annual remuneration total total fees annual annual fees annual deferred annual salary benefits bonus remuneration salary benefits bonus bonus remuneration footnote executive directors dr jp garnier abc dr slaoui mr j heslop nonexecutive directors sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson mr l culp sir deryck maughan dr podolsky former directors mr j coombe cd dr barzach e sir roger hurn sir peter job sir richard sykes dr yamada abc dr l shapiro f total remuneration analysed executive directors nonexecutive directors former directors total remuneration remuneration directors us payroll reported dollars dollar amountsare included totals based conversion sterling average exchangerates year following mergerand order encourage employees convert nonsavings related options held glaxowellcome smithkline beecham shares adss options glaxosmithkline shares adss employees granted additional cash benefit equal grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapses market value qualify additional cash benefit participants retain options least second anniversary effective date merger year dr garnier received dr yamada received relating options exercised page b dr garnier nonexecutive director united technologies corporation respect received form deferred stock units dr garnier receivedin form deferred stock units andstock options grant price dr yamadaisa member advisory board quaker bioventures inc period st january retirement glaxosmithkline st may received c following merger dr garnier mr coombe dr yamada awarded oneoff special deferred bonus members cet awarded amount equivalent annual salary st december notionally invested glaxosmithkline shares adss th february deferred three years deferred bonus vested th february amounts paid equivalent value glaxosmithkline shares adss notionally acquired february plus dividends reinvested period dr garnier received dr yamada received mr coombe waived deferred bonus company made contribution pension plan enhance pension entitlements amount included table mr coombe waived prorated bonus company madecontributionsto pension plan enhance pension entitlements amounts included within fees salary e dr barzach received fees glaxosmithkline france healthcare consultancy provided included within fees salary f although dr shapiro retired board th may continuesto bea member glaxosmithklines scientific advisory boardfor received fees form adss included within fees salary none directors received expenses year requiring separate disclosure required regulations dr burns joined board nonexecutive director onth february therefore fees paid light low take levels response concerns expressed institutional investors relation nonperformance related match provided annual investmentplan aip committee decided discontinue aip open approximately senior executives participated terms last deferral elections aip made respect bonuses earned although aip closed gsk continue manage ongoing administration subsisting awards required aip rules gsk annual report srotcerid eht fo troperremuneration report continued gsk annual report srotcerid eht fo troper nonexecutive directors remuneration total cash sharesadss total cash sharesadss fees current nonexecutive directors sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson mr lculp sir deryck maughan dr podolsky former nonexecutive directors dr l shapiro total remuneration table sets remuneration received nonexecutive directors glaxosmithkline accordingly include dr shapiros fees received member glaxosmithklines scientific advisory board formation gskthe nonexecutive directorshave required take least part total fees form shares allocated share account least nonexecutive directors fees except chairmansee pagefor detailsmust taken fee allocation arrangement nonexecutive directors elect receive either part remaining cash payment form shares adss total value shares adss date award together cash payment forms total fees included within annual remuneration table fees salary table sets value fees received form cash shares adssremuneration report continued table sets accumulated number shares adss held nonexecutive director relation fees received board members st december together movements account year number shares adss dividends nonexecutive directors share arrangements footnote elected reinvested paid current nonexecutive directors shares sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson adss mr lculp sir deryck maughan dr podolsky former nonexecutive directors shares dr l shapiro sir roger hurn b adss dr l shapiro dividends notionally reinvested end financial year payment made table sets settlement former nonexecutive directors share arrangements leaving board value value awards awards payments date leaving allocation leaving current year dr l shapiro ac prior years sir roger hurn b adr shapiros closing balance appears th may date left boardall share arrangements dr shapiro settled september lump sum cash payment b leaving board sir roger hurn elected receive settlement nonexecutive directorsshare arrangements quarterly cash payments july sir roger agreed receive outstanding balance plan lump sum cthe change value awards allocation leaving attributable dividends reinvested change share price dates award dates leaving gsk annual report srotcerid eht fo troperremuneration report continued directors interests following beneficial interests directors company shown register maintained company accordance companies act shares adss rdfebruary st december st january rdfebruary st december st january footnote executive directors dr jp garnier dr slaoui b mr j heslop c nonexecutive directors dr burns mr l culp e sir crispin davis e sir christopher gent e sir deryck maughan e dr podolsky ef sir ian prosser e dr r schmitz e mr de swaan e sir robert wilson e former directors dr yamada ag dr l shapiro eg one glaxosmithkline ads represents two glaxosmithkline shares aincludes equivalent number adss purchased glaxosmithkline stock fund within k plan bin case dr slaoui opening number shares shown th may cincludes shares purchased glaxosmithkline sharereward plan mr heslop totalling st december st december andshares rd february ddr burns joined board onth february eincludes shares adss received part fees described nonexecutive directors share arrangements page dividends received shares adss converted shares adss st december also included directors interests f dr podolsky joined board st july shares glaxosmithkline date gdr yamada left board st may dr shapiro left board th may therefore closing interests recorded table dates included rd february interests abovementioned directors atrdfebruary reflect change yearend date share options options shares granted footnote date grant exercise period grant price number exercised dr slaoui ab mr jheslop options adss granted date grant exercise period grant price number exercised dr jpgarnier dr tyamada c part main option grant occurred th february vesting period th february th february dr garnier dr slaoui awarded ads options respectively grant price part grant mr heslop awarded share options grant price b drslaouijoined boardon th may details cover period th may st december include interests wife also employee gsk cdr yamada retired st may excluded grant options st february retired company within months date grant details cover period st january st may dr yamadas unvested awardswill vest end relevant performance period subject performance gsk annual report srotcerid eht fo troperremuneration report continued options outstanding st december earliest latest vesting lapse dates market price glaxosmithkline share year end given table vesting date lapse date weighted average dr jpgarnier grant price number earliest latest earliest latest market price underwater year end vested options market price year end vested options unvested options total ads options st december vesting date lapse date weighted average dr slaoui grant price number earliest latest earliest latest market price underwater year end vested options unvested options market price year end vested options unvested options totalshareoptions st december includes share options held bydr slaouis wife also employee gsk vesting date lapse date weighted average mr jheslop grant price number earliest latest earliest latest market price underwater year end vested options unvested options market price year end vested options unvested options total share options st december vesting date lapse date weighted average dr tyamada grant price number earliest latest earliest latest market price underwater year end vested options market price year end vested options unvested options total ads options stmay lapse dates dr yamadas options modified reflect retirement gsk annual report srotcerid eht fo troperremuneration report continued gsk grants share options executive directors senior managers annual basis directors hold options various share option plans referred noteto financial statements employee share schemes none directors interest option companys shares table sets forgrants share optionsin respect last four financial years grant year theperformance period whether options vested performance targets performance target annualised growth percentage grant performance period vesting status eps award vesting november vested rpi rpi rpi rpi december vested rpi rpi rpi rpi december yet vested rpi rpi rpi rpi february yet vested rpi rpi rpi rpi rpi following introduction international financial reporting standards ifrs st january committee considered eps measurement basis either ifrsor ukgaap used shareawards performance periods straddled ifrs conversion data committee determined ukgaap would used grant performance period st january st december two three years would reported ukgaap thereafter ifrs would apply grant market options exercised date number price price gain gain dr jpgarnier mr j heslop dr yamada aggregate gain options exercised dr slaoui exercise options thmay st december average exchange rate year gain made dr garnier amounted eoi benefit paid dr garnier exercise options benefit included table page th february dr garnier exercised options agrantprice market price date exercise giving rise gain dr garnier also receivedin respect eoibenefit arising exercise options average rate year gain made dr yamada amounted eoi benefit paid dr yamada exercise options benefit included table page highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline adss year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december prices onrdfebruary per glaxosmithkline share per glaxosmithkline ads gsk annual report srotcerid eht fo troperremuneration report continued incentive plans performance share plan psp awards dr jp garnier adss market additional number price vested deferred ads number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested dr garnier held deferredpsps yearendthe increase balanceofrelates dividends reinvestedduring year psps vested year dr garnier elected defer total value awards vesting dr mslaoui shares adss market additional number price vested exercised shares number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested market additional number price vested exercised adsby number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested includes psps held bydr slaouis wife also employee gsk mr jheslop shares market additional number price vested exercised shares number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested dr tyamada adss market additional number price vested exercised ads number unvested granted date market dividends unvested granted performance period grant number price gain lapsed reinvested dr yamadas unvested awardswill vest end relevant performance period subject performance average exchange rate year gains dr garnier dr yamada amounted respectively total gain vesting psp awards made executive directors psp mediumterm incentive scheme introduced terms psp number shares actually vesting determined following end relevant threeyear measurement period dependent gsks performance period described pagesand share awards previously granted annually november decemberprior start performance period since grant granted february first year performance period measurement period commences onst january ending three years st december awards performance period commencing st january subsequent awards dividends reinvested psps awarded members cet dividends reinvested quarter payment made terms psp us participants may defer receipt part vested awards thepspawards granted december performance period starting st january ending st december vest executives office gsks relative tsr performance median result awards lapsedthe awards made senior executives including dr slaoui mr heslop dependent part tsr performance part eps performance half awards vested gsks eps performance reached target level full vesting gsk annual report srotcerid eht fo troperremuneration report continued share value plan awards dr mslaoui sharesand adss market number number price vested exercised ofadss unvested granted date market unvested granted plan year grant number price gain lapsed capacity svp worldwide business development dr slaoui eligible participate gsk share value planboth dr slaoui wife employee gsk received awards share value plan following announcement appointment board february ceased eligible receive awards plan awards aresubject year vesting period vesting contingent ontheircontinued employment gsk vested additional ads vested deferred dividends deferred participations reinvested participations midterm incentive plan adss dr jp garnier midterm incentive plan mtip share award scheme operated smithkline beecham theplan closed new entrants upon completion merger participations granted final award adss made receipt award may deferred director dr garnier deferred receipt full amounts vested deferred awards together additional adss subsequently received dividend reinvestment arenot included directors interests table pagesince retained mtip paid gsk annual report srotcerid eht fo troper following vesting schedulesapply awards made vesting schedule award performance period tsr rank companies percentage award vesting st january st december st january st december median median vesting schedule award performance period tsr rank companies percentage award vesting st january st december median median performance comparator group awards comprised companies glaxosmithkline aventis sanofisynthelabo comparator group prior merger form sanofiaventis purposes calculating tsrover performance period awards granted december starting price shares two individual companies compared price merged company end performance period adjusted merger ratio dividends treated reinvested performance period tsr measured prorata basis glaxosmithklines performance falls two comparators level vesting determined actual relative level tsr rather simple rankingremuneration report continued average stock appreciation rights sars adss grant price dr l shapiro dr shapiro exerciseanysars gain exercise sars held dr shapiro grant price market price glaxosmithkline ads th may date retired board glaxosmithkline dr shapiro member glaxosmithklines scientific advisory board sab dr shapiro member smithkline beechams sab completion merger glaxo wellcome along members sab received annual grants smithkline beecham sars general vested three years date grant expire years date grant grants sars sab members ceased sars entitle holder cash sum future date based share price growth date grant date exercise full provision made financial statements accrued gains sars date grant connection merger previously granted sars became immediately exercisable pensions accrued annual pension benefits transfer values executive directors retirement set regulations require disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year listing rules require additional disclosure change accrued benefit net inflation transfer value change pensions executive directors disclosed currency pension payable personal change change contributions accrued transfer value accrued accrued accrued made transfer transfer change benefit change benefit benefit benefit scheme value value transfer year net accrued year year value inflation benefit current executive directors dr jp garnier drmslaoui mr jheslop former executive directors dr tyamada theseare shown net contributions made individual drgarnier member theallemployee uscashbalancepensionplan glaxosmithkline makes annual contributions calculated percentage employees base salary bonus glaxosmithkline makes annual contributions dr garniers annual salary bonus detailed contractthe fund increases interest rate set annually advance based year us treasury bond rate provide cash sum retirement cash sum used purchase pension atretirement based annuity rates applicable time plan entitlement spouses pension pension increases reducing executives initial pension transfer value cash sum dr garniers plan increased year result offurther accumulation interest contributions paid company effect st june dr slaoui became member us executivecashbalancepensionplan glaxosmithkline makes annual contributions calculated percentage executives base salary glaxosmithkline makes annual contributions dr slaouis annual salary fund increases interest rate set annually advance based year us treasury bond rate provide cash sum retirementthis cash sum used purchase pension retirement based annuity rates applicable time plan entitlement spouses pension pension increases reducing theexecutive'sown initial pension dr slaoui active participant belgium fortes plan st may plan defined benefit plan lump sum payable normal retirement age plan years agethe transfer value cash sum dr slaouis plan increased year result accumulation interest contributions paid company mr heslop participates glaxo wellcomedefinedbenefitplan accrual rate th final pensionable salary per annum benefits accrued glaxo wellcome ukpension arrangements augmented trustees plans reflect distribution surplus augmentation apply element mr heslops pension earnings st march gsk annual report srotcerid eht fo troperremuneration report continued mrheslops transfer value calculated basis actuarial advice accordance actuarial guidance note gn transfer value represents present value future payments made pension plan mr heslops annual accrued benefit increased excluding effects inflation transfer value less personal contributions increased year increase mr heslops pensionable salary primary reason increase transfer value dr yamada retired st may member employee uscash balance pension plan glaxosmithkline makes annual contributions calculated percentage employees base salary bonus glaxosmithkline made annual contributions dr yamadas annual salary bonus detailed contract fund increases interest rate set annually advance based year us treasury bond rate provide cash sum retirement cash sum used purchase pension retirement based annuity rates applicable time plan entitlement spouses pension pension increases reducing executives initial pension dr yamada commenced pension benefit form annuity st june dr garnier dr slaoui dr yamada also members us retirement savings plan savings scheme open us employees executive supplemental savings plan savings scheme open executives restore us government limits imposed retirement savings plan contributions plans invested range funds value accumulated funds paid retirement contributions paid two schemes company respect dr garnier respect dr slaoui contributions paid scheme respect dr yamada contributions paid scheme gsk annual report srotcerid eht fo troper directors senior management us reporting purposes necessary provide information compensation interests directors senior management asagroup group purposethe group defined directors members cet company secretary forthe financial year total compensation paid members group periods served capacity aggregate increase accrued pension benefits net inflation aggregate payment defined contribution schemes group grantedshare optionsandadsoptions shareoptionscheme shares adssunder performance share planand awarded shares share value plan members group also awarded shares adss reinvestment dividends performance share plan atrdfebruary thegroup comprisingpersons owned shares andadss constituting less issued share capital company group also held date options purchaseshares andadss shares andadss awarded performance share plan including shares adss vested deferred vested deferred adss legacy smithkline beecham midterm incentive planandshares adss awarded thesharevalueplan holdings issued various executive share option plans described noteto financial statements employee share schemes directors interests contracts except described noteto financial statements related party transactions end financial year director connected person material interest contract significance relation groups business group company directors remuneration report approved board directors signed behalf sir christopher gent chairman th februarygsk annual report stnemetats laicnanif financial statements section comprises directors statements responsibility independent auditors report financial statementsand consolidated financial statements consisting principal financial statements supporting notes prepared ifrsas adopted use european union also presentedis balance sheet glaxosmithkline plc prepared ukgaap directors statements responsibility independent auditors report financial statements consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements presentation financial statements accounting policies new accountingrequirements exchange rates segment information operating income operating profit employee costs finance income financecosts associates joint ventures taxation earnings per share dividends property plant equipment goodwill intangible assets investments associates joint ventures investments noncurrent assets inventories trade receivables cash cash equivalents assets held sale trade payables pensions postemployment benefits provisions noncurrent liabilities contingent liabilities net debt share capital share premium account movements equity related party transactions reconciliation ofprofit tax operating cash flows reconciliation net cash flow movement net debt acquisitions disposals commitments post balancesheet events financial instruments related disclosures employee share schemes reconciliation us accounting principles principal group companies legal proceedings balance sheetof glaxosmithkline plc prepared ukgaap directors statements responsibility directors statement responsibility relation directors remuneration consolidated financial statements remuneration report pages sets directors responsible remuneration policies operated glaxosmithkline disclosures directors remuneration disclosable information relating ensuring maintenance proper accounting records directors officers interests prepared disclose reasonable accuracy financial position group accordance companies act complies section time financial statements beprepared b combined code corporate governance comply companies act article ias regulation going concern basis preparing financial statements financial period give making enquiries directors reasonable true fair view accordance ifrs adopted use expectationthat grouphas adequate resources continue european union state affairs thegroup operational existence foreseeable future forthis reason end financial period ofthe profit loss period continue adopt going concern basis inpreparing ensuring operation systems internalcontrol taking financial statements reasonable steps safeguard assets group preventing detecting fraud irregularities internal control financial statements year ended st december board audit committee reviewed comprising principal statements supporting notes set assessment risks internal control framework operates infinancial statements pagestoof report glaxosmithkline considered effectiveness system internal control operation inthegroup year covered directors confirm suitable accounting policies report date approval board directors consistently applied preparation financial statements supported reasonable prudent judgements estimates combined code asnecessary board considers glaxosmithkline plc applies principles responsibilities auditors relation financial combined code corporate governance financial statements set independent auditors report reporting council asdescribed corporate governance opposite pages complied provisions except financial statements year ended st december described page included annual report published hardcopy required listing rules financial services authority printed form made available website directors auditors haveconsidered directors statement compliance responsible maintenance integrity annual report relation points combined code specified website accordance uk legislation governing theirreview preparation dissemination financial statements access website available outside uk comparable legislation annual report may different annual report year ended st december disclosure information auditors comprising report directors remuneration report financial statements additional information investors directors office date report approved board directors signed behalf confirmed far aware relevant audit information companys auditors unaware director taken steps heshe ought taken director make himselfherself aware relevant audit information establish companys auditors aware information sir christopher gent confirmation given interpreted accordance chairman provisions section za companies act thfebruary gsk annual report stnemetats laicnanifindependent auditors report members glaxosmithkline plc audited group financial statements glaxosmithkline consider implications report become aware year ended stdecember comprise primary apparent misstatements material inconsistencies financial statements consolidated income statement group financial statements responsibilities extend consolidated balance sheet theconsolidatedcash flow statement information consolidated statement recognised income expense related notes group financial statements basis audit opinion prepared accounting policies set therein conducted audit accordance international standards reported separately parent company financial auditing uk ireland issued auditing practices board statements glaxosmithkline year ended stdecember audit includes examination test basis evidence relevant information directors remuneration report amounts disclosures group financial statements described audited also includes assessment significant estimates judgements made directors preparation group respective responsibilities directors financial statements whether accounting policies auditors appropriate thegroups circumstances consistently applied adequately disclosed directors responsibilities preparing annual report group financial statements accordance applicable law planned performed audit obtain international financial reporting standards ifrss adopted information explanations considered necessary order european union set statement directors provide us sufficient evidence give reasonable assurance responsibilitiespageopposite group financial statements free material misstatement whether caused fraud irregularity error responsibility audit group financial statements forming opinion also evaluated overall adequacy accordance relevant legal regulatory requirements presentation information thegroup financial statements international standards auditing uk ireland report including opinion prepared opinion companys members body accordance section companies act purposewe giving opinion opinion accept assume responsibility purpose group financial statements give true fair view person report shown whose accordance ifrss adopted european union hands may come save expressly agreed prior consent state thegroups affairs stdecember writing profit cash flows year ended report opinion whether group financial thegroup financial statementshave properly prepared statements give true fair view whether group financial accordance companies act article ias statements properly prepared accordance regulation companies act article ias regulation also report whether opinion information given information given thereport directorsis consistent report directors consistent group group financial statements financial statements separateopinion relation ifrss addition report opinion received information explanations require audit explained note group financial statements group information specified law regarding directors remuneration addition complying legal obligation comply transactions disclosed ifrss adopted european union also complied ifrss issued international accounting standards board review whether corporate governance statement reflects companys compliance nine provisions combined opinion group financial statements give true fair view code specified review listing rules accordance ifrss state thegroups affairs atst financial services authority report december profit cash year ended required consider whether boards statements internal control cover risks controls form opinion effectiveness thegroups corporate governance procedures risk control procedures read information contained annual report consider whether consistent audited group financial pricewaterhousecoopers llp statements information comprises financial chartered accountants registered auditors summary joint statement chairman chief executive london financial trends ratios business review corporate th february governance statement gsk annual report stnemetats laicnanifconsolidated income statement year ended st december notes turnover cost sales gross profit selling general administration research development operating income operating profit finance income financecosts share tax profits associates joint ventures profit disposal interest associates profit taxation taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p gsk annual report stnemetats laicnanifconsolidated balance sheet st december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures otherinvestments deferred tax assets noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax provision pensions postemployment benefits provisions noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity minority interests total equity approved board onth february sir christopher gent chairman gsk annual report stnemetats laicnanifconsolidated cash flow statement year ended st december notes cash flow operating activities cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment proceeds sale intangible assets purchase intangible assets purchase equity investments proceeds sale equity investments share transactions minority shareholders purchase businesses net cash acquired disposal businesses interest associates investments associates joint ventures interest received dividends associates joint ventures net cash outflow investing activities cash flow financing activities increasedecreasein liquidinvestments proceeds shares employee share options issue share capital share capital purchased cancellation purchase treasury shares redemption preference shares issued subsidiary increase longterm loans repayment longterm loans net repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders dividends paid minority interests dividends paid preference shares financing cash flows net cash outflow financing activities decreaseincrease cash bank overdrafts exchange adjustments cash bank overdrafts beginning year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report stnemetats laicnanifconsolidated statement recognised income expense year ended st december exchange movements overseas net assets tax exchange movements fair value movements availableforsale investments deferred tax fair value movementson availableforsale investments exchange movements goodwill reserves actuarialgainslosseson defined benefit plans deferred tax actuarial movements defined benefit plans fair value movements cash flow hedges deferred tax fair value movements cash flow hedges net losses recognised directly equity profit year total recognised income expense year total recognised income expense year attributable shareholders minority interests gsk annual report stnemetats laicnanifnotes financial statements presentation financial statements description business glaxosmithkline major global healthcare group engaged creation discovery development manufacture marketing pharmaceutical products including vaccines overthe counter otc medicines healthrelated consumer products glaxosmithklines principal pharmaceutical products include medicines following therapeutic areas central nervous system respiratory antivirals antibacterials vaccines oncology emesis metabolic cardiovascular urogenital compliance applicable law ifrs financial statements prepared accordance companies act article ias regulation international accounting standards ias international financial reporting standards ifrs related interpretations adoptedby european union gsk differences ifrs adopted use european union full ifrs published international accounting standards board financial period financial statements cover financial year st january stdecember comparative figures financial years st january st december appropriatefrom st january tost december composition group list subsidiary associated undertakings opinion directors principally affected amount profit net assets group given principal group companies note composition financial statements consolidated financial statements drawn accordance ifrs ifrs accounting presentation financial statements comprise consolidated income statement consolidated balance sheet consolidated cash flow statement consolidated statement recognised income expense notes financial statements additional information accordance requirements usgenerally accepted accounting principles us gaap included notes financial statements notea statement differences reconciliations net income shareholders equity ifrs us gaap provided accounting convention financial statements prepared using historical cost convention modified certain items carried fair value stated accounting policies gsk annual report stnemetats laicnanif accounting principles policies preparation financial statements conformity generally accepted accounting principles requires management make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date financial statements reported amounts revenues expenses reporting period actual results could differ estimates financial statements prepared accordance groups accounting policies approved board described note parent company financial statements financial statements parent company glaxosmithkline plc prepared accordance ukgaap uk accounting presentation company balance sheet presented page accounting policies information application accounting policies including areas estimation judgement givenunder critical accounting policies financial review page consolidation consolidated financial statements include assets liabilities results cash flows company subsidiaries including esop trusts groups share theresults net assets associates joint ventures financial statements entities consolidated made st december entities group power govern financial operating policies accounted subsidiaries group ability exercise joint control entities accounted joint ventures group ability exercise significant influence accounted associates interests acquired entities consolidated thedate group acquires controland interests sold deconsolidatedfromthe date control ceases transactions balances subsidiaries eliminated profit tax taken sales subsidiaries sales joint ventures associates products sold customers outside group deferred tax relief unrealised intragroup profit accounted extent considered recoverable goodwill arising acquisition interestsin subsidiaries joint ventures associates representing excess acquisition costover groups share fair values identifiable assets liabilities contingent liabilities acquired capitalised asa separate item case subsidiaries part cost investment case joint ventures associates goodwill denominated currency operation acquired cost acquisition fair value net assets acquired difference recognised directly income statement results assets liabilities associates joint ventures incorporated consolidated financial statements using equity method accountingnotes financial statements continued accounting policies continued research development research development expenditure charged income foreign currency translation statement period incurred development foreign currency transactionsare booked inthe functional currency expenditure capitalised criteria recognising asset group companyat exchange rate ruling date met usually regulatory filing made major transaction foreign currency monetary assets liabilities market approval considered highly probable property plant retranslated local currency rates exchange ruling equipment used research development depreciated balance sheet date exchange differences areincluded income accordance groups policy statement environmental expenditure assets liabilities including related goodwill overseas environmental expenditure related existing conditions resulting subsidiaries associates joint ventures translated intosterling past current operations current future rates exchange ruling balance sheet date results benefit discernible charged income statement group cash flows overseas subsidiaries associates joint ventures recognises liability sitebysite basis reliably translated intosterling using average rates exchange exchange estimated liability includes groups portion total costs adjustments arising opening net assets profits also portion potentially responsible parties costs theyear retained overseas subsidiaries associates joint ventures probable able satisfy respective shares translated intosterling less exchange differences arising related cleanup obligation recoveries reimbursements recorded foreign currency borrowings hedge groups net investment assets virtually certain operations taken separate component equity legal disputes translating intosterling assets liabilities results cash provision made anticipated settlement costs reasonable flows overseas subsidiaries associates joint ventures estimate made likely outcome legal disputes reported currencies hyperinflationary economies adjustments group addition provision made legal aremade reflect current price levels loss net monetary expenses arising claims received disputes respect assetsis charged consolidated income statement product liability claims related products sufficient revenue history claims made settlements incurred revenue recognised income statement goods reported ibnr actuarial technique used determine reasonable services supplied made available external customers estimate groups exposure unasserted claims orders received title risk loss passes customer products provision made basis turnover represents net invoice value deduction discounts provision made unasserted claims allowances given accruals estimated future rebates obligation exists dispute possible make returns methodology assumptions used estimate rebates reasonable estimate costs associated claims made group returns monitored adjusted regularly light third parties charged income statement contractual legal obligations historicaltrendspast experience incurred projected market conditions market conditions evaluated using wholesaler thirdparty analyses market research data pensions postemployment benefits internally generated information turnover also includes co costs providing pensions defined benefit schemes promotion income group records share revenue calculated using projected unit credit method spread related cost sales value added tax sales taxes period benefit expected derived excluded revenue employees services accordance advice qualified actuaries pension obligations measured present value expenditure estimated future cash flows discounted rates reflecting yields expenditure recognised respect goods services received high quality corporate bonds supplied accordance contractual terms provision made obligation exists future liability respect past pension scheme assets measured fair value balance sheet event amount obligation reliably date actuarial gains losses differences expected estimated manufacturing startup costs validation actual returns effect changes actuarial assumptions achievement normal production expensed incurred recognised statement recognised income expense advertising promotion expenditure charged income year arise groups contributions defined statement incurred shipment costs intercompany transfers contribution plans charged income statement incurred charged cost sales distribution costs sales customers costs postemployment liabilities calculated similar included selling general administrative expenditure way defined benefit pension schemes spread period restructuring costs recognised respect direct expenditure benefit expected derived employees business reorganisation plans sufficiently detailed services accordance advice qualified actuaries well advanced appropriate communication affected undertaken stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued accounting policies continued goodwill goodwill stated cost less impairments goodwill deemed employee share plans indefinite useful life tested impairment annually incentives form shares provided employees share option share award schemes options awards fair value interest acquired entitys assets fair valued grant dates cost charged income liabilities contingent liabilities exceeds consideration paid statement relevant vesting periods applied excess recognised immediately gain income statement fully retrospective basis group provides finance esoptrusts intangible assets purchase company shares open market meet intangible assets stated cost less provisions amortisation obligation provide shares employees exercise options impairments awards costs running esop trusts charged income statement shares held esoptrusts deducted licences patents knowhow marketing rights separately acquired reserves transfer made reserves retained acquired part business combination amortised earnings vesting periods related share options estimated useful lives using straightline basisfrom time awards reflect ultimateproceeds receivable employees available use estimated useful lives determining exercise deemed permanent impairment value amortisation charge reviewed annually andtake account also reflected transfer retained earnings estimated time takes bring compounds products market anydevelopment costs incurred group associated property plant equipment acquired licences patents knowhow marketing rights written property plant equipment ppe stated costof purchase income statement whenincurred unless criteria construction less provisions depreciation impairment recognition internally generated intangible asset met usually financing costs capitalised regulatory filing made major market approval depreciation calculated write cost less residual value considered highly probable ppe excluding freehold land using straightline basis overthe brands valued independently part fair value businesses expected useful life residual values lives reviewed acquired third parties brand value appropriate adjusted annually normal expected useful lives substantial longterm brands sold major categories ppeare separately rest businesses acquired brands areamortised estimated useful lives except freehold buildings years considered useful economic life indefinite leasehold land lease term years buildings costs acquiring developing computer software internal plant machinery years use internet sites external use capitalised intangible fixtures equipment years fixed assets software site supports significant business system expenditure leads creation durable asset ondisposal ppe cost related accumulated depreciation erp systems software amortised seven years impairments removed financial statements computer software three five years net amount less proceeds taken income statement impairment noncurrent assets leases carrying values noncurrent assets reviewed leasing agreements transfer group substantially impairment indication assets might benefits risks ownership asset treated finance impaired additionally goodwill intangible assets indefinite leases asset purchased outright assets useful lives intangible assets yet available use included inppe computer software capital elements tested impairment annually provision impairment leasing commitments shown obligations finance charged income statement year concerned leases assets held finance leases depreciated basis consistent similar owned assets lease term shorter investments associates joint ventures interest element lease rental included income investments associates joint ventures carried statement leases operating leases annual rentals consolidated balance sheet groups share oftheir net assets included income statement straightline basis date acquisition postacquisition retained profits lease term losses together goodwill arising acquisition gsk annual report notes financial statements continued accounting policies continued discounting time effect money material balances discounted availableforsale investments current values using appropriate rates interest unwinding liquid investments investments treated availablefor discounts recorded finance incomecosts sale investmentsandare initially recorded cost remeasured subsequent reporting dates fair value unrealised gains losses derivative financial instruments hedging availableforsale investments recognised directly equity derivative financial instruments used manage exposure disposal impairment investments gains losses market risks treasury operations principal derivative equity recycled income statement equity investments instruments used glaxosmithkline foreign currency swaps recorded noncurrent assets unless expected sold interest rate swaps forward foreign exchange contracts within one year group hold issue derivative financial instruments trading speculative purposes purchases sales equity investments accounted trade date purchases sales availableforsale derivative financial instruments initially recognised balance investments accounted settlement date sheet cost remeasured subsequent reporting dates fair value derivatives designated hedging instruments classified equity investments recorded cost inception fair value hedges cash flow hedges net investment inventories hedges changes fair value derivatives designated fair inventories included financial statements lower cost value hedges recorded income statement changes including raw materials direct labour direct costs related fair value hedged asset liability production overheads net realisable value cost generally changes fair value derivatives designated cash flow hedges determined first first basisprelaunch inventoryis held recognised equity extent hedges effective asset whenthere high probability regulatory approval ineffective portions recognised profit loss immediately productbefore point provision made carrying amounts deferred equity recycled income statement value recoverable amount reversed point hedged item affects profit loss whena high probability regulatory approval determined hedges net investments foreign entities accounted trade receivables similar way cash flow hedges trade receivables carried original invoice amount less provisions doubtful debts provisions made changes fair value derivative instruments evidence risk nonpayment taking account ageing qualify hedge accounting recognised immediately previous experience general economic conditions receivables income statement discounted effect material derivative financial instruments hedging cash cash equivalents ias adopted group st january cash cash equivalents comprise cash hand current balances accordance exemption permitted ifrs banks similar institutions highly liquid investments information relating financial instruments remains reported maturities three months less acquired readily ukgaap applying following policies convertible known amounts cash insignificant derivative contracts treated inception economic hedge risk changes value underlying financial instrument matching accounting taxation treatment cash flows derivative instruments longer current tax provided amounts expected paid applying designated hedges restated market value future tax rates enacted substantively enacted changes value taken directly profit loss account balance sheet date currency swaps forward exchange contracts used fix value deferred tax provided full using liability method related asset liability contract currency temporary differences arising tax bases assets contract rate accrued profit loss account life liabilities carrying amounts financial statements contract deferred tax assets recognised extent probable gains losses foreign exchange contracts designated hedges future taxable profits available temporary forecast foreign exchange transactions deferred included differences utilised measurement related foreign currency transactions deferred tax provided temporary differences arising period occur gains losses balance sheet hedges investments subsidiaries associates joint ventures except accrued taken directly reserves except forward timing reversal temporary difference premiumsdiscounts recognised interest life controlled probable temporary difference contracts reverse foreseeable future interest differentials interest swap agreements recognised deferred tax provided using rates tax enacted profit loss account adjustment interest expense substantively enacted balance sheet date deferred tax liabilities life agreement assets discounted stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued new accountingrequirements exchange rates following ifrs ifric interpretationshave issued group uses average exchange rates prevailing iasb likely affect future annual reports although none period translate results cash flows overseas subsidiaries expected material impact results financial position joint ventures associated undertakings intosterling period group end rates translate net assets undertakings currencies influence translations ifrs financial instruments disclosures issued august relevant exchange rates required implemented gskfrom st january new standard incorporates disclosure requirements ias supersedes adds quantitative qualitative average rates disclosures relation financial instruments us euro amendment ias capital disclosures issued august yen required implemented gsk st january period end rates amendment requires new disclosuresabout entity manages us capital resources euro ifrs operating segments issued november yen required implemented gsk st january standard replaces ias aligns segmental reporting segment information requirements equivalent us standard new groups primary segment reporting business sector standard adopts management approach segmental geographical reporting secondary format business information disclosed basis used sectors consist pharmaceuticals prescription pharmaceuticals internal reporting purposes vaccines consumer healthcare oral care otc medicines ifric reassessment embedded derivatives issued march nutritional healthcare geographical sectors usa europe required implemented gskfrom st january international rest world markets reflect groups interpretation clarifies embedded derivative significant regional markets consistent groups assessed inception reassessed change regional market management reporting structure business sector terms relevant contract data includes allocation corporate costs sector appropriate basis sales business sectorsthe ifric interim financial reporting impairment issued july groups activities organised global basis geographical required implemented gsk st january sector figures therefore influenced location groups interpretation impairment losses goodwill operating resources particular manufacturing research equity investments recognised quarterly interim variations time intragroup trading funding arrangements statement may reversed subsequent interim annual turnover shown business sectorby location customerand financial statements location subsidiary geographic information given ifric ifrs group treasury share transactions issued location subsidiary uk segment information gives turnover november required implemented gsk location customer location subsidiary uk operating st january interpretation provides guidance whether profit total assets net assets also shown group sharebased transactions involving group entities accounted copromotes product third party records sale group equity settled cash settled transactions records share revenue copromotion income within turnover nature copromotion activities group records costs sales pharmaceutical turnover includes copromotion revenue million million million gsk annual report notes financial statements continued segment informationcontinued turnover business sector pharmaceuticals consumer healthcare turnover profit business sector pharmaceuticals consumer healthcare operating profit finance income finance costs share ofafter tax profits associates joint ventures pharmaceuticals consumer healthcare profit disposal interest associates profit taxation taxation profit taxation year investments associates joint ventures business sector pharmaceuticals consumer healthcare investment associates joint ventures property plant equipment intangible assets business sector additions pharmaceuticals consumer healthcare total additions depreciationamortisation pharmaceuticals consumer healthcare total depreciationamortisation impairment pharmaceuticals consumer healthcare total impairment impairment reversal pharmaceuticals consumer healthcare total impairment reversal stnemetats laicnanif gsk annual report stnemetats laicnanif notes financial statements continued segment information continued total assets business sector pharmaceuticals consumer healthcare total operating assets investments associatesand joint ventures liquid investments derivative financial instruments cash cash equivalents current deferred taxation tangible assets held sale total assets total liabilities business sector pharmaceuticals consumer healthcare total operating liabilities shortterm borrowings longterm borrowings derivative financial instruments current deferred taxation total liabilities net assets business sector pharmaceuticals consumer healthcare net operating assets net debt investments associatesand joint ventures derivative financial instruments current deferred taxation tangible assets held sale net assets turnover location customer usa europe international turnover turnover location subsidiary undertaking usa europe international turnover including intersegment turnover usa europe international intersegment turnover usa europe international external turnover gsk annual report notes financial statements continued segment information continued property plant equipment intangible asset additions location usa europe international total additions total assets location usa europe international intersegment trading balances total operating assets investments associatesand joint ventures liquid investments derivative financial instruments cash cash equivalents current deferred taxation tangible assets held sale total assets net assets location usa europe international intersegment trading balances net operating assets net debt investments associatesand joint ventures derivative financialinstruments current deferred taxation tangible assets held sale net assets uk segment purposes usgaap information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting turnover location customer turnover including intersegment turnover intersegment turnover turnover location subsidiary operating profit total assets net operating assets stnemetats laicnanif gsk annual report notes financial statements continued operating income royalties asset disposal profits income including fair value adjustments royalties principally core recurring income outlicensing intellectual property asset disposal profits include product divestments disposals equity investments intellectual property tangible property income includes equity investment carrying value adjustments arising stock market changes fair value adjustments arising quest collar theravance put call options operating profit following items charged operating profit employee costs note advertising distribution costs depreciation property plant equipment amortisation intangible assets net foreign exchange lossesgains inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor audit parent company consolidated financial statements feespayable companys auditor associates services reversals prior year writedowns inventories principally arise fromthe reassessment usage demand expectations prior inventory expiration fees payable companys auditor associates services audit accounts ofthe groups uk overseas subsidiaries related pension schemes company pursuant legislation assurance services pursuant legislation tax services services includingregulatory compliance treasury related services st december amount due pricewaterhousecoopers llp associates fees yet invoiced million comprising statutory audit millionand taxation servicesmillion fees respect glaxosmithkline plc pension schemeincluded audit services gsk annual report stnemetats laicnanifnotes financial statements continued employee costs wages salaries social security costs pension postemployment costs note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record page average number persons employed glaxosmithkline plc wasnil nil compensation directorsand senior management members ofthe cet company secretaryin aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans finance income interest income unwinding discount assets interest extended credit receivables net investment hedges fair value adjustments nonhedging derivatives realised gains financial instruments finance costs interest bank loans overdrafts interest loans interest respect finance leases realised losses financial instruments unwinding discount provisions fair value hedges fair value adjustments nonhedging derivatives gsk annual report stnemetats laicnanifstnemetats laicnanif notes financial statements continued associates joint ventures associates share tax profits quest diagnostics inc share tax losses associates share tax lossesprofits joint ventures share turnover joint ventures sales joint ventures associates summarised income statement information respect groups associates set total turnover total profit taxation taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation reconciliation taxation rate group profits ukstatutory rate taxation overseas taxes benefit special tax status rd credits intercompany stock profit impact share based payments tax profit associates differences prior year items tax rate additional uk corporation tax double taxation reliefin arise fromdividends receivedfrom overseas subsidiaries current tax expense reduced benefit million arising previously unrecognised tax losses deferred tax expense reduced benefit million arising changes tax rates group operates countries tax rate differs uktax rate impact overseas taxes companys overall rate tax shown profits arising certain operations singapore puerto rico ireland belgium accorded special status taxed reduced rates compared normal rates tax territories effect reduction taxation charge increased earnings per share byp p p group required ifrsto create deferred tax asset respect unrealised intercompany profit arising stock held group year end applying tax rate country stock held rather tax rate country profit originally made tax paid practice ukand us gaap group tax rate decreased increase increase result increases workinprogress finished goods integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable taxresolution issues continuing fact life gsk gsk annual report notes financial statements continued taxation continued reported last year gsks largest unresolved tax issues us internal revenue service irs ukhmrevenue customs hmrc respect transfer prices related glaxo heritage products th september gsk irs agreed resolution dispute agreement gsk made gross payments irs approximately billion final net cash cost group approximately billion covers federal state local taxes interest benefit tax relief payments made settlement resolved transfer pricing issues dispute period due go trial february also covers subsequent years gsk previously made provision dispute settlement significant impact thegroups reported earnings tax rate year gsk continues dispute hmrc primarily respect transfer pricing controlled foreign companies legislation matters years date parties preparing litigation hmrc formally quantified claims respect matters continues wide difference group hmrc positions mattersgsk also open issues japan canada subject court proceedings japan tax authorities claiming approximately yen billion million respect transactions gsk paid tax claimed required law applied refund court decision expected late march court decision groups dispute canadian revenue authority pricing zantacin years expected first half gsk uses best advice determining transfer pricing methodology seeking manage transfer pricing taxation issues satisfactory conclusion basis external professional advice continues believe made adequate provision liabilities likely arise open assessments ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities except shown annual report provision made taxation would arise distribution profits retained overseas subsidiary associated undertakings grounds remittance profit retained st december required way incremental tax arise aggregate amount unremitted profits balance sheet date approximately billion payable recoverable net movement current tax account st january exchange adjustments chargefor year cash paid movements st december movement deferred tax assets liabilities pensions share accelerated product post legal manu stock option net deferred taxation capital intragroup business retirement tax facturing valuation award temporary assetliability allowances intangibles profit disposals benefits losses disputes restructuring adjustments schemes differences total deferred tax asset st january deferred tax liability st january st january exchange adjustments creditcharge income creditcharge equity transfer tofrom current tax acquisitions movements st december deferred tax asset st december deferred tax liability st december gsk annual report stnemetats laicnanifstnemetats laicnanif notes financial statements continued taxation continued st december group recognised deferred tax asset million million respect income tax losses approximately million million losses million million due expire million million due expire million million available indefinitely st december group recognised deferred tax asset respect income tax losses approximately million million million million due expire million million due expire million million available indefinitely unrecognised losses increased due quantification previously uncertain amounts arising principally group capital losses st december estimated excess billion respect deferred tax asset recognised deferred tax assets recognised probable future taxable profit available utilise lossesall deferred taxation movements arise origination reversal temporary differences net temporary differences include accrued expenses provisions earnings per share p p p basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares periodandany performance conditions attaching scheme met balance sheet date number shares used calculating basic diluted earnings per share reconciledbelow weighted average number shares issue millions millions millions basic dilution share options diluted shares held esop trusts excluded trustees waived rights dividends shares held esop trusts dividends first interim second interim third interim fourth interim total total dividend dividend per share pence paidpayable th july th october th january th april total dividend dividend per share pence paid thjuly th october th january th april total dividend dividend per share pence paid stjuly th september th january th april ifrs interim dividends recognised financial statements paid declared gsknormally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report notes financial statements continued property plant equipment plant land equipment assets buildings vehicles construction total cost st january exchange adjustments additions additions business combinations disposalsand writeoffs reclassifications transfer assets held sale cost st december exchange adjustments additions additions business combinations disposalsand writeoffs reclassifications transfer assets held sale cost st december depreciation st january exchange adjustments provision year disposalsand writeoffs reclassifications transfer assets held sale depreciation st december exchange adjustments provision year disposalsand writeoffs transfer assets held sale depreciation st december impairment st january exchange adjustments disposalsand writeoffs impairment losses reversal impairments transfer assets held sale impairment st december exchange adjustments disposalsand writeoffs impairment losses reversal impairments impairment st december total depreciation impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december net book value st december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million gsk annual report stnemetats laicnanifnotes financial statements continued property plant equipment continued included land buildings st december leased assets cost million million accumulated amortisation million million net book value million million included plant equipment vehicles st december leased assets cost million million accumulated amortisation million million net book value million st january million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sell value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital adjusted appropriate country specific risksthese losses charged throughcost salesmillion rdmillion sgamillion reversals impairment arise subsequent reviews impaired assets conditionswhich gave rise original impairments deemed longer apply principalcomponent reversals relates montrose manufacturing facilityand reversals credited tocost sales goodwill cost st january exchange adjustments additions business combinations disposals impairments cost st december net book value st january net book value st december additions year comprise million acquisition ofcnsinc millionon theacquisitionofpliva research instituteand million acquisition minority interest held glaxosmithkline kk see notefor details impairments year million relate europharmbusinesslocated romaniaandwere determined using fair value less costs sell model carrying value goodwill made balances arising acquisition following companies idbiomedical corporation cns inc nippon glaxo polfa poznan sa corixa corporation others goodwill allocated cash generating units aretested impairment least annually recoverable amounts cash generating units assessed using value use fair value less costs sellmodel depending nature unitvalue use calculated net present value projected riskadjusted fiveyear posttax cash flows plus terminal value cash generating unittowhich goodwill allocated initially posttax discount rate based groups weighted average cost capital adjusted appropriate country specific risks applied calculate net present value posttax cash flows indicates recoverable value unit close carrying value impairment test reperformed using pretax discount rate pre tax cash flows order determine impairment exists establish magnitude fair value iscalculated using discounted cash flow approach case based groups acquisition valuation model cash generating units carrying amount goodwill allocated unit significant comparison total goodwill balance vaccines consumer healthcare japan poland total goodwill million million principally relating acquisitions idbiomedical corixa allocated vaccines unit recoverable value unit determined using fair value less costs sell model goodwill arising acquisition minority interest nippon glaxo million million theacquisitionof polfa poznan million million allocated japan poland cash generating units respectively recoverable value units determined using value use model goodwill arising acquisition cns inc december allocated consumer healthcare cash generating unit gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued computer licences intangible assets software patents etc brands total cost st january exchange adjustments additions additions business combinations disposalsand asset writeoffs reclassifications property plant equipment cost stdecember exchange adjustments additions additions business combinations disposalsand asset writeoffs cost st december amortisation st january exchange adjustments provision year disposalsand asset writeoffs reclassifications property plant equipment amortisation stdecember exchange adjustments provision year disposalsand asset writeoffs amortisation st december impairment st january exchange adjustments impairment losses disposals asset writeoffs impairment stdecember exchange adjustments impairment losses disposals asset writeoffs impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value stdecember net book value st december notes financial statements continued intangible assets continued amortisation impairment havebeen charged rd sga st december net book value computer software included million internally generated additions business combinations year millionincludemillion fromcns incnote brands comprise portfolio products acquired acquisitions ofsterling winthrop inc block drug company cns inc thebook values major brands follows panadol sensodyne breathe right polident corega poligrip solpadeine others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing shortening brands lives considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortisedeach brand istested annually impairment applying fair value less costs sell methodology using five year posttax cash flow forecasts terminal value calculation applying discount rate group posttax weighted average cost capital adjusted appropriate countryspecific risks main assumptions include future sales prices volumes product contributionthe futureexpenditure required maintain products marketability registration relevant jurisdiction products life assumptions reviewedas part managements budgeting strategic planning cycle changes market conditions andsaleserosionthroughcompetition investments associates joint ventures joint associated ventures undertakings total total st january implementation accounting financial instruments ias st january adjusted exchange adjustments additions fair value adjustment retained profit year st december principal associated undertaking quest diagnostics inc us clinical laboratory business listed new york stock exchange investment book value st december million million market value million million st december group owned quest although group holds less ownership interest voting control quest group ability exercise significant influence throughboth significant shareholding andits nominated directorsactive participation quest board directors board subcommittees gsk annual report stnemetats laicnanifnotes financial statements continued investments associates joint ventures continued summarised balance sheet information respect groups associates set total assets total liabilities net assets groups share associates net assets investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interests two joint ventures shionogiglaxosmithkline holdings lp developing specified chemical compounds glaxosmithkline shire biochem primarily comarkets combivir trizivirand epivirin certain territories together interest another joint venture pharmaceutical insurance limitedwhich mutual insurance company covering pharmaceutical property risk gsk hedged part equity value holding quest diagnostics inc series variable sale forward contracts contractsthe equity collar renewed structured five series two million quest shares mature fair value contracts st december liability million million investments st january implementation accounting financial instruments ias st january adjusted exchange adjustments additions fair value movements impairments transfers disposals st december investments comprise noncurrent equity investments availableforsale investmentsrecorded fair value balance sheet date investments traded active market fair value determined reference relevantstockexchange quoted bid price investments fair value estimated reference current market value similar instruments reference discounted cash flows underlying net assets group holds number equity investments frequently entities group entered research collaborations equity investments recorded noncurrent assets unless expected sold within one year case recorded current assets noncurrent equity investments include listed investments million million offer group opportunity return dividend income fair value gains disposal investmentsfair value movements reclassified reserves income statement based average cost impairment losses recorded tables recognised income statement year within operating income together amounts recycled fair value reserve note recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement noncurrent assets amounts recoverable insurance contracts derivative financial instruments pension schemes surplus receivables gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued inventories raw materials consumables work progress finished goods trade receivables trade receivables prepaid pension contributions prepayments accrued income interest receivable employee loans advances derivative financial instruments receivables trade receivables include million million due associates joint ventures movements bad doubtful debt provisionare follows st january exchange adjustments charge year utilised st december cash cash equivalents cash bank hand shortterm deposits commercial paper assets held sale land buildings plant equipment vehicles equity investments trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals derivative financial instruments dividends payable gsk annual report stnemetats laicnanif notes financial statements continued trade payables continued customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa provisions made time sale actual amounts paid based claims made time initial recognition saleasthe amounts estimated may fully reflect final outcome amounts subject change dependent upon amongst things types buying group product sales mix level provision reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions provisions based change could affect future results group pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes postemployment costs costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees thesearrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length ofservice hybrid defined benefit schemes also include defined contribution sections contributions defined benefit schemes determined accordance advice independent professionally qualified actuaries pension costs defined benefit schemes accounting purposes assessed accordance independent actuarial advice using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies liabilities generally assessed annually accordance advice independent actuaries formal independent actuarial valuations groups main plans undertaken regularly normally least every three years theassets funded schemes generally held separately administered trusts insured assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment long term overalltarget asset allocationis equities bonds property actuarial movements year recognised full statement recognised income expense uk discount rate based iboxx year aaindexandthe us discount rate based corporate bond yields reflect term expected benefit payments expected rate returnon bonds reflects portfolio mix indexlinked government corporate bonds equity risk premium added longer term government bond yields give expected rate return equitiesprojected inflation rate pension increases long term predictions based yield gap long term index linked fixed interest gilts uk mortality rates calculated using pa standard mortality tables projected plan obligations increased depending individual schemes mortality experience make allowance future improvements life expectancy usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustmentnotes financial statements continued gsk annual report stnemetats laicnanif pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected mortality assumptions set following review december gsk expects review december group made special funding contributions uk us pension schemes totalling million million gsk formalised agreementwith trustees ukdefined benefit pension schemestomake additional contributionsof tomillion per year addition normal contributions fouryear periodending st december order eliminate pension deficits ias basis uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate amounts recorded income statement statement recognised income expense three years ended st december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarialgainsrecorded statement recognised income expense postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial losses recorded statement recognised income expense gsk annual report stnemetats laicnanif notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial gainslosses recorded statement recognised income expense total actuarial losses recorded statement recognised income expense since st january amount million fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value schemeobligations included noncurrent assets included pensions postemployment benefits actual return plan assets uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets notes financial statements continued pensions postemployment benefits continued uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits movements defined benefit obligations uk usa rest world group group obligations st january exchange adjustments service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial losses scheme participants contributions benefits paid obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial lossesgains scheme participants contributions benefits paid obligations st december liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation reducing per year thereafteron basis liability usscheme assessed million million million gsk annual report stnemetats laicnanifnotes financial statements continued pensions postemployment benefits continued defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded postretirement pensions benefits movements fair value assets uk usa rest world group group assets st january exchange adjustments expected return assets actuarial gains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets actuarial gains employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid assets st december uk defined benefit schemes include defined contribution sections account balances totalling million st december million million information scheme assets us gaap given note employer contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits transition date conversion ifrsfor gsk st january therefore following historical data presented date built rolling five year record next year postretirement pensions benefits history ofexperiencegains losses uk usa rest world group group experiencegains scheme assets percentage scheme assets st december experiencelossesgainsof scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurplusesin schemes gsk annual report stnemetats laicnanifnotes financial statements continued pensions postemployment benefits continued postretirement pensions benefits history ofexperiencegains losses uk usa rest world group group experiencegains scheme assets percentage scheme assets st december experiencelosses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experiencegains scheme assets percentage scheme assets st december experiencelossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experiencegains scheme assets percentage scheme assets st december experiencelossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes sensitivity analysis effect changes inassumptions usedon annual defined benefit pension postretirement costs benefit obligations decrease discount rate would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation gsk annual report stnemetats laicnanifnotes financial statements continued pensions postemployment benefits continued sensitivity analysis decrease expected rates returns assets would following approximate effect increase annual pension cost increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation provisions exchange legal offer merger operational incentive integration excellence disputes provisions total st january exchange adjustments creditcharge year unwinding discount applied reversed unused reclassifications movements st december settled within one year settled one year st december group recognised costs previous years respect plans integration glaxo wellcome smithkline beecham businesses implementation integration following merger substantially completethe exchange offer incentiveprogramme operated time merger encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options incentive paideither employees exercise therelevantoptions options lapseup discount thisprovision increased million million calculated using riskfree rates returncosts recognised inthe remaining merger integration provision respect identified severances expected incurred operational excellence term used group refer continuous worldwide programme cost saving measures carried within areas business majority projects shortterm nature gsk involved number legal disputes including notification possible claims set notelegal proceedings provisions legal disputes include amounts relating us antitrust product liability contract terminations selfinsurance environmental cleanup property rental companys directors taken legal specialist advice established provisions taking account insurance agreements regard relevant facts circumstances matter accordance accounting requirements provisions discounted million million using riskadjusted projected cash flows riskfree rates returnthe effect change discount rate increase discount st december milliona number products history claims made settlements makes possible use ibnr incurred reported actuarial technique determine reasonable estimate groups exposure unasserted claims relation products apart ibnr provision provisions made unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations nature groups business number matters including provided using ibnr actuarial technique may subject negotiation litigation several years largest individual amounts provided expected settled within three years st december expected million million provision made legal disputes reimbursedby third party insurers amount included within current noncurrent assets discussion legal issues refer notelegal proceedings gsk annual report stnemetats laicnanifnotes financial statements continued noncurrent liabilities accruals deferred income derivative financial instruments payables contingent liabilities st december contingent liabilities comprising guarantees letters credit discounted bills items arising normal course business amounted million million st december million million financial assets pledged collateral contingent liabilities discussions tax legal issues refer note taxation note legal proceedings net debt current assets liquid investments cash cash equivalents shortterm borrowings us notes us medium term note commercial paper bank loans overdrafts loans obligations finance leases longterm borrowings us us medium term note european medium term note european medium term note european medium term note european medium term note us us medium term note european medium term note european medium term note us us medium term note loan stock bank loans loans private financing obligations finance leases net debt current assets liquid investments classified availableforsale investments st december includedredeemableshares whichwere fully collateralised highly rated bonds billionmillion government bondsthe effective interest rate liquid investments st december approximately approximately effective interest rate cash cash equivalents st december approximately approximately gsk annual report stnemetats laicnanifnotes financial statements continued net debt continued shortterm borrowings commercial paper comprises us billion programme whichnonewas issue st december million million backed committed facilities days duration million million million million renewable annually liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts st december longterm borrowings loans due one yearare repayable various periods follows one two years two three years three four years four five years five years loans repayable five years carry interest effective rates betweenand repayment dates range average effective interest rate ofall notesat st december wasapproximately approximately secured loans loans amounting million million secured charges noncurrent current assets finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations gsk annual report stnemetats laicnanifnotes financial statements continued share capital share premium account share ordinary shares p premium number share capital authorised st december st december st december share capital issued fully paid st january issued share option schemes purchased cancelled st december issued share option schemes st december issued share option schemes st december st december st december st december number shares issuable outstanding optionsnote number unissued shares option st december issued share capitalshares held esop trustshares held treasury shares andshares free issue issued shares fully paidthe nominalcarrying market values shares held esop trust disclosed note october group announced new share buyback programme totalling billion expected completed three year period exact amount timing future purchases extent repurchased shares held treasury shares rather cancelled determined company dependent market conditions factors group also commenced close period share buybacks operating specific irrevocable agreements put place brokers prior start close period total billion spent company st january st december buying shares cancellation held treasury shares billion spent billion new billion programme million shares purchased period st january tordfebruary cost million purchases made publicly announced buyback programme table sets monthly purchases share buyback programme average share price excluding number shares commission stamp duty month january nil february march april may june july august september october november december total shares purchased held treasury shares details substantial shareholdings refer substantial shareholdings page gsk annual report stnemetats laicnanifnotes financial statements continued movements equity shareholders equity share share retained minority total capital premium earnings reserves total interests equity stjanuary recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares purchased held treasury shares ordinary shares transferred esoptrusts writedown shares held esoptrusts sharebased incentive plans st december implementation accounting financial instruments ias st january adjusted recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased held treasury shares ordinary shares transferred esoptrusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december recognised income expense year changes minority shareholdings distributions minority shareholders dividends shareholders ordinary shares issued ordinary shares purchased held treasury shares ordinary shares transferred esoptrusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december retained earnings reserves amounted million st december million million million million million relates company million million million relates joint ventures associated undertakings cumulative translation exchange equitysince st january shown following table translation exchange st january exchange movements overseas net assets exchange movements goodwill reserves translation exchange st december gsk annual report stnemetats laicnanifnotes financial statements continued movementsin equity continued reserves analysed follows cash flow esop trust fair value hedge shares reserve reserve reserves total atst january ordinary shares purchased cancelled ordinary shares transferred esop trusts writedown shares held esop trusts sharebasedincentive plans st december implementation accounting financial instruments ias st january adjusted recognised income expense year ordinary shares transferred esop trusts writedown shares held esop trusts st december recognised income expense year ordinary shares transferred esop trusts writedown shares held esop trusts st december reserves include merger reserve created merger glaxo wellcome smithkline beecham amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million million related party transactions glaxosmithkline held interest quest diagnostics inc st december group quest diagnostics parties longterm contractual relationship quest diagnostics primary provider clinical laboratory testing support groups clinical trials testing requirements worldwide quest diagnostics provided services million million group st december balance payable glaxosmithkline quest diagnostics million million group shionogi co ltd entered transactions usjoint venture company support research development activities conducted joint venture company glaxosmithkline provided services joint venture million million st december balance due glaxosmithkline joint venture million million dr shapiro former nonexecutive director glaxosmithkline plc received fees form adss subsidiary company membership groups scientific advisory board fees included within annual remuneration remuneration report pagesto aggregate compensation directors cet company secretary given note employee costs gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation ofprofit tax operating cash flows reconciliation ofprofit taxto operating cash flows notes profit tax tax profits share tax profits associates joint ventures profit disposal interest associates finance incomecosts depreciation impairment assets written amortisation intangible assets profitloss sale property plant equipment profitloss saleof intangible assets profit sale equity investments fair value loss inventory sold changes working capital increasedecreasein inventories increase trade receivables increasein trade payables decreasein pension provisions sharebased incentive plans cash generated operations reconciliation net cash flow movement net debt reconciliation net cash flow movement net debt net debt beginning year implementation accounting financial instruments ias decreaseincrease cash bank overdrafts cashoutflowinflowfrom liquid investments net increase longterm loans net repayment shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation net cash flow movement net debt continued analysis changes net debt exchange acquisitions cash flow liquid investments cash cash equivalents overdrafts debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing net debt information significant changes net debt see notenet debt acquisitions disposals details acquisition disposal subsidiary associated undertakings joint ventures businesses given acquisitions cns inc onth december group acquired issued share capital cns inc consumer healthcare companybasedinthe usa cash consideration million company markets breathe rightnasal dilator strips fiberchoicedietary fibre supplements key intangible assets acquired valued using discounted cash flow calculationthistransaction accounted purchase method accounting goodwill arising acquisition reflects thepotential forexpansion brands overseas marketsand expected synergies group cnsinc turnover million million profit million profit million year million turnover nilofprofitrelated period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assetsincluding cash cash equivalents deferred tax provision liabilities goodwill total consideration gsk annual report stnemetats laicnanifnotes financial statements continued acquisitions disposals continued euclid srpartners lp additional million invested euclid srpartners lp associate group share shionogiglaxosmithkline holdings ltd additional million invested shionogi glaxosmithkline holdings ltd joint venture group share pliva research institute ltd may group purchased entire share capital pliva research institute ltd cash consideration million amount million deferred payment made phase clinical trials initiated glaxosmithkline kk august japanese subsidiary group made cash payment million complete purchaseofthe remaining share capital held minorityshareholderthis payment wasprecededin year dividend minority shareholders million representing additional consideration shionogi pliva euclid sr glaxosmithkline research glaxosmith cnsinc partners lp holdings ltd institute kline kk total cash flows cash consideration cash cash equivalents acquired net cash payment acquisitions net cash proceeds disposals acquisitions idbiomedical corporation th december group acquired issued share capital idbiomedical corporation biotechnology company based canada specialising development manufacture vaccines particularly influenza vaccines cash consideration million transaction accounted purchase method accounting goodwill arising acquisition results benefits separately quantified recorded including immediate access additional flu vaccines manufacturing capacity particularly event pandemic skilled workforce good relations us canadian governments regarding supply flu vaccines idbiomedical corporation turnover million million loss million loss million year million turnover million loss related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets deferred tax provision liabilities goodwill total consideration total consideration included directly attributable costs million gsk annual report stnemetats laicnanifnotes financial statements continued acquisitions disposals continued corixa corporation th july group acquired issued share capital corixa corporation biotechnology company specialising developing vaccine adjuvants immunology based products cash consideration million investment increased groups holding corixa group number business relationships corixa prior acquisition date principally relation adjuvant developed corixa used groups vaccines transaction accounted purchase method accounting existing investment corixa book value million previously classified availableforsale investment forms part investment subsidiary existing issued share capital acquired previous years cash consideration million corixa corporation turnover million loss million year million turnover million loss related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets assets liabilities goodwill existing investment total consideration total consideration included directly attributable costs million euclid sr partners lp additional million invested euclid srpartners lp associate group interest glaxosmithkline consumer healthcare limited april indian subsidiary group purchased share capital held minority shareholders cash consideration million glaxosmithkline pharmaceuticals limited may june indian subsidiary group purchased share capital held minority shareholders cash consideration million glaxosmithkline biologicals shanghailimited chinese subsidiary group purchased share capital held minority shareholders cash consideration million disposals ideapharm sa december group disposed ideapharm sa subsidiary located romania cash proceeds million received january net assets disposed year included cash million aseptic technologies sa april group disposed aseptic technologies sa societe regionale dinvestissement de wallonie sa cash proceeds million gsk gsk gsk biologicals aseptic pharma consumer euclid id shanghai tech ceuticals healthcare ideapharm sr corixa biomedical cash flows total cash consideration cash cash equivalents acquired net cash payment acquisitions cash cash equivalents disposed net cash proceeds disposals gsk annual report stnemetats laicnanifnotes financial statements continued acquisitions disposals continued acquisitions fraxiparine fraxodi arixtra september group acquired fraxiparine fraxodiand arixtra andrelated assets including manufacturing facility cash consideration million book fair value net assets value adjustment acquired intangible assets tangible fixed assets inventory provisions onerous contracts euclid sr partners lp additional million invested euclid sr partners lp associate company group interest disposals quest diagnostics inc group disposed million shares investment quest diagnostics inc cash proceeds million reducing groups shareholding st december profit million recognised glaxosmithkline vehicle finance ltd group disposed employee vehicle financing subsidiary resulting loss million glaxosmithkline pharmaceuticals chongqing ltd group disposed glaxosmithkline pharmaceuticals chongqing ltd group subsidiary located china million profit disposal million realised beeyar investments pty ltd july group disposed beeyar investments pty ltd subsidiary located south africa cash proceeds million realising profit million optilead srl year part groups holding associated undertaking optilead srl sold resulting loss million fraxiparine gsk gsk fraxodi quest vehicle pharmaceuticals beeyar arixtra euclid sr diagnostics finance chongqing investments total cash flows cash consideration paid net cash proceeds disposals gsk annual report stnemetats laicnanifnotes financial statements continued commitments contractual obligations commitments contracted provided financial statements intangible assets plant property equipment investments purchase commitments businesscombinations pensions theravance put option agreement commitments interest loans commitments related intangible assets include milestone payments dependent successful clinical development represent maximum would paid milestones achieved number commitments made licensing agreements including chemocentryx inc epix pharmaceuticals inc genmab st december genmab agreement subject review us government hartscottrodino act approval received th february th december gskentered agreement acquire domantis limited million cash st december acquisition agreement subject clearance hartscottrodino actapproval received onth january st december gskentered agreement acquire outstanding shares praecis pharmaceuticals inc approximately million million means cash tender offer early gskformalised agreementwith trustees ukpension schemes make additional contributions ofup tomillion per yearin addition normal contributionsover fouryear period endingst december order eliminate pension deficits anias basis point table shows commitment excludes normal ongoing annual funding requirement approximately million gsk also committed eliminate future deficits may arise rolling fiveyear period commitments made past st december group entered put option agreement whereby theravances shareholders sell half theravance shares gsk predetermined price given maximum number shares subject put option groups obligation capped million expiry date august group also commitmentswhich principally relateto revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments operating leases post balance sheet events th january gsk completed acquisition domantis limited million cash th february fda approved orlistat otc use usa brand name alli th february gskentered second hedging contract additional million shares quest diagnostics inc another series variable sale forward contracts maturing betweenand th february gsk completed cash tender offer praecis pharmaceuticals inc th february gsk roche group settled arbitration proceedings relating licensing comarketing carvedilol gsk acquired roche otc marketing rights orlistat outside usa gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued financial instruments related disclosures borrowings denominated swapped foreign currencies match investments overseas group assets treated hedge financial risk management relevant net assets glaxosmithkline plc reports insterling pays dividends sterling profits role corporate treasury gsk manage st december group outstanding contracts sell monitor groups external internal funding requirements purchase foreign currency total gross notional principal financial risks support group corporate objectives treasury amount million million majority activities governed policies procedures approved contracts periods months less board monitored treasury management group based composition net debt st december gsk maintains treasury control systems procedures monitor appreciation insterling major currencies would result foreign exchange interest rate liquidity credit financial risks reduction groups net debt approximately million weakening insterling major currencies would result gsk uses variety financial instruments including derivatives increase groups net debt approximately million finance operation manage market risks operations financial instrumentsinclude cash liquid resources interest rate risk management borrowings spot foreign exchange contracts gsks policy interest rate risk management requires amount net borrowings fixed rates increases ratio number derivative financial instruments used manage forecast net interest payable trading profit market risks treasury operations derivative instruments principally comprising forward foreign currency contracts interest group uses limited number interest rate swaps rate currency swaps used swap borrowings liquid redenominate external borrowings interest rate coupon assets currencies required group purposes manage required group purposes duration swaps matches exposure funding risks changes foreign exchange rates duration principal instruments interest rate derivative interest rates instruments accounted fair value cash flow hedges relevant assets liabilities gsk balances use borrowings liquid assets regard tothe cash flow operating activities thecurrencies group manages centrally shortterm cash surpluses earned tax cost intragroup distributions currencies borrowing requirements subsidiary companies uses forward business assets denominated posttax cost contracts hedge future repayments back originating currency borrowings compared totheposttax return liquid assets sensitivity analysis considers sensitivity groups net debt liquid assets surplus immediate operating requirements hypothetical changes market rates assumes group companies generally invested managed centrally variables remain constantbased composition net debt corporate treasuryrequirements group companies operating financing arrangements st december taking finance met whenever possible central resources consideration fixed rate borrowings place one percentage point basis pointsdecreasein average interest rates would result external borrowings mainly managed centrally corporate treasury increase groups annual net interest charge comprise portfolio long mediumterm instruments approximately million shortterm finance market risk financial assets gsk hold issue derivative financial instruments trading group invests centrally managed liquid assets government purposes groups treasury policies specifically prohibit bonds shortterm corporate debt instruments minimum short activity transactions financial instruments undertaken term credit rating ap money market funds credit rating manage risks arising underlying business activities aaaaaa structured investmentscredit ratings shown speculation standard poors moodys investors services foreign exchange risk management respectively theseinvestments classified availableforsale gsk foreign currency transaction exposure arising normal trade equity investments classified availableforsale investments flows respect external intragroup trade group manages disposals meet overall business requirements hedged gsks policy minimise exposure overseas arise group regularly monitors value equity operating subsidiaries transaction risk matching local currency investments enters hedges selectively approval income local currency costs purpose intragroup trading board transactions matched centrally intragroup payment terms managed reduce risk exceptional foreign currency cash flows credit risk hedged selectively management corporate treasury usa line pharmaceutical companies group sells products small number wholesalers addition group seeks denominate borrowings currencies hospitals pharmacies physicians groups sales principal assets cash flowsthese primarily denominated three largest wholesalers amounted approximatelyof us dollars euros sterling certain borrowings groups us pharmaceutical sales st december group swapped currencies required group purposes trade receivables due three wholesalers totalling million st december millionfinancial instruments related disclosures cash cash equivalents approximates carrying amount continued liquid investments based quoted market pricesin case group exposed concentration credit risk respect marketable securities based principal amounts case wholesalers one affected nonmarketable securities short repricing periods financial difficulty could materially adversely affect groups shortterm loans overdrafts approximates carrying financial results amount short maturity instruments group believe exposed major concentrations longterm loans based quoted market prices case credit risk onother classes financial instruments group eurobonds fixed rate borrowings approximates exposed creditrelated losses event nonperformance carrying amount case offloating rate bank loans counterparties financial instruments expect loans counterparties fail meet obligations group significant investments single counterparty collateral forward exchange contracts based market prices exchange obtained order reduce risk rates balance sheet date group applies boardapproved limits amount credit currency swaps based market valuations balance exposure one counterparty employs strict minimum credit sheetdate worthiness criteria choice counterparty quest equity collar theravance put call options based liquidity option pricing model uses significant assumptions group operates globally primarily subsidiary companies respect price volatility dividend yield interest rates established markets group trades due interest rate instruments based net present value nature groups business patent protection many discounted cash flows products groups portfolio groups products compete largely product efficacy rather price selling margins receivables payables approximates carrying amount sufficient toexceed normal operating costs groups operating lease obligations approximates carryingamount subsidiaries substantially cash generative year ended st december total amount operating cash flow used fund investment research change fair values estimated using valuation techniques referred development new products well routine outflows capital resulted credit income statement million expenditure tax dividends repayment maturing debt million group may time time additional demands finance forshare purchases business acquisitions fair value investments ingsk shares atst december esop trusts held gsk ordinary shares gsk operates high level interest cover low levels carrying value million million net debt relative market capitalisation addition strong fair value million million based quoted positive cash flow normal trading activities additional liquidity market price shares represent purchases esop trusts readily available via commercial paper programme short satisfy future exercises options awards employee term investments group also aeuropean medium term incentive schemes thecarrying value lower cost note programme billion billion issue expected proceeds shares recognised st december march group established us deduction reserves st december gsk held shelf registration billion st december billion treasury shares cost million million billion issue deducted retained earnings fair value financial assets liabilities committed facilities table pagepresents carrying amounts ifrs group committed facilities back commercial paper fair values groups financial assets liabilities st programme million million million december st december million days duration renewable annually st fair values financial assets liabilities included atthe december undrawn committed facilities totalled million amount instrument could exchanged current million million million transaction willing parties forced liquidationsale following methods assumptions used estimate thefair values equity investments investments traded active market determined reference relevant stock exchange quoted bid price investments determined reference current market value similar instruments reference discounted cash flows underlying net assets gsk annual report stnemetats laicnanif notes financial statements continuedgsk annual report stnemetats laicnanif notes financial statements continued financial instruments related disclosures continued classification fair values financial assets liabilities following table sets classification financial assets liabilities receivables payables included extent classified financial assets liabilities accordance ias appropriate currency interest rate swaps presented alongside underlying principal instrument carrying amounts instruments adjusted effect currency interest rate swaps acting hedges carrying fair carrying fair value value value value st december liquid investments cash cash equivalents current asset financial instruments notes bonds usnotes bondsand private financing notes bonds swapped us currency swaps interest rate swaps notesswapped yen currency swaps notes interest rate swap othershortterm borrowings otherlongterm borrowings total borrowingsand related swaps equity investments receivables payables otherderivatives assets otherderivatives liabilities financial assets financial liabilities net financial assets liabilities total financial assets total financial liabilities reconciliation net debt liquid investments cash cash equivalents total borrowings less net effect interest rate currency swaps net debt notes financial statements continued gsk annual report stnemetats laicnanif financial instruments related disclosures continued interest rate profiles financial assets liabilities following tables set exposure financial assets andliabilities either fixed interest rates floating interest rates orno interest rates maturity profile financial assets liabilities exposed interest rate risk tables indicates contractual repricing maturity dates instruments cash st december liquid cash financial investments investments equivalents receivables assets total financial assets less one year one two years two three years three four years four five years greater five years total interest earning analysed fixed rate interest floating rate interest total interest earning noninterest earning total cash st december liquid cash financial investments investments equivalents receivables assets total financial assets less one year one two years two three years three four years four five years greater five years total interest earning analysed fixed rate interest floating rate interest total interest earning noninterest earning total notes financial statements continued financial instruments related disclosures continued effect obligations st december interest rate finance financial debt swaps leases payables liabilities total financial liabilities less one year one two years two three years three four years four five years greater five years total interest bearing analysed fixed rate interest floating rate interest total interest bearing noninterest bearing total effect obligations st december interest rate finance financial debt swaps leases payables liabilities total financial liabilities less one year one two years two three years three four years four five years greater five years total interest bearing analysed fixed rate interest floating rate interest total interest bearing noninterest bearing total maturity analysis interest earning financial assets maturity analysis interest earning financial assets equivalent maturity analysis presented interest rate profile table maturity analysis interest bearing financial liabilities st december finance debt leases payables total financial liabilities within one year demand one two years two three years three four years four five years five years gsk annual report stnemetats laicnanifnotes financial statements continued financial instruments related disclosures continued st december finance financial debt leases payables liabilities total financial liabilities within one year demand one two years two three years three four years four five years five years currency profiles financial assets liabilities groups currency exposures give rise net currency gains losses recognised income statement arise principally companies sterlingfunctional currency tablesbelow setout exposures financial assets liabilities held currencies functional currencies group companies effect currency swaps st december sterling us euro yen total financial assets investments cash cash equivalents receivables financial assets st december sterling us euro yen total financial assets investments cash cash equivalents receivables financial assets st december sterling us euro yen total financial liabilities debt obligations finance leases payables st december sterling us euro yen total financial liabilities debt obligations finance leases payables gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued financial instruments related disclosures continued derivative financial instruments table sets net principal amount fair value derivative contracts held gsk fair value contract underlying principal amount assets liabilities currency interest related instruments foreign exchange contracts cross currency swaps interest rate swaps equity related instruments options warrants equity collar embedded derivatives total derivative financial instruments fair value contract underlying principal amount assets liabilities currency interest related instruments foreign exchange contracts cross currency swaps interest rate swaps equity related instruments options warrants equity collar embedded derivatives total derivative financial instruments derivative financial instruments included equity related instruments variable sale forward contracts quest diagnostics inc options theravance inc detailed gskhedged part equity value holdings quest largest equity investmentthrough series variable sale forward contracts contracts equity collar renewed structured five series overtwomillion quest shares mature fair value contracts st december liability million million million milliona second hedging contract additional million shares entered th february see note post balance sheet events group entered put option agreement whereby theravances shareholders sell half theravance shares gsk predetermined price given maximum number shares subject put option groups obligation capped million st december option recorded liability million million million million st december maximum potential exposure gsk fair value movements options therefore approximately million million million million expiry date august group entered call option agreement whereby purchase half outstanding theravance shares issue pre determined price st december option recorded asset million million million million st december maximum potential exposure gsk fair value movements option therefore million expiry date july notes financial statements continued financial instruments related disclosures continued following table sets principal amount fair values derivative contracts qualify hedge accounting treatment contract underlying fair value contract underlying fair value principalamount derivative contract principal amount derivative contract cash flow hedges cross currency swaps fair value hedges foreign exchange contracts interest rate swaps cross currency swaps net investment hedges foreign exchange contracts cross currency swaps cash flow hedges group entered cross currency swap designated cash flow hedge converting fixed euro coupons payable annually fixed yen payments bond matures risk hedged variability cash flows arising currency fluctuations fair value hedges group designated interest rate swaps interest element cross currency swaps fair value hedges risk hedged variability fair value bonds arising interest rate fluctuations net investment hedges foreign exchange contracts currency element cross currency swaps designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment usdollar euro yen foreign operations employee share schemes group operates share option schemes whereby options granted employees acquire shares adss glaxosmithkline plc grant price savingsrelated share option schemes share award schemes whereby awards granted employees acquire shares adss glaxosmithkline plc cost subject tothe achievement group specified performance targets group introduced new share award scheme share value plan whereby awards granted employees acquire shares adss glaxosmithkline plc cost three year vesting period granting restricted share awards replaced granting options certain employees cost scheme readily equates potential gain made employee grants share option schemes normally exercisable three ten years date grant grants restricted shares share awards normally exercisable end three year vestingperformance period grants savingsrelated share option schemes normally exercisable three years saving options share option schemes granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant share options awarded directors effect grant cet subject performance criteria laid remuneration report stockbased compensation charge recorded income statement follows cost sales selling general administration research development gsk annual report stnemetats laicnanifnotes financial statements continued employee share schemes continued option pricing purposes valuing options arrive stockbased compensation charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option schemes years years years weighted average share price grants year ordinary shares adss volatility determined based three year share price history fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value st january options granted options exercised optionslapsed st december options granted options exercised optionslapsed st december options granted options exercised optionslapsed st december range exercise prices weighted average remaining contractual life years years years total intrinsic value amount share price exceeded exercise price option options exercised million million aggregate intrinsic value options outstanding st december million gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued employee share schemes continued order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline beecham shares adss glaxosmithkline shares adss programme established give additional cash benefit exercise price original option provided employee voluntarily leave group two years date merger exercise option earlier six months expiry date original option two years date merger cash benefit also paid options expire unexercised market price exercise price date expiry options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes st december weighted latest weighted latest latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options exercisable except options shares adss granted savingsrelated share options granted total number nonvested options st december share options ads options share options ads options options weighted average grant date fair value forshare options ads options savingsrelated share options respectively change effective exercise price outstanding options year options exercisable share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value st december st december st december weighted average remaining years years years contractual life options vested year theaggregateintrinsic value options exercisable st december millionthe total fair value options vesting year million million milliongsk annual report stnemetats laicnanif notes financial statements continued employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group three year measurement period performance conditions consist two parts applies award awards granted first part condition compares glaxosmithklines total shareholder return tsr period tsr companies ukftse index period awards granted subsequent years first part condition compares glaxosmithklines tsr period tsr pharmaceutical companies comparator group period second part performance condition compares glaxosmithklines earnings per share growth increase ukretail prices index three year performance period awards granted directors members cet th december subject single performance condition compares glaxosmithklines tsr period tsr companies comparator group period shares weighted adss weighted number shares adss issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached shares weighted adss weighted number shares adss issuable number fair value number fair value st january awards granted st december awards granted awards exercised awardscancelled st december awards granted awards exercised awards cancelled st december notes financial statements continued employee share schemes continued employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares onthe open market finance provided group way loans contributionscosts running esop trusts charged income statement shares held esoptrusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report stnemetats laicnanifreconciliation usaccounting principles us gaap goodwill arising acquisitions prior th june capitalised amortised period exceeding analyses reconciliations presented note represent years july financial accounting standards board fasb financial information prepared basis us generally accepted issued statement financial accounting standard sfas accounting principles usgaap rather ifrs goodwill intangible assetslike ifrs sfas requires summary material differences ifrs goodwillmust amortisedand annual impairment us gaap tests goodwill must undertaken implementation sfas acquisition smithkline beecham year earlier groups transition ifrs results group exercised exemption available ifrs first goodwill balances acquired reflecting one timeadoption ifrs restate business combinations prior year less amortisation usgaap ifrs date transition groups reporting gaap uk ifrs costs incurred integrating restructuring generally accepted accounting principles ukgaap ifrs wellcome smithkline beecham block drug businesses following therefore combination glaxo wellcome plc acquisitions respectively charged smithkline beecham plc continues accounted merger income statement post acquisition similarly integration pooling interests accordance withukgaapat time restructuring costs arising respect acquisitions ofcns us gaap business combination qualify pooling andcorixa idbiomedical charged interests accounting glaxo wellcome deemed income statement ifrs usgaap certain ofthese costs accounting acquirer purchase business combination considered allocation purchase consideration thereby accordingly net assets smithkline beecham recognised affecting goodwill arising acquisition fair valueas date acquisition result fair value inprocess research development iprd exercise increases values smithkline beechams inventory ifrs iprd projects acquired business combination property plant equipment intangible assets investments capitalised remain balance sheet subject pension obligations recognised fair market values attributed impairment writedowns amortisation charged assets internallygenerated intangible assets mainly product rights estimated useful lives point assets became inclusive patents andtrademarks inprocess research available use usgaap assets recognised development together appropriate deferred taxation effects opening balance sheet written immediately difference cost acquisition fair value income statement technological feasibility iprd assets liabilities smithkline beecham recorded yet established alternative future use goodwill ifrs deferred tax provided iprd assets acquired capitalised interest business combination usgaap provide deferred tax ifrs group capitalise interest usgaap requires assets resulting reconciling adjustment deferred interest incurred part cost constructing fixed assetto tax goodwill capitalised amortised life asset iprd acquired transactions business combinations goodwill discussed intangible assets group exercised exemption available ifrs intangible assets restate business combinations prior date transition ifrs certain intangible assets related specific compounds groups reporting gaap ukgaap ifrs ukgaap products purchased third party developed goodwill arising acquisitions accounted commercial applications capitalised subject purchase method eliminated equity ifrs amortisation regulatory approval obtained usgaap future disposal closure business goodwill previously taken payments madein respect compounds products directly equity former gaap charged still development yet received regulatory approval income ukgaap goodwill arising acquisitions charged directly theincome statement capitalised amortised period exceeding years date groups transition ifrs st january ifrs intangible assets amortised estimated useful amortisation ceased accordance ifrs business economic life except case certain acquired brands combinations group must instead identify value reporting end useful economic life brand foreseen units purpose assessing least annually potential us gaap implementation sfas goodwill impairment goodwill allocated reporting unit permitted intangible assets intangible assets including business combinations exemption available ifrs brands amortised finite life implementation sfas amortisation arising prior reversed intangible assets deemed indefinite lives longer amortised result difference accounting treatment prior implementation sfas carrying values ofindefinite lived brandsare affected amortisation charged usgaap gsk annual report stnemetats laicnanif notes financial statements continuedreconciliation us accounting principles proceeds sale marketable securities usgaap continued million year ended st december million proceeds include rollover liquid funds restructuring costs shortterm deposit gross gains losses reflected ifrs restructuring costs incurred following acquisitionsare consolidated income statement respect marketable securities charged profit loss account post acquisition usgaap million nil respectively million nil purposes certain costsarerecognised liabilities upon acquisition opening balance sheet pensions postretirement benefits key differencebetween ifrs usgaap method restructuring costs recorded provision ifrs recognition actuarial gains losses gsk opted ifrs restructuring plan announced usgaap recognise actuarial gains lossesin statement recognised provision may recognised criteria met income expense year arise usgaap liability incurred therefore adjustments made actuarial gains losses recognised using corridor eliminateprovisions restructuring costs notmeet us approach deferred actuarial gains losses amortised gaaprequirements stockbased compensation marketable securities ifrs sharebasedpayment share options fair valued marketable securities consist primarily equity securities certain grant dates cost charged income statement liquid investments principally government bonds short relevant vesting periods usgaap group applies sfas term corporate debt instrumentsunder sfas accounting r sharebased payment related accounting interpretations certaininvestments indebt andequitysecurities securities accounting option plans also require options fair considered available sale carried fair value valued grant date andcharged tothe income statement unrealised gains losses net tax recorded separate vesting period options minor differences arise result component shareholders equity ifrsthese accounted differing definitions grant date certain sharebased availableforsale financial assetsin accordance ias payments accounting treatment share optionswith financialinstruments recognition andmeasurement certainconditions linked inflation classified liabilities accounting treatment marketable securities usgaap sfasr ifrs issimilar however differences arise principally result derivative instruments category marketable securities defined sfas sfas accounting derivative instruments hedging smaller category availableforsale financial assets activities amended sfas sfas interpreted defined ias investments marketable securities derivatives implementation group adopted group sfas definition accounted cost less effect st january sfas establishes accounting impairments usgaap rather fair value reporting standards derivative instruments including certain group adopt ias st january derivative instruments embedded contracts collectively accordance exemption available ifrs presented referred derivatives hedging activities sfas requires financial instruments comparative periods accordance entity recognise derivatives either assets liabilities ukgaap therefore securities stated lower consolidated balance sheet measure instruments fair cost net realisable value value changes fair value period recorded current earnings unless hedge accounting obtained sfas prescribes marketable securities reviewed leasteveryquarterfor requirements designation documentation hedging temporary impairment equity securities factors relationships ongoing assessments effectiveness order considered include qualify hedge accounting investees current financial performance future prospects group also evaluates contracts embedded derivatives general market condition geographic industry area accordance sfas requirements embedded derivatives investee operates clearly closely related host contract accounted duration extent market value separately host contract derivatives cost key differences ifrs groups financial gross unrealised gains losses marketable securities statements prepared usgaap groups application million andless million respectively st december respective requirements million million respectively fair value marketable securities unrealised losses st december certain derivatives designated group hedging million millionall marketable securities instruments ias designated hedging continuous loss position less months instruments sfas accordingly hedge accounting deferred tax provided unrealised gains losses st applied usgaap respect arrangements december million million gains million reclassified accumulated comprehensive income income statement disposals equity investments year million gain gsk annual report stnemetats laicnanif notes financial statements continuednotes financial statements continued reconciliation us accounting principles continued following adjustments also included reconciliations definition derivatives within scope sfas excludes computer software ifrs group capitalises costs incurred instruments liquid market leads certain acquiring developing computer software internal use items recognised balance sheet although software supports significant business system accounted derivatives ifrs notably call option expenditure leads creation durable asset us gaap theravance shares group applies sop accounting costs computer software developed obtained internal use restricts ias exemption requirement recognise categories costs capitalised embedded foreign currency derivatives currency commonly used economic environment host contract variable interest entities fasbs interpretation sfas grant similar exemption group revised fin r consolidation variable interest entities certain identifies separately accounts embedded derivatives entities known variable interest entities vies must us gaap ifrs consolidated primary beneficiary entity primary beneficiary generally defined majority risks group exercised exemption available ifrs rewards arising vie additionally vies present financial instruments comparative periods accordance significant majority variable interest held certain ukgaap ukgaap derivative instruments used disclosures required groupregularlyreviewspotential vies hedges recognised balance sheet matching consequenceconsolidated theravance inc may principle used match gain loss hedging february see note c page vies contracts foreign currency transaction profits group primary beneficiary identified relatedgains losses related fair value adjustments derivative instruments therefore reconciling itemsin fixed asset inventory impairments reversals impairments comparative period presented reconciliation profitin previously recorded carrying value assets permitted group designate derivatives ifrs certain circumstances usgaap permit qualifying hedge instruments sfas reversals impairments hedging arrangements usgaap various small adjustments st december group applied million consolidated summary statement cash flows borrowings billion hedge foreign currency usgaap cash flow statement reportsthree categories cash exposures groups net investment certain foreign operations flows operating activities including tax interest investing borrowings designated hedges net investments activities including capital expenditure acquisitions disposals effective portion foreign exchange gains losses hedges together cash flows availableforsale current asset recorded part foreign currency translation component investments andfinancing activities including dividends paid comprehensive income million tax gains summary statement ofcash flows presented page million tax losses recorded comprehensive income comprehensive income statement requirement sfas reporting comprehensive income valuation derivative instruments provide comprehensive income statement met ifrs fair value derivative instruments sensitive movements statement recognised income expense page underlying market rates variables group monitors fair value derivative instruments least quarterly basis recent pronouncements derivatives including interest rate swaps crosscurrency swaps sharebased payment valued using standard valuation models counterparty valuations st january group adopted sfasr sharebased third party valuations standard valuation models used payment using modified prospective application method prior group consider relevant discount rates market yield curve gsk applied fair value provisions sfas accounting valuation date forward currency exchange rates counterparty stockbased compensation accounting employee share risk significant rates variables obtained market based compensation awardsthe adoption sfasrhad sources valuations based remaining term maturity following impact groups consolidated financial statements instrument sfas group elected account forfeiture foreign exchange contracts valued using forward rates observed nonvested stock options incurred result adopting quoted prices relevant markets possible group sfasr group required estimate total forfeitures assumes parties longterm contracts economically viable grant date revise estimate throughout vesting reserves right exercise early termination rights economically period impact ofestimating levelof option forfeitures beneficial rights exist contract advance actual occurrence reduces cumulative compensation cost recognised respect options outstanding date dividends adoption sfasr st january million ifrs gsk plcs quarterly dividends recognised million net tax recognised cumulative effect payment usgaap dividends recognised change accounting principle financial statements declared gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles group adopted sfasin initially recognised continued funded status defined benefit postretirement plan provided required disclosures st december sfasr share options whose vesting indexed factor retrospective application permittedtherefore market performance service condition classified actuarial gains losses recognised using liabilities balance sheet remeasured fair value corridor approach deferred actuarial gains losses reporting date accordingly share options granted gsk amortised condition linked inflation accounted liabilities usgaap ifrs options accounted impact adoption sfas thegroups consolidated equitysettled sharebased paymentssotheir fair value measured financial statementsis disclosed note f within thisnote grant date andthis isrecognised vesting period accounting uncertain tax positions shareholders funds impact accounting options july fasb issuedfin accounting uncertain tax outstanding st january revisedusgaapbasis positions fin clarifies accounting uncertainty income increases cumulative compensation cost recognised taxes recognised enterprises financial statements us million million net tax recognised gaap accordance sfas accounting income taxes cumulative effect change accounting principle interpretation prescribes recognition threshold sfas group allocated share option compensation measurement attribute financial statement recognition expense based nominal vesting period rather measurement tax position taken expected taken tax expected time achieve retirement eligibility sfasr specifies return fin also provides guidance derecognition classification sharebased award considered vested expense interest penalties disclosure transitionthe group currently attribution purposes employees retention award evaluatingthe potential impacts fin usgaap financial longer contingent upon providing subsequent service statements group interpretation effectivefrom accordingly group prospectively revised expense st january attribution method related compensation cost pronouncements recognised period grant date date retirement eligibility achieved less stated vesting period sfas september fasb issued sfas fair impact change significant value measurements statement defines fair value establishes framework measuring fair value usgaap expands year ended st december compensation expense disclosures fair value measurements thestatementrefers types sharebased payment arrangements related accounting pronouncements require permit fair value income tax benefit recognised million million measurements fasb previously concluded respectively group continued account compensation accounting pronouncements fair value relevant expense fair value provisions sfas measurement attributethis statement require new compensation expense would materially different fair value measurements group statement sfasr expense year effective st january st december gsk approximately million total unrecognised compensation cost related nonvested sharebased sfas february fasb issued sfas fair compensation arrangements granted plans value option financial assets financial liabilities million relates share option schemes total cost expected statement permitsentities choose elect specified election recognised weightedaverage period ofyears dates measure eligible financial instruments fair value years share option schemes unrealised gains losses items fair value option elected would reported net income tax benefit realised share options exercised subsequent reporting date andupfront costs fees related million items would recognised net incomeas incurred pensions post retirement benefits deferred group unlikely elect exercise fair september fasb issued sfas employers value option accounting defined benefit pension postretirement plans sfas requires gskto recognise overfunded sab september sec staff issued staff accounting underfunded status defined benefit plan multi bulletin sab establishes dual approach qualifying employer plan asset liability changes funded financial statement errors requiring evaluationof errors status recognised comprehensive income ii measure iron curtain rollover methods guidance applies funded status plan yearend date iii provide groups usgaap financial information additional disclosures accordingly hasbeen adopted group sab impact usgaapfinancial information presented note gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued following summary material adjustments profit shareholders funds would required us gaap applied instead ifrs profit notes profit taxation year ifrs profit attributable minority interests profit attributable shareholders ifrs usgaap adjustments goodwill impairment amortisation impairment intangible assets b acquisition disposal product rights b writeoff inprocess rd acquired business combinations b depreciation impairment assets capitalised interest disposal interests associates subsidiaries investments pensions postretirement benefits f stockbased compensation derivative instruments hedging fair value put option granted minority shareholders c restructuringcosts tax benefits exercise stock options deferred taxation net income usgaapbefore cumulative effect change accounting principle cumulative effect change accounting principle net income us gaap earnings per share usgaap p p p basic net income per sharebefore cumulative effect change accounting principle cumulative effect change accounting principle per share basic net income per share cumulative effect change accounting principle diluted net income per share cumulative effect change accounting principle cumulative effect change accounting principle per share diluted net income per share cumulative effect change accounting principle earnings per ads usgaap basic net income per ads cumulative effect change accounting principle cumulative effect change accounting principle per ads basic net income per ads cumulative effect change accounting principle diluted net income per ads cumulative effect change accounting principle cumulative effect change accounting principle per ads diluted net income per ads cumulative effect change accounting principle gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued equity shareholders funds notes total equity ifrs minority interests shareholders equity ifrs usgaapadjustments goodwill product rights b pension intangible asset f fixed assets inventory impairment reversals capitalised interest investments pensions postretirement benefits f restructuring costs derivative instruments dividends deferred taxation e shareholders equity us gaap consolidated statement cash flows usgaap net cash provided operating activities net cash used investing activities net cash used financing activities net increase cash cash equivalents exchange rate movements cash cash equivalents beginning year cash cash equivalents end year gsk annual report stnemetats laicnanifnotes financial statements continued reconciliation us accounting principles continued notes profit equity shareholders funds reconciliations goodwill following tables set ifrs usgaap adjustments required ifrs balance sheet respect goodwill balance sheet goodwill ifrs goodwill usgaap ifrs usgaap adjustments millionusgaap goodwill balance st december million million million respect goodwill arising acquisition smithkline beecham glaxo wellcome following tablepresentsthe changes goodwill allocated groups reportable segments consumer pharmaceuticals healthcare total st january additions disposals exchange adjustments st december additions exchange adjustments st december b intangible assets following tables set ifrsto usgaap adjustments required ifrs income statement balance sheet respect intangible assets income statement amortisation charge ifrs amortisation charge usgaap ifrsto usgaap adjustment amortisation impairment charge ifrs impairment charge usgaap ifrs usgaap adjustment impairment addition adjustments amortisation impairments ifrs usgaap adjustments arose year million million million respect acquisition disposal inprocess rd licences patents etc capitalised ifrs charged directly research development expense usgaap nil nil million respect disposals product rights higher carrying value usgaap ifrs gsk annual report stnemetats laicnanifgsk annual report stnemetats laicnanif notes financial statements continued reconciliation us accounting principles continued balance sheet product rights intangible assets ifrs product rights intangible assets usgaap net ifrsto usgaapadjustmentforproduct rights intangible assets product rights intangible assets usgaap analysed follows acquired products brands subject indefinite licences patents etc amortisation lived brands total cost accumulated amortisation impairment carrying value cost accumulated amortisation impairment carrying value acquired products licencesandpatents pharmaceutical products principally arising acquisition smithkline beecham plc consumer healthcare products book values net accumulated amortisation impairment follows avandia seroxatpaxil augmentin fluviral havrix infanrix fraxiparine twinrix engerixb hycamtin coreg others acquired products licences patents etcintangible assets usgaap indefinite lived brands relate large number consumer healthcare products principally arising acquisitions smithkline beecham plc including products previously acquired smithkline beecham sterling winthrop inc block drug company book values follows panadol aquafresh lucozade horlicks ribena nicorette odol tums nicoderm sensodyne others indefinite lived brands intangible assets us gaap gsk annual report stnemetats laicnanif notes financial statements continued reconciliation us accounting principles c theravance continued may group formed strategic alliance theravance inc develop commercialise novel medicines across variety brands considered indefinite life given important therapeutic areas terms alliance strength durability brand level marketing theravance received million significant part related support brands relatively stable profitable market groups purchase theravance shares group call sectors size diversification market shares mean option increase ownership risk marketrelated factors causing shortening brands lives significant premium price paid transaction considered relatively low group aware theravances shareholders put option lower exercise material legal regulatory contractual competitive economic price cause glaxosmithkline acquire half factor could limit useful lives accordingly outstanding stock given maximum number shares amortised brand tested annually impairment applying subject put option groups obligation capped fair value less costs sell methodology using five year posttax million group exclusive option license potential new cash flow forecasts terminal value calculation applying medicines theravances programmes august discount rate group posttax weighted average cost capital upon exercising option theravance programme group adjusted appropriate countryspecific risks responsible relevant development manufacturing carrying values certain intangibles subject amortisation commercialisation activities depending success reviewed impairment million million programmes theravance receive clinical regulatory recorded million million relates commercial milestone payments royalties subsequent sales pharmaceutical products nil million consumer medicines based assessment performed may healthcare products impairment charge respect consumer group primary beneficiary theravance defined fin healthcare intangible assets subject amortisation million r result theravance consolidated groups us recognised million gaap financial statements date net assets acquired measured fair value principal adjustment carrying discussed note legal proceedings number distributors value net assets theravances balance sheet prior generic drugs filed applications market generic versions acquisition recognition inprocess research development number groups products prior expiration iprd valuation million iprdwas written groups patents generic versions products launched future immediately acquisition accordance usgaap periods earlier dates group currently expects impairments purchase accounting carrying value products may arise february theravance completed secondary offering estimated future amortisation expense next five years common stock reconsideration event defined fin intangible assets subject amortisation st december r assessment date indicated group longer follows primary beneficiary theravances variable interests accordingly year theravance deconsolidated groups results usgaap since february additionally group previously accounted theravance put option discussed accordance sfas accounting certain financial instruments characteristics liabilities equity requires group record fair value put option liability since theravance ceased subsidiary total group finr february put option inprocess rd million million nil arising accounted accordance sfas accounting acquisitions cns pliva idbiomedical derivative instruments hedging activities also requires corixa written valued fair value put option recorded liability fair value basis intangible assets acquired relates theravance put option st december million various development projects preapproval stage million accordance sfas call option technological feasibility projects established recognised financial statements readily point acquisition convertible cashgsk annual report stnemetats laicnanif notes financial statements continued reconciliation us accounting principles continued taxation total tax expense ifrs current tax expense deferred tax creditexpense total tax expense us gaap current tax expense deferred tax credit total tax expense ifrsto usgaap adjustments current tax expense deferred tax credit total tax expense ifrs usgaap adjustment respect current tax expense includes million million million groups share tax expense associates recognised taxation charge income statement usgaap recorded share tax profits associates income statement presented accordance ifrs e deferred taxation usgaap liabilities stock valuation adjustment timing differences current deferred taxation liabilities accelerated capital allowances product rights product business disposals pensions postretirement benefits tax losses legal disputes manufacturing restructuring share option award schemes timing differences valuation allowances total deferred taxation liabilities assets intragroup profit stock valuation adjustment timing differences current deferred taxation assets accelerated capital allowances productrights pensions postretirement benefits tax losses restructuring legal disputes share option award schemes timing differences valuation allowances total deferred taxation assets gsk annual report stnemetats laicnanif notes financial statements continued reconciliation us accounting principles continued e deferred taxation usgaap continued net deferred taxation us gaap net deferred taxation ifrs ifrs usgaap adjustment f pensions postretirement costs usgaap uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs disclosures include additional information required sfas r sfas pension costs uk us major overseas defined benefit pension plans restated following tables accordance us gaap minor retirement plans pension costs million million million recalculated accordance requirements sfas excluded net periodic pension cost major retirement plans service cost interest cost expected return plan assets amortisation prior service cost amortisation transition obligation amortisation net actuarial loss net periodic pension cost us gaap termination benefits curtailment costs assumptions used ias within note similar disclosed following table presented weighted average basis major assumptions used computing pension costs pa pa pa rates future pay increases discount rate expected longterm rates return plan assets aggregate average international plan assumptions vary significantly us assumptions estimated future benefit payments gsk annual report stnemetats laicnanif notes financial statements continued reconciliation us accounting principles continued change benefit obligation benefit obligation st january amendments service cost interest cost plan participants contributions actuarial loss benefits paid termination benefits curtailment costs exchange adjustments benefit obligation st december benefit obligation st december pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation st december million million change plan assets fair value plan assets st january actual return plan assets employer contributions plan participants contributions benefits paid exchange adjustments fair value plan assets st december fair value plan assets end year pension plans accumulated benefit obligations excess plan assets plan assets consist primarily investments uk overseas equities fixed interest securities indexlinked securities property st december uk equities includedmillion gsk shares million shares market value million million analysis theproportionsof total plan assets major category disclosed note thatanalysis includes assets valued million minor retirement plans excluded usgaap tables funded statusbefore adoption sfas funded status unrecognised net actuarial loss unrecognised prior service cost unrecognised transition obligation net amount recognisedbefore adoption sfas amounts recognised statement financial positionbefore adoption sfas prepaid benefit cost accrued pension liability intangible asset accumulated comprehensive income net amount recognisedbefore adoption sfas gsk annual report stnemetats laicnanif notes financial statements continued reconciliation us accounting principles continued incremental adoption effect adoption sfas sfas sfas amount recognised statement financial position prepaidaccrued intangible asset deferred tax asset accumulatedother comprehensive income net deferred tax st december total amountsestimated recognised net periodic pension cost net actuarial loss prior service cost transition obligation postretirement healthcare usgaap postretirement healthcare costs uk us major overseas postretirement healthcare schemes restated following tables accordance usgaap minor healthcare plans costs million million nil recalculated excluded net healthcare cost service cost interest cost amortisation prior service cost amortisation net actuarial loss net healthcare cost major assumptions used calculating net healthcare cost pa pa pa rate future healthcare inflation discount rate change benefit obligation benefit obligation st january amendments service cost interest cost plan participants contributions actuarial gainloss benefits paid exchange benefit obligation st december change plan assets fair value plan assets st january employer plan participants contributions benefits paid fair value plan assets st december gsk annual report stnemetats laicnanif notes financial statements continued reconciliation us accounting principles continued funded status adoption sfas funded status unrecognised net actuarial loss unrecognised prior service cost accrued postretirement healthcare cost adoption sfas amount recognised statement financial position adoption sfas accrued benefit cost accrued postretirement healthcare cost adoption sfas incremental adoption effect adoption sfas sfas sfas amount recognised statement financial position prepaidaccrued deferred tax asset accumulatedother comprehensive income net deferred tax st december total amountsestimated recognised net periodic pension cost net actuarial loss prior service cost decrease increase impact variation assumed rate future healthcare inflation effect total service interest cost postretirement healthcare effect obligation postretirement healthcare medicare gross subsidy net estimated future benefit payments stnemetats laicnanif notes financial statements continued principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group stdecember details given principal country operation location headquarters business segment business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary undertaking segment activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holdings onelimited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc ph f brentford smithkline beecham plc phch e h p r brentford wellcome limited phch h greenford glaxo group limited ph h greenford glaxo operations uk limited ph p brentford glaxo wellcome international bvi phch h brentford glaxo wellcome investments bvi phch h stockley park glaxo wellcome uk limited ph h p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uklimited ph p brentford smithkline beecham investments limited phch f brentford smithkline beecham swg limited ch e brentford setfirst limited phch h greenford wellcome foundation limited ph p austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biologicals sa ph e p r rixensart glaxosmithkline biologicals manufacturing sa ph h czech republic prague glaxosmithklinesro phch denmark ballerup glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithklinepharma gmbh ph h greece athens glaxosmithkline aebe phch h guernsey st peter port smithkline beecham limited phch st peter port setfirst nolimited phch h hungary budapest glaxosmithklinemedicine healthcare products limited phch e italy verona glaxosmithkline spa ph h r milan glaxosmithkline consumer healthcare spa ch h luxembourg mamer glaxosmithkline international luxembourg sa phch f h gsk annual report stnemetats laicnanif notes financial statements continued principal group companies continued europe location subsidiary undertaking segment activity netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spzoo ph warsaw glaxosmithkline consumer healthcare spzoo ch e portugal alges glaxosmithklineprodutos farmaceuticos limitada ph republic carrigaline smithkline beecham cork limitedii ph p ireland carrigaline glaxosmithkline trading services limitedii ph e dublin glaxosmithkline consumer healthcare ireland limited ii ch russian moscow glaxosmithkline trading ph federation spain madrid glaxosmithklinesa ph p madrid glaxosmithkline consumer healthcare sa ch sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa hamilton corixa corporation ph p minneapolis cnsinc ch p philadelphia smithkline beecham corporation phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h p wilmington glaxosmithkline holdings americas inc phch h americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r oakville glaxosmithkline consumer healthcare inc ch laval idbiomedical corporation ph p r asia pacific australia boronia glaxo wellcome australia pty ltd phch e p r china hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd ph p r india mumbai glaxosmithkline pharmaceuticals limited ph p nabha glaxosmithkline consumer healthcare limitediii ch p malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd ph south korea seoul glaxosmithkline korea ph p taiwan taipei glaxo wellcome taiwan limited ph p gsk annual report notes financial statements continued principal group companies continued japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk phch p r latin america argentina buenos aires glaxosmithkline argentina sa phch p brazil rio de janeiro glaxosmithkline brasil ltda phch p colombia bogota glaxosmithkline colombia sa phch mexico delegacion tlalpan glaxosmithkline mexicosade cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph san juan sb pharmco puerto rico inc ph p venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae ph p south africa bryanston glaxosmithkline south africa pty ltd phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p usa location associated undertaking business usa teterboro quest diagnostics incorporatediv clinical testing incorporated netherlands ii exempt provisions section companies amendmentact ireland iii consolidated subsidiary undertaking accordance section companies act grounds dominant influence iv equity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc key business segment ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r researchs service full details group subsidiary associated undertakings attached companys annual return filed registrar ofcompanies stnemetats laicnanif gsk annual report notes financial statements continued legal proceedings avandia avandamet august group filed action us district court group involved significant legal administrative district new jersey teva pharmaceuticals usa inc proceedings principally product liability intellectual property tax anti infringement groups patent relating maleate salt form trust governmental investigations related private litigation rosiglitazone active ingredient avandia expires group makes provision proceedings regular basis september group filed comparable action assummarisedin notesand group may make additional court drreddys laboratories alleging infringement significant provisions legal proceedings required patent actions filed response abbreviated event developments matters consistent new drug application anda filings fda drreddys generally accepted accounting principles litigation particularly laboratories teva certifications groups maleate salt usa inherently unpredictable excessive awards may patent invalid teva subsequently filed additional certification justified evidence may occur group could future challenging validity groups basic compound patent incur judgements enter settlements claims could result rosiglitazone january group commenced action payments exceed current provisions amount teva court infringement patent would material adverse effect groups financial basic compound patent currently expires giving effect condition results operations andor cash flows patent term restoration paediatric exclusivity actions intellectual property claims include challenges validity consolidatedanda trial date set th august groups patents various products processes assertions groups actions teva basic compound maleate salt noninfringement patents loss cases could patents dr reddys maleate salt patent result loss patent protection product issue teva dr reddys tentative fda approval dosage consequences loss could significant decrease sales strengths hatchwaxman stays final fdaapproval product could materially affect future results operations respect andas filed companies expired group november legal expenses incurred provisions related legal claims january group filed action us district court charged selling general administration costs provisions district new jersey teva infringement made taking appropriate legal specialist advice two patents basic compound maleate salt patents reasonable estimate made likely outcome rosiglitazone teva filed anda fda generic disputebeginning group established actuarially version avandametwith certification patents invalid determined provision product liability claims incurred yet infringed fda approval anda stayed earlier reported described note st december june resolution patent infringement action since groups aggregate provision legal disputes including avandametis protected patents avandia earlier tax matters described taxation notewas billion holding invalidity avandiacases would dispositive ultimate liability legal claims may vary amounts avandametas well provided dependent upon outcome litigation proceedings investigations possible settlement negotiations imitrex december group commenced action us district significant matters described court southern district new york dr reddys intellectual property laboratories alleging infringement one two primary advair compound patents sumatriptan active ingredient imitrex september group applied us patent patent issue affords protection february trademark office uspto reissue combination patent giving effect grant paediatric exclusivity fda advair inhaled combination salmeterol fluticasone defendant filed anda fda sumatriptan oral propionate expires september followed tablets certification invalidity compound patent internal review concluded language patent may certify invalidity noninfringement accurately describe circumstances invention compound patent expires june giving effect may claim invention precisely could objective paediatric exclusivity seeking reissuance strengthen protection afforded march group commenced infringement action patent january group received notice allowance cobalt pharmaceuticals transferred us finding pharmaceutical composition claims patentable district court southern district new york defendant issued patent september expiration date filed anda forsumatriptanoral tablets certification original composition patentand belisted register invalidity noninfringement compound patent issue pharmaceutical patents maintained us food drug drreddys case administration fda orange book february group commenced infringement action group holds us patents relating advair including various us district court district delaware spectrum patents relating diskusdevice expire period pharmaceuticals defendant filed anda injectable various patents relating hfa formulation sumatriptan certification invalidity noninfringement mdi device expire period compound patent issue drreddys cobalt cases stnemetats laicnanif gsk annual report notes financial statements continued legal proceedings continued group filed actions apotex us district court eastern district pennsylvania october group reacheda settlement agreement dr infringement additional groups patents december reddys provides dr reddys may exclusively distribute judge granted part denied part summary authorisedgeneric versions sumatriptan tablets usa judgementmotions filed apotex result issues expected launch date late fourth quarter november validity infringement three four new patents remained group reached settlement cobalt provides trialin july judge certified patent held cobalt may distribute generic version sumatriptan tablets invalid appeal us circuit court cafc february usa expected launch date early first quarter cafc affirmed judges ruling invalidity patent december group reached settlement spectrum provides spectrum may exclusively distribute group also commenced actions us district court authorisedversions certain sumatriptan injection products eastern district pennsylvania geneva alphapharm andrx usa expected launch groups sumatriptan pharmaceuticals zenith teva pharmaceuticals connection paediatric exclusivity period begins august anda filings paxiland basf sumika fine chemicals launch occurring later early november connection supply paroxetine hydrochloride use andasall groups patent infringement claims lamictal defendants resolved august group commenced action us district court district new jersey teva pharmaceuticals usa apotex launched generic product usa september inc alleging infringement groups compound patent additional generic products launched defendants lamotrigine active ingredient lamictaloral tablets patent march affords protection january giving effect grant groups us patent litigation synthon bv settled paediatric exclusivity fda teva filed anda december enabling us marketing synthons paroxetine fda certification invalidity groups patent parties mesylate product followed settlement august reached settlement agreement pursuant group groups nonus patent litigation synthon granted teva exclusive royaltybearing license distribute consequence synthon free market paroxetine usa generic version lamotrigine chewable tablets addition mesylate product many markets globally obtained teva granted exclusive right manufacture sell tevas marketing authorisations paroxetine mesylate different salt form generic version lamotrigine tablets usa paroxetine used marketed form seroxatpaxil expected launch date certain markets litigation synthon ongoing synthon paxilseroxat asserting counterclaims unfair competition group usa number distributors generic drugs filed applications generic products containing anhydrate form paroxetine fda market generic versions paxilseroxatparoxetine hydrochloride market european countries hydrochloride prior expiration groups patent whilst products subject continuing litigation paroxetine hyrdrochloride hemihydrate distributors sought actions settled expected bring market anhydrate versions paroxetine settled future uk litigation several years standing hydrochloride one case paroxetine mesylate response group apotex culminated appeal court group filed actions distributors infringement decision groups anhydrate process patent valid various groups patents basis generic anhydrate infringedfollowing litigation canada apotex several versions infringe contain andor convert patents related paroxetine apotex launched generic hemihydrate form andor infringe group patents product canada october apotex alleged result july group filed action apotex us district litigation enjoined launching product court northern district illinois infringement receipt regulatory approval action apotex recover groups patent paroxetine hydrochloride hemihydrate apotex damages related delay occasioned injunctions filed anda fda seeking approval introduce generic ongoing form paxil following trial february judge ruled paxil cr groups patent valid infringed apotexs product november mylan pharmaceuticals filed anda paxil cr groups appeal us court appeals federal circuit paroxetine hydrochloride controlled release formulation cafc hears appeals us district courts patent certification invalidity noninfringement several patents listed matters cafc ruled groups patent infringed fda orange book certification invalidity invalid based upon public use clinical trials prior filing date noninfringement patent covering paroxetine hydrochloride usathe group filed petition cafc rehearing hemihydrate mylan admitted active ingredient appeal full court april full cafc vacated product patent expires june giving effect judgement remanded matter panel grant paediatric exclusivity fda group notfile concurrently entry decision panel issued new patent infringement action mylan within day period opinion ruling patent invalid alternative theory provided hatchwaxman month stay fda approval mylan anda stnemetats laicnanif gsk annual report legal proceedings continued wellbutrin xl december biovail commenced actions us district court requip central district california anchen pharmaceuticals april group commenced action us district us district court southern district florida court district delaware teva pharmaceutical usa abrika pharmaceuticals case alleging infringement biovail inc alleging infringement groups compound patent formulation patents wellbutrin xl april biovail filed ropinirole hydrochloride active ingredient requip action us district court eastern district pennsylvania method use patent treatment parkinsons disease impax laboratories infringement patents listed fda orange book compound patent patents expire anchen abrika impax expires december method use patent may filed anda fda certification invalidity non defendant filed anda fda certification infringement biovail patents group licensee invalidity noninfringement patents fda approval patents august judge granted anchens motion anda stayed earlier august resolution ruled anchens anda product infringe biovails patent infringement action december judge ruled patent biovail appealed decision cafc hearing conclusion trial groups method use abrikas motion summary judgementwas heard april ropinirole treat parkinsons disease novel nonobvious date report decision announced impax rejecting tevas claims grounds tevas claim filed motion summary judgementof nonfringement august patent unenforceable inequitable conduct remains date report decision judge evidence reviewed trial issue announced group party actions decided basis deposition testimony documents september biovail commenced actions us district court consideration potential filings parties tevas original southern district new york watson laboratories challenge groups basic compound patent withdrawn alleging infringement biovail formulation patents watsons trial teva accepted fda approve third party counterclaim group based listing activities product prior expiration patent associated fda orange book dismissed october valtrex fda given final approval anchens anda generic may group commenced action us district version wellbutrin xland impax generic mg tablet court district new jersey ranbaxy laboratories product mg generic product launched usa alleging infringement groups compound patent end december generic version mg tablet valacyclovir active ingredient valtrex patent expires launched date report defendant filed anda fda certification groups compound patent invalid december andrx pharmaceuticals filed action infringed august ranbaxy filed motion partial summary group us district court southern district florida judgementthat patent invalid public use alleging manufacture importation sale mg one year filing patent application wellbutrin xlproduct infringes patent issued andrx june group filed motion patent invalid asking treble damages attorneys fees group grounds march court ruled groups favour others acting concert enjoinedin february patent invalid grounds parties reached settlement providing group pay andrx million license fee andrx grant group royalty st february ranbaxy receivedfda approval generic bearing license us patents covering wellbutrin xl valacyclovir product notified group sought market product usa terms earlier agreement zofran companies previously approved court ranbaxy august group commenced action us district agreed groupappliedfor preliminary injunction court district new jersey reddycheminor dr within daysof notificationranbaxywouldnot launch reddys laboratories drreddy certified invalidity three patents product court either ruledon preliminary injunction ondansetron active ingredient zofrantablets including decidedthe pending court case conference court compound patent expired july two method use th february trial date case set th august patents later expired december parties agreed would necessary instances taking account extension paediatric exclusivity group file request preliminary injunction july group filed action drreddys laboratories district court infringement groups patents related orally disintegrating tablet presentation zofran october group filed action westward pharmaceuticals inc district court infringement groups patents related injectable presentation zofran drreddys disintegrating tablet case westward case consolidated earlier drreddys case gsk annual report stnemetats laicnanif notes financial statements continuednotes financial statements continued legal proceedings continued group received lawsuits filed state federal courts usa canada behalf thousands plaintiffs including purported prior trial reddycheminor westward withdrew class actions alleging paroxetine active ingredient paxil challenge compound patent trial infringement addictive causes dependency withdrawal reactions plaintiffs validity groups method use process patents sought remedies including compensatory punitive statutory completed june closing arguments heard may damages cost fund medical monitoring parties subsequently reached settlement agreement federal judge us district court central district terms remain confidential california denied class action certifications nationwide class march group filed similar action teva california statewide class cases filed federal court pharmaceuticals usa inc us district court district district subsequently petition plaintiffs counsel federal delaware alleging infringement two method use patents court cases transferred district court consolidation ondansetron teva certified invalidity noninfringement multidistrict litigation mdl january conditional two method use patents teva challenge compound settlement agreement included per cent patent trial judge ruled groups favour upholding pending claims based symptoms discontinuing paxiltreatment validity method use patents following appeal teva became effective group part settlement admit cafc parties reached settlement agreement terms liability respect allegations suits virtually remain confidential personal injury lawsuits concerning discontinuation symptoms resolved settlement dismissal one purported january group commenced action kali class action consumer fraud lawsuit focused discontinuation laboratories par pharmaceutical company us district symptoms continues california state court alsopurported court district new jersey involving orally disintegrating class action litigation canada concerning symptoms zofran tablets trial judge denied kalis summary judgement discontinuation paxil motion granted groups summary judgementmotions june july affirming validity groups method group received numerous claims lawsuits alleging use patents holding kalis proposed generic product would treatment paxil caused homicidal suicidal behaviour infringe patents following appeal kali cafc exhibited users product class certification denied parties reached settlement agreement terms january one purported personal injury class action lawsuit remain confidential pending us district court eastern district pennsylvania january fda approved black box warning following settlement agreements referred generic antidepressants increased risk suicidal thoughts behaviour ondansetron tablet products launched number paediatric patients strengthened warnings selective distributors usa december serotonin reuptake inhibitor ssri products including paxil class productliability may paxilus label updated warn young adults preclinical clinical trials conducted development especially major depressive disorder may increased potential products determine safety efficacy products risk suicidal behaviour treatment paroxetine use humans following approval regulatory bodies december fda held advisory committee meeting notwithstanding efforts drugs vaccines following review data regarding suicidal thoughts behaviours introduced marketplace unanticipated side effects may clinical studies various antidepressants adults fda become evident group currently defendant number expected update label antidepressants class advise product liability lawsuits related groups pharmaceutical possible increased risk suicidal behaviour young adults products significant matters described group received numerous lawsuits claims alleging use paxil paxilduring first trimester pregnancy resulted birth group received lawsuits claims filed behalf patients child heart defect birth defect group also alleging suffered symptoms discontinuing involved litigation alleging use paxilduring pregnancy treatment paxilparoxetine separately group received resulted birth baby primary pulmonary hypertension lawsuits claims patients commenced paxil newborn september us label paxilwas updated treatment committed attempted commit suicide andor acts reflect new information suggested increased risk violence group also received lawsuits claims alleging congenital malformations particularly cardiovascular malformations use paxilduring pregnancy resulted birth child infants born mothers took paxilduring first trimester birth defects health issues pregnancy december paxilus label updated include new data strengthen pregnancy warning category c category indicates evidence risk foetus potential benefits use drug pregnant women may outweigh risk may paxilus label updated include class warning concerning persistentpulmonary hypertension newborn mothers took paxilafter th week pregnancy gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued fenphen fda became aware reports cardiac valvular phenylpropanolamine problems individuals fenfluramine dexfenfluramine following report yale haemorrhagic stroke project alone combination phentermine prescribed part found suggestion association first use regimen weight reduction requested voluntary phenylpropanolamine ppa decongestant haemorrhagic stroke withdrawal fenfluramine dexfenfluramine market group manufacturers voluntarily withdrawn reports cardiac valvular problems subsequent consumer healthcare products ppa active ingredient withdrawal products form market spawned numerous since ppa product withdrawal group named product liability lawsuits filed manufacturers defendant numerous personal injury class action lawsuits filed distributors fenfluramine dexfenfluramine phentermine state federal courts alleging personal injury increased risk one number manufacturers phentermine group injury use products containing ppa unfair deceptive remains defendant less one hundred several thousand business practices plaintiffs seek remedies including compensatory lawsuits filed various state federal district courts punitive damages refunds usa group defendants federal cases consolidated multidistrict litigation lawsuits seek relief including combination proceeding us district court district washington compensatory punitive damages medical monitoring refunds judge responsible proceedings denied class certification purchases drugs judicial panel multidistrict struck class allegations federal personal injury litigation issued order consolidating transferring federal consumer refund class actions class certification denied actions us district court eastern district pennsylvania california state court pennsylvania state court putative class court approved global settlement proposed defendant action dismissed leaving putative class actions pending wyeth sold fenfluramine dexfenfluramine settlement group litigation substantial number cases subsequently approved third circuit court appeals group manufacturers defendants reached include phentermine defendants including group trial state federal courts manufacturers part individual plaintiffs may elect opt class settlement received favourable outcomes trial pursue claims individually tens thousands plaintiffs baycol elected wyeth continues settle individual state court august bayer ag withdrew baycolcerivastatin sodium cases trial group continues dismissed worldwide light reports adverse events including deaths lawsuits settled wyeth involving rhabdomyolosis group participated thimerosal marketing baycol usa pursuant copromotion group along number pharmaceutical companies agreement bayer licence holder manufacturer named defendant numerous individual personal injury product lawsuits state federal district courts usa alleging following withdrawal bayer group named thimerosal preservative used manufacture vaccines causes defendants thousands lawsuits filed state federal courts neurodevelopmental disorders injuries including autism usa behalf individuals putative classes former two cases purported class actions although baycolusers number suits allege plaintiffs determination whether cases permitted suffered personal injuries including rhabdomyolosis use proceed class action number purported class actions baycol others claim persons took baycol although jurisdictions withdrawn dismissed plaintiffs seek injured may risk future injury may suffered economic remedies including compensatory punitive statutory damages damages purchasing using baycol plaintiffs seek remedies cost fund medical monitoring research including compensatory punitive statutory damages creation date report cases scheduled trial funds medical monitoring group defendant group bayer corporation principal us subsidiary bayer ag signed allocation agreement bayer corporation agreed pay per cent settlements compensatory damages judgements party retaining responsibility attorneys fees punitive damages federal cases consolidated amdlproceeding us district court district minnesota date two statewide class actions certified medical monitoring case pennsylvania consumer fraud deceptive business practices act case illinois medical monitoring action dismissed court summary judgement another class action gsk named defendant certified oklahoma substantial number claims death serious injury settled many others alleging muscle aches pains voluntarily involuntarily dismissed gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued average wholesale price gsk responded subpoenas office inspector sales andmarketing andregulation general us department health human services hhs marketing andpromotion us department justice states texas california february group received subpoena us connection allegations pharmaceutical companies including attorneys office colorado regarding groups sales gsk violated federal fraud abuse laws federal promotional practices relating nine largest selling products false claims act respect texas california comparable period january present particular state laws result way average wholesale price awp government inquired alleged promotion drugs determined reported certain drugs way medicare offlabel uses well group sponsored continuing medical medicaid programmes reimburse drugs september education programmes speaker events special issue boards group reached civil settlement us department advisory boards speaker training programmes clinical studies justice us attorney district massachusetts related grants fees travel entertainment although original office inspector general hhs doj settlement subpoena issued us attorneys office colorado scope group agreed pay government civil settlement million inquiry nationwide group cooperating included settlement amounts states claims investigation providing requested information group settled part settlement corporate integrity earlier responded october letter fdas agreement group party amended address division drug marketing advertising communication issues raised course government investigation requesting information groups alleged promotion wellbutrin srfor offlabel use subsequent initial subpoenas number states respective attorneys general counties new york june group pharmaceutical manufacturers state filed civil lawsuits state federal courts gsk received letter us senate finance committee many drug companies actions claim behalf states committee expressed concern educational grants payers cases behalf instate patients improperly used promote drug products requesting consumers damages restitution due awpbased price company provide detailed information documents use reporting pharmaceutical products covered states medicaid educational grants january group programmes cases governmental programmes manufacturers received second letter committee asking addition private payer class action lawsuits filed gsk additional information groups internal grant approval multiple federal district state courts federal cases process grants medicalphysicianprofessional organisations consolidated amdlproceeding us district court academic institutions state agencies support journal articles district massachusetts publications grants patient education advocacy groups group cooperating committees investigation august judge mdl proceeding granted part providing requested information denied part privatepayer plaintiffs motion class certification thereby narrowing scope class claims february verona public prosecutor commenced criminal august group reached civil settlements resolve class investigation gsks sales marketing practices italy action litigation certain state attorney general claims specific areas investigation include medical education programmes group agreed nationwide settlement subject court approval clinical studies congresses well interaction million resolve claims group separately resolved gsk representatives physicians us securities exchange potential awp claims state medicaid programmes commission sec staff initiated investigation twothirds states procedures established allegations group cooperating doj settlement also fully resolved awp lawsuits filed investigations threatened number state attorneys general litigation february group received subpoena sec concerning awp issues continuing group state respect groups participation united nations oil food attorneys general well new york counties programme group cooperating sec providing nominal pricing documents responsive subpoenathe usdepartment justice group responded two letter requests us senate also investigating matter committee finance dated april february documents information relating nominal price exception best price reporting requirements medicaid drug rebate programme activity connection inquiry committee group since september may group advised us department justice investigating certain groups nominal pricing arrangements determine whether arrangements qualify exception best price reporting requirements violate civil statutes laws group cooperating investigation provided documents information department justice regarding nominal pricing arrangements number groups products gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued april group received subpoena us attorneys office boston requesting production records regarding paxilseroxat manufacturing cidra site covering type information following announcement new york state attorney generals collected us government puerto rico officeaboutthe states lawsuit subsequently settled august group cooperating us attorneys office producing alleging failure disclose data use paxilin children records responsive subpoena group also named adolescents similar cases purport class actions two purported consumer fraud class action lawsuits one filed filed state federal canadian courts private california state court us district court plaintiffs seeking recover amounts paid paxilpurchased use district puerto rico alleging paxil cr andor paxil oral patients age group reached class settlement suspension manufactured according gmp plaintiffs seek agreement illinois state court action would include economic statutory punitive damages along request persons usa bought paxilfor someone age injunctive relief yet determination whether group denies liability agreement relates cost either case permitted proceed class action purchasing paxilfor use paediatric patients include personal injury claims settlement received preliminary antitrust approval judge madison county illinois october paxilseroxat final fairness hearing settlement scheduled paroxetine patent infringement actions brought group th april described intellectual property apotex alphapharm basf sumika filed antitrust unfair competition uk investigation remains pending uk medicines counterclaims group us district court healthcare products regulatory agency mhra determine eastern district pennsylvania based allegations group whether group complied pharmacovigilence monopoliseda market paxilby bringing allegedly sham patent obligations reporting data clinical trials seroxatpaxilin litigation allegedly abusing regulatory procedures children adolescents listing patents fda orange book whilst apotex matter cidra puerto rico manufacturing site remains discovery stage alphapharm basf matters following fda inspections october november resolved settlement agreement principle resulted observations possible deficiencies reached sumika manufacturing practices groups manufacturing facility cidra november us federal trade commission ftc staff puerto rico march fda halted distribution supplies advised group conducting nonpublic paxil cr avandamet due manufacturing issues fda investigation determine whether group violating section observations related certain aspects production controls process federal trade commission act monopolising validation laboratory investigations attempting tomonopolise market paroxetine hydrochloride cidra site engaged tableting packaging range preventing generic competition paxiland requested group glaxosmithkline products primarily us market including submit certain information connection investigation paxil paxil cr coreg avandia avandamet april october ftc closed investigation basis group reached agreement fda consent decree finding action warranted consent decree provides independent expert review following public reference ftc investigation regarding paxila manufacturing processes site compliance fda good number governmental private civil actions claims manufacturing practice gmp requirements provided initiated usaall resolved exception consent decree group provided report fda private indirect purchaser optout lawsuit brought minnesota state deficiencies identified review setting corrective plan court matter discovery phase additionally class actions timetable completion group remains fully committed filed provincial courts canada behalf direct working cooperatively fda address issues timely indirect purchasers cases early stages fashion group resumed manufacture products site june fda confirmed status site upgraded voluntary action indicated means fda deems site acceptable export products routine manufacturing operations financial penalties imposed consent decree consent decree allows potential future penalties maximum million year group fails meet terms theconsent decree gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued commercial corporate relenza october competition directorate european may biota holdings limited filed complaint victorian commission initiated inspection concerning allegations supreme court australia alleging group failed tofulfil group abused dominant position marketplace concerning development promotion production obligations zanamivir enforcement intellectual property rights litigation surrounding relenza terms licence agreement regulatory approvals marketing seroxatin europe october group biota biota seeking substantial cash damages commission made formal request information group believes adhered obligations licence group continues cooperate fully commission agreement parties involved extensive discovery canadian importation securities class action group named seven purported class action lawsuits september attorneys representing purported class along eight pharmaceutical companies following purchasers glaxosmithkline shares american depositary shares groups actions reduce illegal importation prescription adss filed second amended securities class action complaint drugs canada lawsuits alleged companies entered group us district court southern district unlawful conspiracy prevent canadian pharmacies new york alleging group violated us securities laws selling products us customers lawsuits failure disclose unfavourable clinical data studies paxil consolidated one action us district court misrepresentation remaining patent protection paxiland district minnesota groups motion dismiss consolidated augmentinand violation federal false claims act basis action granted court affirmed us circuit court groups recent awp settlement government appeals eighth circuit november october judge entered order dismissing complaint relation matter minnesota state attorney general plaintiffs filed appeal us court appeals filed civil investigative demand subsequently complaint second circuit alleging group violated state antitrust commercial overtime claims laws case still discovery phase december two purported class actions filed us group also named defendant along thirteen district courts central southern districts california drug companies state court action california group behalf groups us pharmaceutical plaintiffs independent pharmacies allege defendants sales representatives actions allege representatives unlawfully conspired keep prices artificially high usa exempt employees us fair labor standards act detriment plaintiffs december trial judge granted consequently entitled overtime pay suits seek double damages groups motion summary judgementplaintiffs filed overtime allegedly worked groups sales representatives appeal california court appeals threeyear period together attorneys fees similar actions filed pharmaceutical companies cases wellbutrin sr early stages december january february lawsuits several purported class actions filed us district environmental matters court eastern district pennsylvania group gsk notified potential responsibility relating past behalf direct indirect purchasers wellbutrin sr operations past waste disposal practices certain sites complaints allege violations us antitrust laws sham primarily usa matters subject litigation fraud patent office group obtaining litigation including proceedings initiated us federal state enforcing patents covering wellbutrin sr complaints follow governments waste disposal site remediation costs tort actions introduction generic competition wellbutrin srin april brought private parties district appellate court rulings generic manufacturer gsk advised may responsible party infringe groups patents parties involved approximately sites appear national priority discovery list created comprehensive environmental response secondary wholesaler compensation liability act superfund july rxusawholesale inc secondary wholesaler filed suit group many pharmaceutical manufacturers wholesalers us district court eastern district new york complaint alleges defendants engaged conspiracy refuse supply pharmaceutical products rxusa violation federal state antitrust laws groups motion dismiss complaint pending gsk annual report stnemetats laicnanifnotes financial statements continued legal proceedings continued proceedings seek require operators hazardous waste facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs instances gsk involved alleged generator hazardous waste although sites gsk involved current former operator facility although superfund provides defendants jointly severally liable cleanup costs proceedings frequently resolved basis nature quantity waste disposed site generator gsks proportionate liability cleanup costs substantially determined sites referred gsks potential liability varies greatly site site cost investigation study remediation sites could time substantial gsk routinely accrues amounts related share liability matters tax matters pending tax matters described note gsk annual report stnemetats laicnanifglaxosmithkline plc directors statements responsibility directors statement responsibility relation directors remuneration companys financial statements remuneration report pages sets directors remuneration policies operated glaxosmithkline disclosures directors remuneration disclosable information relating responsible ensuring maintenance proper accounting directors officers interests prepared records disclose reasonable accuracy financial accordance companies act complies section position company time financial b combined code corporate governance statements prepared comply companies act going concern basis required law prepare financial statements financial making enquiries directors reasonable period give true fair view state affairs expectationthat company adequate resources continue company end financial period ofthe profit operational existence foreseeable future forthis reason loss period continue adopt going concern basis inpreparing responsible also ensuring operation systems financial statements internalcontrol taking reasonable steps safeguard assets company preventing detecting fraud combined code irregularities board considers glaxosmithkline plc applies principles balance sheet year ended st december combined code corporate governance financial supporting notes set pagestoof report reporting council asdescribed corporate governance pages complied provisions except directors confirm suitable accounting policies described page consistently applied preparation financial statements supported reasonable prudent judgements estimates required listing rules financial services authority asnecessary applicable accounting standards followed auditors haveconsidered directors statement compliance financial statements prepared going relation points combined code specified concern basis theirreview responsibilities auditors relation financial statements set independent auditors report page annual report published hardcopy printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation sir christopher gent dissemination financial statements access website available chairman outside uk comparable legislation may different th february disclosure information auditors directors office date report confirmed far aware relevant audit information companys auditors unaware director taken steps heshe ought taken director make himselfherself aware relevant audit information establish companys auditors aware information confirmation given interpreted accordance provisions section za companies act gsk annual report stnemetats laicnanifglaxosmithkline plc gsk annual report stnemetats laicnanif independent auditors report members glaxosmithkline plc audited parent company financial statements basis audit opinion glaxosmithkline plc year ended st december conducted audit accordance international standards comprisethe balance sheet related notes parent auditing uk ireland issued auditing practices board company financial statements prepared audit includes examination test basis evidence relevant accounting policies set therein also audited amounts disclosures parent company financial information directors remuneration report described statements part directors remuneration report audited audited also includes assessment significant estimates reported separately group financial statements judgements made directors preparation glaxosmithkline year ended st december parent company financial statements whether accounting policies appropriate companys circumstances consistently respective responsibilities directors applied adequately disclosed auditors planned performed audit obtain directors responsibilities preparing annual report information explanations considered necessary order directors remuneration report parent company financial provide us sufficient evidence give reasonable assurance statements accordance applicable law united kingdom parent company financial statements part accounting standards united kingdom generally accepted directors remuneration report audited free material accounting practice set statement directors misstatement whether caused fraud irregularity error responsibilities forming opinion also evaluated overall adequacy presentation information parent company financial responsibility audit parent company financial statements statements part directors remuneration report part directors remuneration report audited audited accordance relevant legal regulatory requirements international standards auditing uk ireland report opinion including opinion prepared companys members body accordance section opinion companies act purposewe giving parent company financial statements give true fair opinion accept assume responsibility purpose view accordance united kingdom generally accepted person report shown whose accounting practice state companys affairs hands may come save expressly agreed prior consent stdecember writing parent company financial statements part report opinion whether parent company directors remuneration report audited properly financial statements give true fair view whether parent prepared accordance companies act company financial statements part directors remuneration report audited properly prepared information given thereport directorsis consistent accordance companies act also report parent company financial statements whether opinion information given thereport directors consistent parent company financial statements addition report opinion company kept proper accounting records received information explanations require audit information specified law regarding directors remuneration pricewaterhousecoopers llp transactions disclosed chartered accountants registered auditors read information contained annual report london consider whether consistent audited parent company th february financial statements information comprises financial summary joint statement chairman chief executive financial trends ratios business review corporate governance statement unaudited parts remuneration report consider implications report become aware apparent misstatements material inconsistencies parent company financial statements responsibilities extend informationglaxosmithkline plc company balance sheet uk gaap atst december restated notes investmentin subsidiary companies fixed assets e debtors f cash bank current assets creditors amounts due within one year g net current liabilities net assets capital reserves called share capital h share premium account h reserves profit loss account equity shareholders funds approved board onthfebruary sir christopher gent chairman gsk annual report stnemetats laicnanifglaxosmithkline plc gsk annual report stnemetats laicnanif notes company balance sheet uk gaap apresentation financial statements share based payments issuance company subsidiaries grant description business companys options represents additional capital contributions glaxosmithkline plc parent company gsk major global company subsidiaries additional investment subsidiaries healthcare group engaged creation discovery results corresponding increase shareholders equity development manufacture marketing pharmaceutical additional capital contribution based fair value grant products including vaccines overthecounter otc medicines issued allocated underlying grants vesting period healthrelated consumer products taxation preparation financial statements current tax provided amounts expected paid applying financial statements drawn accordance uk tax rates enacted substantially enacted generally accepted accounting principles ukgaap uk balance sheet date accounting presentation st december comparative figures st december company accounts taxation deferred accelerated reason timing differences originated permitted companies act profit loss reversed balance sheet date deferred tax assets account company presented annual report recognised extent considered recoverable accounting convention standards future taxable profits balance sheet prepared using historical cost deferred tax measured average tax rates expected convention complies applicable uk accounting standards apply periods timing differences expected accounting principles policies reverse deferred tax liabilities assets discounted preparation balance sheet conformity generally financial guarantees accepted accounting principles requires management financial guarantees issued company subsidiaries make estimates assumptions affect reported held fair value amortised life guarantee amounts assets liabilities disclosure contingent assets liabilities date balance sheet actual amounts cnew accounting policies could differ estimates asb issued amendment frs financial instruments balance sheet prepared accordance measurementinapril adopted company companys accounting policies approved board described amended standardimplementsthe sections ias noteb relating recognition derecognition adoption amended standard effect recognising fair value baccounting policies financial guarantees issued company result foreign currency transactions comparative figures company restatedby increasing foreign currency transactions recorded exchange rate ruling investment subsidiary companies creditors date transaction forward rate hedged million impact profits previously reported forward exchangecontract foreign currency assets liabilities translated rates exchange ruling balance sheet date doperating profit forward rate fee relating audit dividends paid received company charged operating profit dividends paid received included accounts period related dividends actually paid received expenditure expenditure recognised respect goods services received supplied accordance contractual terms provision made obligation exists future liability respect past event amount obligation reliably estimated investments subsidiary companies investments subsidiary companies held cost less provision permanent diminution value impairment investments carrying value investments reviewed impairment indication investment might impaired provision resulting impairment review charged income statement year concernedglaxosmithkline plc notes company balance sheet uk gaap continued efixed assets restated shares glaxosmithkline finance plc shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited capital contribution relating share based paymentsand financial guarantees year company formed new subsidiary glaxosmithkline holdings limited sold entire shareholding glaxosmithkline finance plc glaxosmithkline holdings limited issued new shares company considerationthe company also paid million consideration issue new shares glaxosmithkline services unlimited fdebtors amounts due within one year corporate tax amounts owed group undertakings gcreditors restated amounts due within one year dividends payable amounts owed group undertakings creditors hshare capital share premium account share ordinary shares p premium number share capital authorised st december st december share capital issued fully paid st january issued share option schemes st december issued share option schemes st december st december st december number shares issuable outstanding options number unissued shares option st december issued share capitalshares held esop trustshares held treasury shares andshares free issue issued shares fully paidthe nominalcarrying market valuesof shares held esoptrust disclosedinnote stnemetats laicnanif gsk annual report glaxosmithkline plc gsk annual report stnemetats laicnanif notes company balance sheet uk gaap continued ireserves profit reserves loss account total st january profitattributable shareholders dividends shareholders ordinary shares purchased held treasury shares capital contribution relating share based payments st december profit attributable shareholders dividends shareholders ordinary shares purchased held treasury shares capital contribution relating share based payments st december profit glaxosmithkline plc year million million dividends million million gave retainedprofitof million loss million cost ofshares purchased held treasury shares million million profit loss account reserve st december stood million million million unrealised millionnoitamrofni rotsevni investor information section includes financial record presenting historical information analysed accordance current reporting practice transition date ifrs gskwasst january therefore information included fiveyear record accordance ifrs information accordance ukgaap provide link ifrs uk gaap information presented also ukgaap accounting policies used preparation ukgaap information disclosed annual report information prepared ifrs directly comparable information prepared uk gaap five year record also presents information accordance us gaap section also discusses shareholder return form dividends share price movements provides information shareholders financial record quarterly trend five year record shareholder information taxation information shareholders gsk annual report noitamrofni rotsevni financial record quarterly trend unaudited analysis provided quarter group results pharmaceutical sales therapeutic area insterling financial year income statement months q cer cer turnoverpharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income financecosts share tax profitsofassociates andjoint ventures profit taxation taxation tax rate profitafter taxation theperiod profit attributable minority interests profit attributable shareholders basic earnings per sharepence p p diluted earnings per sharepence p p gsk annual report noitamrofni rotsevni financial record continued q q q cer cer cer p p p p p p gsk annual report financial record continued gsk annual report noitamrofni rotsevni pharmaceutical turnover total group q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis infanrix pediarix boostrix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine antibacterials augmentin zinnatceftin oncology emesis zofran hycamtin zantac total pharmaceutical turnover includes copromotion incomefinancial record continued pharmaceutical turnover usa q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis infanrix pediarix boostrix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine antibacterials augmentin zinnatceftin oncology emesis zofran hycamtin zantac total pharmaceutical turnover includes copromotion income gsk annual report noitamrofni rotsevnifinancial record continued gsk annual report noitamrofni rotsevni pharmaceutical turnover europe q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis infanrix pediarix boostrix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine antibacterials augmentin zinnatceftin oncology emesis zofran hycamtin zantac total pharmaceutical turnover includes copromotion incomefinancial record continued pharmaceutical turnover international q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpes valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccines hepatitis infanrix pediarix boostrix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine antibacterials augmentin zinnatceftin oncology emesis zofran hycamtin zantac total pharmaceutical turnover includes copromotion income gsk annual report noitamrofni rotsevnifinancial record continued five year record record financial performance provided analysed accordance current reporting practice transition date ifrs glaxosmithkline st january therefore information included fiveyearrecord accordance ifrs adopted use european union gsk differences ifrs adopted use european union full ifrs published international accounting standards board information accordance ukgaap provide link ifrs uk gaap information also presented uk gaap accounting policies used preparation uk gaap information disclosed annual report information prepared ifrs directly comparable information prepared uk gaap five year record also presents information accordance us gaap turnover business segment ifrs pharmaceuticals consumer healthcare turnover business segment ukgaap pharmaceuticals consumer healthcare pharmaceutical turnover therapeutic area ifrs respiratory central nervous system antivirals metabolic vaccines cardiovascular urogenital antibacterials oncology emesis pharmaceutical turnover therapeutic area ukgaap respiratory central nervous system antivirals metabolic vaccines cardiovascular urogenital antibacterials oncology emesis others pharmaceutical turnover geographic area ifrs usa europe international asia pacific japan middle east africa latin america canada international gsk annual report noitamrofni rotsevnifinancial record continued pharmaceutical turnover geographic area ukgaap usa europe international asia pacific japan middle east africa latin america canada international pharmaceutical turnover includes copromotion income consumer healthcare turnover ifrs otc medicines oral care nutritional healthcare consumer healthcare turnover ukgaap otc medicines oral care nutritional healthcare financial results ifrs turnover operating profit profit taxation profitafter taxation basic earnings per share pence p p p p diluted earnings per share pence p p p p weighted average number shares issue basic diluted return capital employed financial results ukgaap turnover operating profit profit taxation profitafter taxation basic earnings per share pence p p diluted earnings per share pence p p weighted average number shares issue basic diluted return capital employed return capital employed calculated statutory profit taxation percentage average capital employed year gsk annual report noitamrofni rotsevnifinancial record continued amounts accordance us gaap turnover net income basic net income per share pence p p p p p diluted net income per share pence p p p p p information presented accordance us gaap derived financial information prepared ifrs adopted use european union uk gaap balance sheet ifrs noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets equity shareholders equity minority interests balance sheet uk gaap fixed assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets equity shareholders equity minority interests amounts accordance us gaap total assets net assets longterm borrowings shareholders equity gsk annual report noitamrofni rotsevnifinancial record continued number employees usa europe international asia pacific japan middle east africa latin america canada international manufacturing selling administration research development number employees number permanent employed staff end financial period excludes employees employed managed glaxosmithkline contract basis exchange rates guide holders adrs following tables set periods indicated information exchange rate us dollars forsterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates last day month year feb jan dec nov oct sept high low noon buying rate rd february us gsk annual report noitamrofni rotsevnishareholder information share price st january high year low year st december decreaseincrease table sets middle market closing prices derived london stock exchange daily official list companys share pricedecreased byin price st january st december compares anincrease ftse index year share price rd february market capitalisation market capitalisation based shares public issue glaxosmithkline st december billion date gsk thefourthlargest company market capitalisation ftse index smithkline beecham plc floating rate unsecured loan stock loan stock listed exchange holders may require smithkline beecham plc redeem loan stock par ie every loan stock held first business day march june september december holders wishing redeem part loan stock complete notice back loan stock certificate return registrar arrive least days relevant redemption date taxation general information concerning uk us tax effects share ownership set 'taxation information shareholders ' page dividends glaxosmithkline pays dividends quarterly details dividends declared amount payment dates given note dividends per share table sets dividends per sharein last five years year pence gsk annual report noitamrofni rotsevni dividends per ads table sets dividends per adsin us dollars last five years translated us dollars applicable exchange rates year us dividend calendar fourth quarter exdividend date th february record date th february payable th april first quarter exdividend date nd may record date th may payable th july second quarter exdividend date st august record date rd august payable th october third quarter exdividend date st october record date nd november payable th january internet information company including details share price available gsks website wwwgskcom information made available website constitute part annual report investor relations investor relations may contacted follows uk great west road brentford middlesex tw gs tel usa one franklin plaza po box philadelphia pa tel toll free tel outside usashareholder information continued analysis shareholdings number total total number analysis shareholdings st december accounts accounts shares shares holding shares totals held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline totals bank new yorks holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value rd february number holders record shares usa waswith holdings ofshares thenumberof registered holders adrs waswith holdings ofadrs certain shares adrs held brokers nominees result number holders record registered holders usa representative number beneficial holders orofthe residence beneficial holders control company far known company directly indirectly owned controlled one corporations government thecompany know arrangements operation might result change control company major shareholders voting rights per share shareholders substantial shareholdings rd february company received notification following interests shares issue excluding treasury shares bnynominees limited holdsshares representing shares held behalf holders adrs evidence adss legal general investment management limited holdsshares representing barclays plc holdsshares representing far known company person owner shares issue excluding treasury shares company directors officers interests directors officers companyin share optionsas defined thecompanies act company given remuneration report pagesto exchange controls limitations affecting securityholders currently uk laws decrees regulations restricting import export capital affecting remittance dividends orother payments holders companys shares nonresidents uk limitations relating nonresidents uk english law companys memorandum articles association right tobe holder tovote respect companys shares documents display memorandum articles association company documents referred annual report available inspection registered office company publications late march gsk publish website corporate responsibility report covering performance areas including community investment ethics integrity access medicines rdandenvironment health safety gsk annual report noitamrofni rotsevnishareholder information continued nature trading market annual general meeting ordinary shares company listed london stock queen elizabeth ii conference centre rd may exchange th december shares also listed broad sanctuary westminster new york stock exchange nyse inthe form american depositary london swp ee shares adss date annual general meeting company 's principal forum following tables set periods indicated high communication private shareholders addition formal low middle market closing quotations pence shares business presentation chief executive officer london stock exchange high low last reported sales performance group future development prices us dollars adss thenyse opportunity questions board chairmen board 's committees take questions matters relating glaxosmithkline pence per share committees high low investors holding shares company nominee service quarter ended st march arrange nominee service appointed february corporate representative proxy respect shareholding january order attend vote meeting december november adr holders wishing attend meeting must obtain proxy october bank new york enable attend vote september business transacted adr holders may instruct bank quarter ended st december new york way shares represented adrs quarter ended th september voted completing returning voting card provided quarter ended th june bank accordance instructions given quarter ended st march quarter ended st december financial reporting quarter ended th september financial reporting calendar quarter ended th june quarter ended st march announcement st quarter results april year ended st december announcement nd quarter results july year ended st december announcement rd quarter results october year ended st december preliminary announcement annual results february publication annual reportreview march us dollars per ads high low results announcements quarter ended st march results announcements issued london stock exchange february available news service shortly afterwards january issued media made available website sent december ussecurities exchange commission nyse november october financial reports september company publishes annual report investor quarter ended st december needing full detail report annual review quarter ended th september available date publication website quarter ended th june annual review sent shareholders shareholders may also quarter ended st march elect receive annual report writing companys quarter ended st december registrars alternatively shareholders may elect receive notification quarter ended th september email publication financial reports registering quarter ended th june wwwshareviewcouk quarter ended st march year ended st december copies previous financial reports available website year ended st december printed copies obtained registrar uk year ended st december thegskresponse center usa tord february queries relating receipt duplicate copies gsks publications addressed registrars gsk annual report noitamrofni rotsevnigsk annual report noitamrofni rotsevni shareholder information continued ordinary shares companys shares listed london stock exchange registrar companys registrars lloyds tsb registrars causeway worthing west sussex bn da wwwshareviewcouk tel inside uk tel outside uk registrars also provide following services glaxosmithkline investment plan glaxosmithkline individual savings account glaxosmithkline corporate sponsored nominee shareview service shareview dealing service dividend reinvestment plan share dealing service shareholders may buy sell shares internet telephone shareviewdealing share dealing service provided lloyds tsb registrars internet purchases sales log wwwshareviewcoukdealing telephone purchases sales call inside ukonly pm monday friday glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel provision details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser american depositary shares companys shares listed nyse form american depositary shares evidenced american depositary receipts adrs one represents twoordinaryshares general nyses rules permit company follow uk corporate governance practices instead apply usa provided company explains significant variations explanation provided companys website adr programme administrator adr programme administered bank new york shareholder relations po box church street station new york ny wwwadrbnycom tel toll free tel outside usa administrators also provide global buydirect direct ads purchasesale dividend reinvestment plan adr holders gskresponse center tel toll freegsk annual report noitamrofni rotsevni taxation information shareholders information shareholders us shareholders summary main tax consequences holders shares following summary certain uk taxation usa federal adrs citizens residents uk usa set income tax considerations may relevant usholder complete analysis possible tax consequences shares adrs summary applies shareholder holds purchase ownership securities intended shares adrs capital assets citizen resident usa general guide holders advised consult advisers domestic corporation otherwise subject united states respect tax consequences purchase ownership federal income taxation net income basis respect shares shares adrs consequences state local tax adrs resident uk uktax purposes laws usa implications thecurrentukus income hold shares purposes trade profession vocation tax convention carried uk branch agency statement based upon uk us tax laws practices taxation dividends date report gross amount dividends receivedwithout reduction uk withholding tax treated foreign source dividend income us us holders adrs generally treated owners tax purposes eligible dividend received deduction underlying shares purposes current usuk double allowed us corporations dividends adrs payable us taxation conventions relating income gains income tax dollars dividends shares payable sterling dividends paid convention estate gift taxes estate gift tax convention pounds sterling included income us dollar amount purposes us internal revenue code calculated reference exchange rate day dividends amended code received holder subject certain exceptions short term hedged positions individual eligible us holder uk shareholders subject us taxation maximum rate respect taxation dividends qualified dividends received shareholders advised th april rate tax credits reduced one ninth consult tax advisers confirm eligibility result compensating reductions rate tax dividend taxation capital gains income increase tax borne uk resident individual generally us holders subject uk capital gains tax shareholders tax credits however longer repayable subject us tax capital gains realised sale shareholders tax liability less associated tax credit disposal shares adrs taxation capital gains estate gift taxes uk shareholders may liable uk tax gains disposal estate gift tax convention us shareholder shares adrs may also entitled indexation relief generally subject uk inheritance tax taper relief sales indexation relief calculated market value shares st march cost subsequent stamp duty purchases date purchase indexation relief uk stamp duty sdrt subject certain exemptions payable individual shareholders ceased th april taper relief issue transfer shares adr custodian depository available individual shareholders hold deemed hold rate price issued amount shares least three years sold consideration provided transferred sale value transferred consideration inheritance tax individual shareholders may liable inheritance tax transfer sdrt would payable transfer adr uk stamp shares adrs tax may charged amount duty payable transfer adr provided value shareholder 's estate reduced result transfer instrument transfer executed remains times outside way gift disposal less full market value uk stamp duty transfer adr would payable rate consideration transfer sale gift disposal subject uk inheritance tax underlying shares would result liability uk stamp duty us estate gift tax estate gift tax convention would case may sdrt rate minimum charge generally provide tax paid usa credited tax stamp duty liability arises payable uk stamp duty uk stamp duty stamp duty reserve tax sdrt subject certain exemptions payable purchase shares rate purchase price minimum charge stamp duty liability arisesgsk annual report noitamrofni rotsevni glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation advance corporation tax act advance payment uk tax made dividends paid direct us equivalent american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents twoordinaryshares american depositary shares adss ordinary shares registered new york stock exchange basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc creditors accounts payable currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates debtors accounts receivable defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements bymaking offsetting commitments intangible fixed assets assets without physical substance brands licences patents knowhow marketing rights purchased outside parties nonequity minority interest preference shares issued subsidiary outside parties preference shares shares issued varying dividend rates treated outside interests profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue shares outstanding statement recognised income expense statement comprehensive income stocks inventories subsidiary undertaking affiliate glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenuegsk annual report noitamrofni rotsevni index performance overview governance policy accounting policies improvingaccess medicines accounting presentation incentive plans acquisitions disposals independent auditors report annual general meeting intellectual property annual remuneration interest rate risk management assets held sale internal control framework associates joint ventures inventories beingthe best place best people investments associates joint ventures best work investor information board key performance indicators business review legal proceedings cash cash equivalents movements equity chairmans ceos summary net debt combined code new accountingrequirements commitments nonexecutive director terms conditions fees committee reports nonexecutive directors remuneration consolidated balance sheet notes financial statements consolidated cash flow statement operating profit consolidated income statement optimising performance key products consolidated statement recognised income intangible assets expense investments consumer healthcare noncurrent assets contact details noncurrent liabilities contingent liabilities operating income corporate executive team provisions corporate governance outlook risk factors corporate responsibilityand community pensions postemployment benefits investment pharmaceutical turnover critical accounting policies post balance sheet events delivering product pipeline patients presentation financial statements dialogue shareholders principal group companies directors senior management remuneration products competition directors interests property plant equipment directors interests contracts quarterly trend directors statements responsibility reconciliation net cash flow movement net debt dividends reconciliation profit tax operating cash flows earnings per share reconciliation us accounting principles employee costs regulatory environment employee share schemes related party transactions exchange rates remuneration policy executive director terms conditions remuneration remuneration report finance costs report directors finance income responsibility environment health safety financial instruments related disclosures risk factors financial position resources segment information financial record share capital share premium financial review share options financial review shareholder information financial statements taxation financial statements glaxosmithkline plc taxation information shareholders financial summary ifc totalequity financial trends ratios trade payables five year record trade receivables foreign exchange risk management trademarks global manufacturing supply treasury policies glossary terms us law regulation goodwill world economy corporate annual responsibility report report financial summary chairmans ceos letter chairmans ceos summary corporate responsibility gsk performance overview access medicines business review research innovation would corporate governance ethical conduct remuneration report like know supply chain financial statements employment gsk notes financial environment statements wwwgskcom working communities investor information corporate annual responsibility review review chairmans ceos summary chairmans ceos letter delivering product pipeline qa patients access medicines optimising performance research innovation key products website ethical conduct improving access medicines employment best place best environment people best work working communities running business managing cr responsibly us data summary performance overview products business operating review health summary remuneration report responsibility corporate governance work communities summary financial statements research development shareholder information investors media centre careers feel better live longer head office registered office glaxosmithkline plc great west road designed cgi london brentford middlesex tw gs printed uk midas press paper used united kingdom production document made pulps harvested tel sustainable forests also using sawmill residues wwwgskcom forest thinnings elemental chlorinefree